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Abstract 
 
Exercise is beneficial for all individuals; it lowers blood pressure, keeps the heart 
healthy and increases insulin sensitivity. Recent studies have shown the power that 
regular exercise has to improve metabolic health, which in turn works to prevent 
and to reverse the onset of the widespread epidemics of type 2 diabetes (T2DM). 
However, diabetics taking insulin are required to meticulously plan exercise 
around meals and intake of insulin as they face an increased risk of hypoglycaemia 
from physical activity, which can discourage them from taking part. 
This thesis describes the use of systems of ordinary differential equations to model 
the effects of exercise on the glucose regulatory system, for both healthy and diabetic 
individuals. A particular focus is given to the role of glucagon, whose role is often 
neglected in glucoregulatory models, and its ability to enhance hepatic glucose 
production and so to prevent hypoglycaemia. Models of glucose-insulin-glucagon 
dynamics are first developed to describe an Intravenous glucose tolerance test 
(IVGTT), as the processes involved are simpler than in exercise and already widely 
modelled for glucose and insulin, thus is a good basis for validating the incorporation 
of glucagon. 
Mathematical models are used as tools within biological applications as they allow 
for an investigation into the dynamics that are involved in complex regulatory 
processes. The mathematical models in this thesis serve as accurate tools to predict 
blood glucose levels during exercise for both a non-diabetic and type 1 diabetic 
individual (T1DM) and emphasise exercise as a key element in the prevention of 
T2DM. By mathematically modelling the system and the mechanisms that occur to 
maintain glucose homeostasis an insight is gained into what the principal factors are 
for the greatest increase in insulin sensitivity and for the reduction in the likelihood 
of either hypoglycaemic or hyperglycaemic episodes. This may lead to 
recommendations for exercise plans which not only provide the greatest benefits for 
everyday health ant to assist with preventing the onset of diabetes but also to offer 
safer regimes for individuals with T1DM. 
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1  
Chapter 1 Introduction 
 
1.1. Motivation for Study 
 
In 2014, it was reported that, in England alone, 3.2 million people (7.4% of the 
population) had either been diagnosed with or were unaware that they had diabetes 
(Gatineau et al., 2014). This number is predicted to escalate to 5 million by 2025 
(Diabetes.co.uk, 2016) primarily due to changes in lifestyle related to economic 
development (Amos et al., 1997). 
Complications frequently associated with diabetes include retinopathy, nephropathy, 
peripheral neuropathy and blindness (Derouich and Boutayeb, 2002), projecting the 
disease to be the 7th leading cause of global deaths by 2030 (World Health 
Organisation, 2016). 
Evidently, diabetes is a growing problem, and a great amount of research goes into 
understanding the development of the disease in addition to how we can prevent and 
treat diabetes. The use of mathematical models as an approach to aid our 
understanding of glucose regulation has grown rapidly over recent years, providing 
new insights into the underlying mechanisms involved and the dynamic behaviour of 
the complex biological system (Ajmera et al., 2013). Practical uses of these models 
include the assessment of insulin sensitivity and glucose effectiveness (Vicini et al. 
1997), as tools for automated insulin dosage adjustment based on glucose 
measurements (Lehmann and Deutsch, 1992) and as valuable elements for the 
progression of the development of an artificial pancreas (Herrero et al. 2013). 
Despite the vast number of mathematical models developed there is still a 
requirement for further modelling of the glucose regulatory system, in order to 
bridge the gap between the growing amounts of knowledge and data gained from 
experimental approaches (Ajmera et al. 2013). A lack of reliable, predictive and 
suitable models is also considered a hindrance to the development of diabetes 
treatments and artificial pancreases (Huang et al., 2012), (Herrero et al. 2014). 
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1.2. The Glucose Regulatory System 
 
Used and stored for energy, glucose is an important source of fuel and in order to 
maintain good health it is essential that plasma glucose levels are maintained within 
the homeostatic range, which typically lies between 70-110mg/dl (Makroglou et al., 
2006) or 3.8-6.1mmol/L in SI units. This thesis will use the conventional units for 
glucose, insulin and glucagon (mg/dl, µU/ml and pg/ml) for comparison purposes, as 
they are used in the majority of mathematical models. This will also simplify the 
analysis of parameter values obtained in the proposed models to the acceptable 
ranges available in existing literature. The regulation of blood glucose levels ensures 
that a sufficient amount of glucose is delivered to cells, where it is then broken down 
and used as an energy source to fuel cellular processes such as the functioning of the 
brain and the physical movement of muscles. This process of glucose regulation, the 
components involved and relationships they have with each other are referred to as 
the glucose regulatory system. 
Glucose appears in the system as a result of either internal production by the liver or 
from an external administration, such as a meal containing carbohydrates, which 
typically takes 15-30 minutes after consumption to increase blood sugar levels. 
Glucose is removed from the system by conversion into glycogen, used as a form of 
energy by the brain, red blood cells and the peripherals, and, when there is an 
excessive amount of glucose, it is cleared by the kidneys or stored as fat. 
 
Glucose homeostasis is primarily regulated by two hormones, insulin and glucagon, 
which are released in response to signals as they travel through the circulatory 
system. They regulate the system by ensuring the plasma glucose concentration stays 
in the desired range, thus not getting too high (hyperglycaemic state) or too low 
(hypoglycaemic state). Both hormones target the muscles, adipose tissues and liver 
(MacLaren and Morton, 2012), affecting various biochemical processes as a means of 
regulation. It is the ratio of glucagon to insulin that primarily controls fuel 
mobilization (Plowman and Smith, 2010). 
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Figure 1.1: The blood glucose-insulin-glucagon feedback system 
 
Insulin is released continuously by the beta cells in the pancreas into the blood 
stream, which, for healthy patients, means a basal insulin level of <25 µU/mL 
(Buppajarntham, 2014), and is cleared from plasma by the liver. An increase in 
insulin secretions occurs in response to a high concentration of blood glucose; for 
example: after consuming a meal, insulin is released to lower glucose levels, restoring 
the homeostatic state by stimulating anabolic reactions for the macronutrients 
consumed. The plasma glucose threshold for insulin secretion is given typically as 
81mg/dl (Goodwin, 2010) so that when glucose falls to this threshold value insulin 
secretion is suppressed. However this value will differ between individuals. 
Glucagon is produced by the alpha cells in the pancreas and is recognised as the 
primary counter regulatory hormone to counteract a fall in glucose levels. Typically 
the threshold value of glucose levels for glucagon release is defined as any 
concentration less than 67-80mg/dl (Goodwin, 2010) (Liu and Tang, 2008) . The role 
of Glucagon is to mobilize fuel (Plowman and Smith, 2010) and is realised during 
periods of starvation or prolonged physical activity, where the level of circulating 
plasma glucose is not sufficient to meet the individual’s demands for energy. 
Glucagon achieves an increase in plasma glucose through the means of promoting 
both glycogenolysis and gluconeogenesis (Teixeira and Malin, 2008). 
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Glucose is cleared from the plasma by a number of ways; hepatic uptake, in which 
glucose is stored by the liver (Moore et al., 2012), utilization by the brain and red 
blood cells, clearance by the kidneys when glucose levels are excessive and uptake by 
the peripherals (Sulston et al., 2006). Glucose uptake by the peripherals (muscle and 
tissue) is considered as insulin-dependent glucose uptake, as insulin activity is 
required to absorb glucose. The liver is also considered as insulin-dependent, despite 
its ability to respond independently to high glucose levels, as the majority of the 
liver’s functions for glucose regulation require insulin (Brandt, 1999). 
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1.3. Diabetes 
Insufficient secretion or a hypoactivity of insulin can result in diabetes mellitus, a 
metabolic disorder characterised by persistent hyperglycaemia. Diabetes is typically 
categorised as either type 1 or type 2. 
 
Type 1 diabetes, typically diagnosed earlier in life, is an autoimmune disease leading 
to the destruction of the pancreatic beta-cells (Magdelaine et al, 2015), whereby the 
functionality of the pancreases is severely impaired or it is unable to naturally secrete 
insulin in response to high glucose levels. In order to prevent fatality, the patient 
depends on regular exogenous doses of insulin to maintain homeostatic levels of 
blood glucose. 
Type 2 diabetes (T2DM) is most commonly diagnosed in the older generation, with 
the majority of adults diagnosed with the disease in 2012 aged between 45 and 64 
(Krucik, 2014). The most significant factors linked to the cause of T2DM are being 
overweight, abdominal obesity and physical inactivity (Stumvoll et al. 2005). The 
aetiology of T2DM includes β-cell dysfunction and, for the majority of diabetic 
individuals, insulin resistance (Bergman et al. 2002), i.e. resistance to insulin- 
stimulate glucose uptake (Reaven, 1988). 
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1.4. Glucose Tolerance Testing 
 
Diabetes is provisionally diagnosed and classified by a fasting glucose of ≥126mg/dl 
(American Diabetes Association, 2004). Often if an individual is thought to be at risk 
of developing or having diabetes they will undergo a glucose tolerance test (GTT), 
which tests their ability to breakdown glucose. The patient must arrive for the test in 
a fasting state, due to the fact that an impaired β-cell function manifests itself in a 
different manner in fasting and glucose-stimulated conditions (Del Prato et al. 2002). 
There are two different types of GTTs: the oral glucose tolerance test (OGTT) and the 
intravenous glucose tolerance test (IVGTT). 
 
During an OGTT a patient will receive an oral solution containing 75g of glucose at the 
beginning of the test. Blood glucose samples are then taken every 15 minutes for the 
first hour, and every 30 minutes for the following two hours. The diagnosis of 
diabetes is based on the ability of the system to clear the glucose from the plasma 
within a reasonable time frame, which is typically between 90-120 minutes in a 
healthy individual. 
The IVGTT follows a similar protocol as the OGTT the main difference being that the 
IVGTT consists of a bolus of glucose being administered intravenously. 
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1.5. Thesis Outline 
 
This thesis is structured as follows: 
 
Chapter 1 – Introduction and Background 
 
The first chapter will provide an introduction to the basic anatomy of the 
glucose regulation system, defining diabetes is along with the impacts it has on the 
system, and the problems involved with blood glucose regulation which motivate this 
study. 
Chapter 2 – Introduction to Glucose Regulation Models 
 
A description of the key models developed for glucose regulation will be presented 
and critically reviewed. 
Chapter 3 – Development of Mathematical Models with Glucagon Dynamics 
 
Chapter 3 will contain the implementation of the primary hormone Glucagon into a 
glucose regulatory model, since it is the key regulatory hormone in periods of low 
glucose concentrations. This will lead to the development of a model accounting for 
the physiological effects on the system during exercise. This chapter includes the 
implementation of the proposed models into MATLAB, and a discussion of the 
simulated results. 
Chapter 4 – Introduction to Exercise 
 
In this chapter a summary of the key exercise induced effects on the glucose 
regulatory system is given in addition to the motivation for developing a model for 
exercise. 
Chapter 5 – Glucagon Models for Exercise 
 
Chapter 5 presents two mathematical models designed to be capable of predicting 
blood glucose levels during exercise. The models are implemented in MATLAB 
followed by a discussion of the model proposed. 
Chapter 6 – Glucagon Minimal Model for Exercise with Exogenous Insulin 
Administration 
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Chapter 6 extends the models proposed previously in the thesis to consider 
exogenous insulin supply. 
Chapter 7 – Conclusion and Future Work 
 
This chapter concludes the work of the thesis, discussing the accuracy of the models 
proposed and further work for the study. 
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Chapter 2 Introduction to Glucose-Regulation 
 
2.1. Introduction to Modelling Glucose-Insulin Dynamics 
 
The use of mathematical models within biological applications has become 
increasingly frequent due to their ability to act as powerful tools in improving our 
understanding of complex biological systems. Mathematical models allow researchers 
to investigate how complex regulatory processes are connected and how disruptions 
of these processes may contribute to the development of disease (Fischer, 2008). 
Therefore, it is no surprise that mathematical models frequently appear in research 
addressing the issue of the growing prevalence of diabetes. 
During the past five decades, there has been an increase in the number of 
mathematical models available in literature, created to improve our understanding of 
the complex behaviour and relationships involved in glucose homeostasis. 
Mathematical models for blood glucose dynamics can allow for measurements of 
important aspects within the glucose regulatory system, such as the beta cell 
responsivity, insulin sensitivity and glucose effectiveness. Assigning numerical values 
to these aspects admits an insight into the metabolic portrait of an individual, and can 
be perceived as whether the individual is healthy, facing the onset of or has developed 
diabetes. As well as diagnostic purposes, mathematical models are also used as 
epidemiological tools within diabetes management, assessing means of controlling 
the disease and analysing other factors affecting the regulatory system. In more 
recent developments, predictions of blood glucose levels made by mathematical 
models have allowed for advances made in the artificial pancreases, which are 
capable of transforming the way diabetes is treated. 
10  
2.2. Linear Models and Early Modelling Approaches 
 
One of the earliest studies to have a significant impact on modelling the glucose 
regulatory system was that of Bolie (1961), who developed a linear model to capture 
the dynamics between glucose and its regulatory hormone insulin within a healthy 
subject. 
The model was designed to capture the average response of the glucose regulatory 
system to glucose and insulin. The model consisted of a system of two differential 
equations, one to represent plasma glucose, the other for plasma insulin: 
𝑑𝑥 
=  − 𝛼𝑥(𝑡) + 𝛽𝑦(𝑡); (2.1) 
𝑑𝑡 
𝑑𝑦 
=  − 𝛾𝑥(𝑡) −  𝛿𝑦(𝑡); (2.2) 
𝑑𝑡 
 
 
The system assumes a linear relationship between the terms in the model, where x(t) 
and y(t) represent the differences between the concentrations, at time t, and the 
resting values of both plasma insulin and glucose respectively. Table 2.1 lists the 
primary definitions of the variables and coefficients in the model, as specified by Bolie. 
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Table 2.1. Bolie’s Model Nomenclature 
 
Symbol Meaning Dimension 
𝑥 The difference between the extracellular insulin 
concentration and the mean physiological value of 
extracellular insulin 
Units/litre 
𝑦 The difference between the extracellular glucose 
concentration and the mean physiological value of 
extracellular glucose 
Grams/litre 
𝑝 Rate of insulin injection of the volume of the 
extracellular fluid 
Units/hour/litre 
𝑞 Rate of glucose injection of the volume of the 
extracellular fluid 
Grams/hour/litre 
𝛼 Rate of insulin destruction Units/hour 
𝛽 Rate of insulin production Units/hour 
𝛾 Rate of accumulation of glucose in the liver Grams/hour 
𝛿 Rate of tissue utilization of glucose Grams/hour 
 
 
Following the work of Bolie, Ackerman et al. (1965) continued developments in 
modelling the glucose regulatory system, introducing a new linearized model to 
capture the blood glucose response to orally administered glucose. However, linear 
equations are typically judged as unacceptable in glucose modelling due to the fact 
that they provide poor fits to experimental data (Li and Kuang, 2001) and cannot 
account for the diverse and complicated dynamics that constitute biological processes 
such as those involved in glucose-insulin kinetics. Sorensen (1985) criticised the 
work of the likes of Bolie and Ackerman for their oversimplification, particularly in 
regard to the assumption that the blood glucose response to insulin is proportional to 
the amount of insulin in the plasma. 
Despite its drawbacks, linear models have been commended for their simplistic 
approach to modelling and for providing the foundation on which many other 
acknowledged researchers in glucose regulation modelling would go on to base their 
work (Sulston et al, 2006). 
12  
2.3. The Minimal Model 
 
The most frequently modelled scenario is of a glucose tolerance test (GTT), as 
described in the previous chapter. Considered as a major breakthrough in diabetes 
modelling (Ajmera et al., 2013), the Minimal Model was developed to describe the 
glucose-insulin dynamics following an intravenous glucose tolerance test (IVGTT). 
Since its development, the model has become the most widely accepted and 
frequently used within physiological research on glucose metabolism (De Gaetano 
and Arino, 2000). 
Figure 2.2: Compartmental Diagram of the Minimal Model 
 
Developed by Bergman et al. (1979) the minimal model consists of three 
compartments, one for the plasma concentrations of both glucose (G) and insulin (I) 
and one for interstitial insulin activity (X), a compartment introduced to describe the 
insulin effect on net glucose disappearance (Pacini and Bergman, 1986) . 
The original Minimal Model (Bergman et al., 1979) is given as follows: 
 
               
𝑑𝐺
𝑑𝑡
=  −𝑝1(𝐺(𝑡) − 𝐺𝑏) − 𝑝4𝑋(𝑡)𝐺(𝑡) −
𝑢2(𝑡)
𝑉𝑜𝑙𝐺
,                          (2.3) 
               
𝑑𝑋
𝑑𝑡
= −𝑝2𝑋(𝑡) + 𝑝3(𝐼(𝑡) − 𝐼𝑏),                                                       (2.4) 
               
𝑑𝐼
𝑑𝑡
= −𝑛𝐼(𝑡) + 𝛾(𝐺(𝑡) − ℎ),                                                             (2.5) 
 
Subject to the initial conditions 
G(0) = 𝐺0, X(0) = 0, 𝐼(0) = 𝐼0 
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𝐺0 and 𝐼0 are treated as unknown parameters, since the model does not account for 
the glucose intravenously entering the blood stream, but simply assumes plasma 
glucose and insulin levels have peaked at the start of the test. The model consists of 
two subsystems; equations (2.3) and (2.4) to model glucose disappearance and 
equation (2.5) for insulin kinetics. 
A description of the variables and parameters is provided in table 2.2. 
Table 2.2. Minimal Model Nomenclature 
 
 
Symbol Meaning Dimension 
𝐺(𝑡) Plasma glucose concentration at time t 𝑚𝑔/𝑑𝑙 
𝑋(𝑡) Interstitial insulin at time t 𝑚𝑖𝑛−1 
𝐼(𝑡) Plasma insulin at time t µ𝑈𝑙/𝑚𝑙 
𝐺𝑏 Baseline plasma glucose 𝑚𝑔/𝑑𝑙 
𝐼𝑏 Baseline plasma µ𝑈𝑙/𝑚𝑙 
𝑝1 Insulin independent rate of glucose uptake in 
tissues, often referred to as ‘Glucose 
Effectiveness’ 
𝑚𝑖𝑛−1 
𝑝2 Decline in ability of glucose uptake in tissues 𝑚𝑖𝑛
−1 
𝑝3 Increased insulin dependent ability of glucose 
uptake in tissues 
𝑚𝑖𝑛−2(µ𝑈𝑙/𝑚𝑙)−1 
ℎ Target glycaemia 𝑚𝑔/𝑑𝑙 
𝛾 Rate of release of insulin in response to excess 
plasma glucose 
(µ𝑈𝑙/𝑚𝑙) 
(𝑚𝑔/𝑑𝑙)−1𝑚𝑖𝑛−1 
𝑛 Decay rate for plasma insulin 𝑚𝑖𝑛−1 
𝑆𝐼   = 𝑝3⁄𝑝2 Insulin sensitivity, 𝑝3⁄𝑝2, the increase in the 
fractional clearance rate of glucose per unit 
change in the plasma insulin concentration 
(Bergman et al. 1981) 
𝑚𝑖𝑛−1/µ𝑈/𝑚𝑙 
𝑆𝐺   = 𝑝1 Glucose effectiveness,  𝑝1 𝑚𝑖𝑛
−1/𝑚𝑔/𝑑𝑙 
 
Both the time-courses for plasma glucose and insulin concentrations treat each other 
as known forcing functions, which are separately estimated by available data (De 
Gaetano and Arino, 2000).  Following the predicted behaviour for plasma insulin (eq. 
5) the Minimal Model method provides characteristic parameters for the insulin 
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responsiveness to glucose (Bergman et al. 1981).The interstitial insulin compartment 
(eq. 4) conceptualizes the activity of insulin outside of the plasma compartment in the 
model, for example its role in promoting the uptake of glucose by both hepatic and 
extra hepatic tissues (Roy and Parker, 2007). 
 
The minimal model has made a positive impact to the study of diabetology and was 
first model of its kind to capture the parameter values for insulin sensitivity, 𝑆𝐼, and 
glucose effectiveness, 𝑆𝐺, both which whose numerical value offers an effective 
insight into the metabolic portrait for an individual. 
 
In spite of its popularity; the Minimal Model does have its drawbacks. It is often 
criticised for providing poor estimates of the values for the glucose effectiveness and 
insulin sensitivity (Quon et al., 1994), (Marmarelis and Mitsis, 2014), (McDonald et al., 
1999) as a result of its over simplification of glucose physiology (Muniyappa et al., 
2008). 
Other researchers and experimentalists have also questioned the reliability of some 
of the physiological assumptions and implications of the model, such as the ability of 
the pancreas to increase its rate of insulin secretion with time linearly (De Gaetano 
and Arino, 2000). 
 
An ongoing debate has also arisen on the issue of the model being too simplistic, as it 
was developed to interpret data, not to take full consideration of the underlying 
physiological processes involved (Tornøe et al., 2004). 
 
Despite the shortcomings of the model, its simplicity and popularity has meant it has 
been selected as the basis for many developments and extensions in modelling the 
glucose regulatory system, involved currently in over 500 studies in the literature 
and versions are often applied in the development for an artificial pancreas 
(Magdelaine et al., 2015). 
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2.4. Recent Studies 
 
Since the pioneering work of Bergman et al. (1979) many models have been 
developed based on the original Minimal Model. 
In 1998 Cobelli and co-workers introduced a model that builds on the work of 
Bergman et al. (1979) in order to overcome the overestimate of glucose effectiveness 
and underestimate of insulin sensitivity. To do so the authors presented the ‘Two- 
Compartment Minimal Model’, a model that differed from the original Minimal Model 
by introducing an additional compartment for glucose. This added complexity to the 
model, as it required the use of Bayesian estimation techniques for some of the new 
unknown parameters. There is some debate as to whether an additional 
compartment for glucose is or is not beneficial. Muniyappa et al. (2008) reported an 
improvement in the results of the Minimal Model, whereas Natalucci et al. (2000) 
found no significant difference between the ability of the models to detect impaired 
glucose effectiveness and insulin resistance. 
Dalla Man et al. (2004) adapted the minimal model by adding a term to enable the 
model to consider the rate of appearance of glucose as it is absorbed following oral 
consumption, based on multiple tracer meal validation studies. The ‘Oral Minimal 
Model’ was validated and accepted for its ability to measure the rate of glucose 
absorption in addition to insulin sensitivity, such that the minimal model can be used 
to analyse results from an OGTT. However this model did not consider any 
abnormalities in the system, such as diabetes, which was later addressed by Dalla 
Man et al. (2006). 
Many other adaptions of the Minimal Model have appeared in the literature since its 
development, including models for exercise (Derouich and Boutayeb, 2002), (Roy and 
Parker, 2007), statistical adaptations (Andersen and Højbjerre, 2005) and 
considerations for type 1 diabetes (Fernandez et al. 2009). 
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2.5. Summary 
 
This section has discussed some of the most influential mathematical models to have 
been developed and the contributions they have made towards Diabetology. 
Undoubtedly, the Minimal Model has had the biggest impact on modelling of the 
glucose regulatory system, due to its simple yet accurate ability to simulate glucose 
levels and identify an impaired glucose response. Therefore the majority of models 
introduced in this thesis will be founded on the minimal model. 
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Chapter 3 Glucagon 
 
3.1. Introduction to the Glucagon-Glucose-Insulin Control 
Loop 
Currently the majority of existing mathematical models are restricted to considering 
insulin-glucose dynamics (Lehmann et al., 2007) neglecting to take into account the 
effects of the counter regulatory hormone glucagon. This may be due to the fact that, 
as discussed in chapter 2, the most frequently modelled scenario is the glucose 
tolerance test, where the counter-regulatory hormones have a minimal role. Despite 
the negligible role during a glucose regulatory test, the counter regulatory hormones, 
such as glucagon, are essential in the fasted state, acting to prevent hypoglycaemia 
which, if left untreated, can result in health problems, such as: unconsciousness, 
brain damage and death (Brandt, 1999). 
Since the aim of this thesis is to successfully develop a mathematical model that is 
capable of predicting blood glucose levels during exercise, it is essential that the 
model includes the effects of counter-regulatory hormones in order to avoid 
hypoglycaemia. To begin with developing a model capable of simulating scenarios 
where blood glucose levels are low, a model will be developed to take into account 
the effects of glucagon on blood glucose regulation. Glucagon has been chosen in 
favour of the other counter-regulatory hormones (such as epinephrine), as it is 
considered as a potent regulator of the glucose metabolism in addition to insulin 
(Aronoff et al., 2004). 
The first scenario modelled in this thesis will be the Intravenous Glucose Tolerance 
Test (IVGTT). An IVGTT has been chosen as the data sets consist of a large number of 
measurement samples taken at frequent intervals, in addition to the fact that it is 
already a widely modelled scenario, allowing for validation against other models 
available in the literature. A model will be chosen based on the model accuracy along 
with the insight and understanding it offers into the glucose regulatory system. 
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3.2. Critical Review of Glucagon Models 
 
This section will review the models that have been developed so far in the available 
literature that include the role of glucagon on glucose homeostasis. 
In 2006 Sulston and co-workers developed a model of glucose regulation including its 
hormonal regulation. The model consisted of three equations, one each for 
concentrations in the plasma of glucose, insulin and glucagon and was capable of 
highlighting the importance of the two hormones in maintaining glucose within the 
narrow desired range. The model was simulated for both healthy and diabetic 
patients, simulating individuals during short periods without food (60 minutes) and 
following a meal (based on the term from glucose absorption proposed by Yates and 
Fletcher (2000)). 
Herrero et al. (2013) extended the original minimal model of Bergman et al. (1979) 
by introducing a new term for glucagon action. The new compartment represents the 
pharmacodynamics of glucagon and its ability to stimulate glucose production. 
The model was developed to be used as a bi-hormonal simulator to be used in an 
artificial pancreas, which could consider the use of exogenous glucagon as a 
treatment for hypoglycaemia. An additional term was added to blood glucose to 
account for glucose absorption from a meal, offering a model more representative of 
day-day activity in comparison with the minimal model. The model was tested with a 
bi-hormonal controller and successfully validated against experimental data obtained 
from the study. 
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3.3. Model Formulations 
 
This section will detail the development of three mathematical models proposed to 
describe glucose-insulin-glucagon dynamics during an IVGTT. Each subsection will 
study the relationships between the compartments proposed and go on to form a set 
of mathematical equations. The following sections will include a mathematical 
analysis of the models and simulations against experimental data, in order to 
determine the accuracy and suitability of the models. 
3.3.1. Linear Model 
 
When formulating a mathematical model, the main aim is to develop a model such 
that the variables relate to the observations of the behaviour and relationships that 
exist within the physical system being modelled. From a simulation perspective it is 
desirable that the model is relatively simple allowing for a fast, yet accurate, 
execution. Therefore the first model proposed, derived in Fitches (2015), consists 
only of linear relationships between the compartments involved, one each for the 
concentration in the plasma of glucose, insulin and glucagon. The relationships are 
shown in figure 3.1., where the dashed lines represent the control signals and the 
solid lines are the fluxes in the amount of glucose or regulatory hormones in the 
plasma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Linear bi-hormonal regulation of the glucose regulatory system 
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In this model glucose levels are considered to be directly affected by the 
concentrations of insulin and glucagon in the blood, based on the approach by Boilie 
(1961), and either decrease or increase in a linearly proportional manner to the 
increase in the concentration of the hormones in the plasma above the corresponding 
basal levels, 𝐼𝑏and 𝐸𝑏.  
A description for each rate constant, 𝑝1  − 𝑝7, is provided in the following table. 
 
Table 3.1: Linear Glucagon Model Parameter Nomenclature 
 
Parameter Physiological Description Unit 
𝑝1 Insulin independent glucose uptake (Glucose 
effectiveness) 
𝑚𝑖𝑛−1 
𝑝2 Glucagon stimulated glucose production (𝑚𝑔/𝑑𝑙) 𝑚𝑖𝑛
−2 
𝑝3 Insulin dependent glucose uptake and insulin inhibiting 
effect on glucose production 
𝑚𝑖𝑛−1 
𝑝4 Glucose stimulated insulin secretion (𝜇𝑈/𝑚𝑙) 𝑚𝑖𝑛
−2 
𝑝5 Insulin production/clearance 𝑚𝑖𝑛
−1 
𝑝6 Glucose stimulated glucagon secretion (𝑝𝑔/𝑚𝑙) 𝑚𝑖𝑛−2 
𝑝7 Glucagon production/clearance 𝑚𝑖𝑛−1 
 
Consequently, the following system of equations for describing an IVGTT is derived: 
 
               
𝑑𝐺
𝑑𝑡
= −𝑝1(𝐺(𝑡) − 𝐺𝑏) + 𝑝2(𝐸(𝑡) − 𝐸𝑏) − 𝑝3(𝐼(𝑡) − 𝐼𝑏),              (3.1) 
               
𝑑𝐼
𝑑𝑡
= 𝑝4(𝐺(𝑡) − 𝐺𝑏)
+ − 𝑝5(𝐼(𝑡) − 𝐼𝑏),                                                 (3.2) 
              
𝑑𝐸
𝑑𝑡
= 𝑝6(𝐺𝑏 − 𝐺(𝑡))
+
− 𝑝7(𝐸(𝑡) − 𝐸𝑏),                                              (3.3) 
 
Subject to the initial conditions: 
(0) = 𝐺0, (0) = 𝐼0, 𝐸(0) = 𝐸𝑏. 
 
where G (mg/dl) is the glucose concentration, I (μU/ml) is the insulin concentration 
and E (pg/ml) is the glucagon concentration, all within the plasma. Both 𝐺0 and 𝐼0 are 
considered to be unknown parameters, since this model follows the simple approach 
of the minimal model and, rather than modelling the rate at which glucose enters the 
plasma from , the model assumes glucose levels to have reached their peak value at the 
beginning of the test. Since the individual is in the fed state at the start of the test 
glucagon activity will be supressed; therefore it is assumed that glucagon levels will start 
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at the basal level, 𝐸𝑏. The positive inflections in equations 3.2 and 3.3 indicate that the 
terms can only take a positive value; if the term is to become negative it will be set to 
zero. 
Note the system models an individual with a pancreas capable of producing insulin and 
does not assume T1DM. 
This model provides a simple overview of glucose-insulin-glucagon dynamics, which can 
be solved analytically. However linear models of blood glucose regulation have been 
criticised for their inability to describe the complex processes that occur, therefore may 
provide a poor fit to the data. Therefore, a model with non-linear dynamics may be 
preferable
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3.3.2. Glucagon Minimal Model 
 
The Minimal Model was originally designed by Bergman et al. (1979) to analyse the 
results from an Intravenous Glucose Tolerance Test (IVGTT) and to determine key 
parameters such as glucose effectiveness and insulin sensitivity. Given that the well- 
fed condition leads to the secretion of insulin the original minimal model did not 
include the effects of glucagon, since glucagon secretion is minimal until a couple of 
hours after the glucose. Since the minimal model is a well-documented model in 
Diabetology, successfully extending the model for glucagon will develop a model that 
can be adapted for scenarios of low blood glucose, such as exercise. 
A graphical representation of the interactions between compartments in the 
extended minimal model is given in figure 3.2. 
Figure 3.2: Compartment diagram of non-linear bi-hormonal regulation of the 
glucose regulatory system 
The solid lines represent the constant rates, the dark blue dotted lines show 
signalling of blood glucose levels to the pancreas and the light blue dashed lines show 
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the control actions on glucose levels. The mathematical description of the parameter 
rates are described in table 3.2. 
Table 3.2. Glucagon Minimal Model Nomenclature 
 
Variable Description Unit 
G Plasma glucose concentration 𝑚𝑔/𝑑𝑙 
X Interstitial insulin activity 𝑚𝑖𝑛−1 
I Plasma insulin concentration µ𝑈/𝑚𝑙 
Y Glucagon activity 𝑚𝑖𝑛−1 
E Plasma glucagon concentration 𝑝𝑔/𝑚𝑙 
𝑝1 Glucose Effectiveness 𝑚𝑖𝑛−1 
𝑝2 Decrease of glucose uptake ability in the 
peripherals 
𝑚𝑖𝑛−1 
𝑝3 Increase in peripheral glucose uptake ability, 
proportional to per unit of insulin above baseline 
𝑚𝑖𝑛−2 (µ𝑈/𝑚𝑙)−1 
𝑝4 Insulin clearance 𝑚𝑖𝑛−1 
𝑝5 Insulin secretion, proportional to per unit of 
glucose above baseline 
𝑚𝑖𝑛−2 (µ𝑈/𝑚𝑙) 
𝑝6 Decrease of glucose production ability in the liver 𝑚𝑖𝑛−1 
𝑝7 Increase in hepatic glucose production ability, 
proportional to per unit of glucagon above 
baseline 
𝑚𝑖𝑛−2 (𝑝𝑔/𝑚𝑙)−1 
𝑝8 Glucagon Clearance 𝑚𝑖𝑛−1 
𝑝9 Glucagon secretion, proportional to per unit of 
glucose below baseline 
𝑚𝑖𝑛−2 (𝑝𝑔/𝑚𝑙) 
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Thus a system of equations, adapted from Fitches (2015), for the model is 
introduced. 
𝑑𝐺
𝑑𝑡
= −𝑝1(𝐺(𝑡) − 𝐺𝑏) + 𝐺(𝑡)(𝑌(𝑡) − 𝑋(𝑡)),                              (3.4) 
𝑑𝑋
𝑑𝑡
= −𝑝2𝑋(𝑡) + 𝑝3(𝐼(𝑡) − 𝐼𝑏)
+,                                                    (3.5) 
𝑑𝐼
𝑑𝑡
= −𝑝4(𝐼(𝑡) − 𝐼𝑏) + 𝑝5(𝐺(𝑡) − 𝐺𝑏)
+𝑡,                                     (3.6) 
𝑑𝑌
𝑑𝑡
=  −𝑝6𝑌(𝑡) + 𝑝7(𝐸(𝑡) − 𝐸𝑏)
+,                                                 (3.7) 
𝑑𝐸
𝑑𝑡
= −𝑝8(𝐸(𝑡) − 𝐸𝑏) + 𝑝9(𝐺𝑏 − 𝐺(𝑡))
+
𝑡,                                 (3.8) 
 
 
Subject to the following initial conditions: 
(0) =  0, 𝑋(0) =  0, 𝐼(0) = 𝐼0 𝑌(0) = 0 𝐸(0) = 𝐸𝑏 
 
Where Y represents the glucagon activity on the liver, X represents the interstitial 
insulin activity and G, I and E are the quantities of glucose, insulin and glucagon in the 
plasma. Note 𝐸(0) = 𝐸𝑏 since both the initial insulin and glucose levels are high; 
therefore would inhibit excess glucagon production, so glucagon is assumed to be at 
the resting concentration at the beginning of the test. 
This model has increased complexity in comparison with the linear model, however is 
still relatively simple and minimalistic with respect to the terms used to describe the 
glucose regulatory processes.  The added complexity comes from the non-linear 
terms introduced into equation (3.4) to model the effects of the regulatory hormones 
on blood glucose through insulin in the interstitial space and glucagon action, rather 
than directly by the concentrations of the hormones themselves. Since the role of 
glucagon in an IVGTT is relatively small, the next model will investigate the effects on 
assuming the change in blood glucose levels to be linear proportional to the amount 
of glucagon in the blood, whilst maintaining non- linear glucose-insulin dynamics. 
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3.3.3. Linear Glucagon Minimal Model 
 
For the third system developed for modelling glucose-insulin-glucagon dynamics 
during an IVGTT, the term for cellular glucagon, (𝑡), will be removed, assuming that 
glucose production in response to an excess of glucagon is linearly proportional to the 
rise in plasma glucagon above the basal level. 
 
 
Figure 3.3: Compartment diagram of non-linear insulin and linear glucagon 
regulation of the glucose regulatory system 
The solid lines represent the constant rates, the dark blue dotted lines show 
signalling of blood glucose levels to the pancreas and the light blue dashed lines show 
the control actions on glucose levels. The mathematical description of the parameter 
rates are described in table 3.3. 
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Table 3.3. Linear Glucagon Minimal Model Nomenclature 
 
Variable Description Unit 
G Plasma glucose concentration 𝑚𝑔/𝑑𝑙 
X Interstitial insulin activity 𝑚𝑖𝑛−1 
I Plasma insulin concentration µ𝑈/𝑚𝑙 
Y Glucagon activity 𝑚𝑖𝑛−1 
E Plasma glucagon concentration 𝑝𝑔/𝑚𝑙 
𝑝1 Glucose Effectiveness 𝑚𝑖𝑛−1 
𝑝2 Decrease of glucose uptake ability in the 
peripherals 
𝑚𝑖𝑛−1 
𝑝3 Increase in peripheral glucose uptake ability, 
proportional to per unit of insulin above baseline 
𝑚𝑖𝑛−2 (µ𝑈/𝑚𝑙)−1 
𝑝4 Insulin clearance 𝑚𝑖𝑛−1 
𝑝5 Insulin secretion, proportional to per unit of 
glucose above baseline 
𝑚𝑖𝑛−2 (µ𝑈/𝑚𝑙) 
𝑝6 Glucagon Clearance 𝑚𝑖𝑛−1 
𝑝7 Glucagon secretion, proportional to per unit of 
glucose below baseline 
𝑚𝑖𝑛−2 (𝑝𝑔/𝑚𝑙) 
𝑝8 Glucagon stimulated glucose production (𝑚𝑔/𝑑𝑙) 𝑚𝑖𝑛−2 
 
 
The system of equations is given mathematically as: 
𝑑𝐺
𝑑𝑡
= −𝑝1(𝐺(𝑡) − 𝐺𝑏) − 𝐺(𝑡)𝑋(𝑡) + 𝑝8(𝐸(𝑡) − 𝐸𝑏),                    (3.9) 
𝑑𝑋
𝑑𝑡
= −𝑝2𝑋(𝑡) + 𝑝3(𝐼(𝑡) − 𝐼𝑏)
+,                                                        (3.10) 
𝑑𝐼
𝑑𝑡
= −𝑝4(𝐼(𝑡) − 𝐼𝑏) + 𝑝5(𝐺(𝑡) − 𝐺𝑏)
+𝑡,                                         (3.11) 
𝑑𝐸
𝑑𝑡
= −𝑝6(𝐸(𝑡) − 𝐸𝑏) + 𝑝7(𝐺𝑏 − 𝐺(𝑡))
+
𝑡,                                     (3.12) 
 
Subject to the following initial conditions: 
 
(0) = 𝐺0,   (0) = 0,   𝐼(0) = 𝐼0,   𝐸(0) =   𝐸𝑏. 
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3.4. Model Analyses 
 
This section will analyse the three models proposed mathematically, determining the 
critical points of the systems and reviewing the stability. 
3.4.1. Linear Model 
 
An autonomous differential equation is an equation in which the independent 
variable does not appear explicitly (Zill, 2013). Therefore, if it is the independent 
variable, a first-order differential equation may be written in normal form as 
𝑑𝑦
𝑑𝑡
= 𝑓(𝑦). 
 
To find the critical points of the linear model, equations (3.1-3.3) can be set to be 
equal to 0 and may be rewritten to give the following: 
𝐺∗ = 𝐺𝑏 +
𝑝2
𝑝1
∗ (𝐸∗ − 𝐸𝑏)
+ −
𝑝3
𝑝1
(𝐼∗ − 𝐼𝑏)
+,                              (3.13) 
𝐼∗ =
𝑝4
𝑝5
∗ (𝐺∗ − 𝐺𝑏)
+ + 𝐼𝑏,                                                                                         (3.14) 
𝐸∗ =
𝑝6
𝑝7
∗ (𝐺𝑏 − 𝐺
∗)+ + 𝐸𝑏 ,                                                             (3.15) 
Where G*, I* and E* represent the concentrations of glucose, insulin and glucagon at the 
equilibrium point respectively. 
Therefore it can be deduced that 
 
lim  (𝑡) = 𝐺𝑏,  lim  𝐼(𝑡) = 𝐼𝑏  𝑎𝑛𝑑   lim  𝐸(𝑡) = 𝐸𝑏. 
𝑡→ ∞ 𝑡→ ∞ 𝑡→ ∞ 
Resulting in an existing equilibrium point (𝐺𝑏, 𝐼𝑏, 𝐸𝑏). 
 
This means that after any perturbation to the system, for example a meal containing 
a large amount of carbohydrates, the system will always return back to its basal 
state. 
The linear model admits one equilibrium point, (𝐺𝑏,,𝐸𝑏), such that any solution to 
the system will converge towards it. Solutions and time derivatives of all three 
equations are all positive and bounded. 
The stability analysis of the linear glucagon model and all later linear or linearized 
versions of models proposed in the thesis will be determined by the Routh-
Hurwitz Critera (see definitions and abbreviations). 
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One form of stability analysis for linear systems is eigenvalue analysis (DeJesus and 
Kaufamn, 1987). In order to obtain the eigenvalues for the system, the 
characteristic equation must be determined, which can be found by the Jacobian 
matrix. The Jacobian matrix for the linear model is given by: 
J0  = 
(
 
 
d2G(t)
dtdG
d2G(t)
dtdI
d2G(t)
dtdE
d2I(t)
dtdG
d2I(t)
dtdI
d2I(t)
dtdE
d2E(t)
dtdG
d2E(t)
dtdI
d2E(t)
dtdE )
 
 
= (
−p1 −p3 p2
p4 −p5 0
−p6 0 −p7
)                           (3.16) 
Which can be written in the form of (3.17) as: 
(𝜆𝐼 − 𝐽0) = (
𝜆 + 𝑝1 −𝑝3 −𝑝2
−𝑝4 𝜆 + 𝑝5 0
−𝑝6 0 𝜆 + 𝑝7
)                                                     (3.17)     
  
Thus the characteristic polynomial is: 
𝑝(𝜆) = 𝜆3  + 𝜆2(𝑝7  + 𝑝5  + 𝑝1) + 𝜆(𝑝1𝑝5  + 𝑝1𝑝7  + 𝑝5𝑝7  − 𝑝3𝑝4  − 𝑝2𝑝6) − 𝑝2𝑝5𝑝6 
+ 𝑝1𝑝5𝑝7  − 𝑝3𝑝4𝑝7 = 0, (3.18) 
 
The roots were determined using the Roots function in Mathematica, an example of 
which can be found in Appendix C. The roots will not be written explicitly in this 
thesis due to the complexity and length of the values, however it is noted that these 
values are all negative, thus the stability criteria for the linear model holds. 
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3.4.2. Glucagon Minimal Model 
 
In mathematical analysis, non-dimensionalizing, or rescaling, is performed in order to 
simplify the equations by reducing the number of variables in the system, analyse the 
system behaviour with no regard to the units and to rescale the parameters and 
variables such that all quantities are of similar magnitudes (De Pillis, 2005). The 
simplified equations result in fewer parameters. This process reveals the dependence 
of the system on parameters or groups of parameters. 
In this section the glucagon Minimal Model will be non-dimensionalized in order to 
investigate the behaviour of the system. 
Table 3.4 consists of both the state variables and parameters in the system, defining 
their meanings, range of measurements in the specified units and their 
corresponding dimensions, given in the fundamental units; Mass (M), length (L) and 
time (T). 
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Table 3.4: Values, units and dimensions of variables and parameters in the Glucagon 
Minimal Model 
 
Symbol Description Unit Dimension 
M L T 
G(t) Plasma Glucose concentration at time 
t 
mg/dl (𝑚𝑔/𝐿−1) 1 -3 0 
I(t) Plasma Insulin concentration at time t µ𝑈/𝑚𝑙 1 -3 0 
X(t) Interstitial Insulin activity at time t 𝑚𝑖𝑛−1 0 0 -1 
Y(t) Glucagon activity at time t 𝑚𝑖𝑛−1 0 0 -1 
E(t) Plasma Glucagon concentration at 
time t 
pg/ml 1 -3 0 
𝑝1 𝐺𝑙𝑢𝑐𝑜𝑠𝑒 𝐸𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒𝑛𝑒𝑠𝑠 𝑚𝑖𝑛
−1 0 0 -1 
𝑝2 Rate of tissue glucose uptake ability 𝑚𝑖𝑛
−1 0 0 -1 
𝑝3 Rate of excess plasma insulin 
stimulated insulin activity 
𝑚𝑖𝑛−2 (µ𝑈/𝑚𝑙)−1 -1 3 -2 
𝑝4 Insulin disappearance 𝑚𝑖𝑛
−1 0 0 -1 
𝑝5 Rate of second phase insulin secretion 
(glucose dependent) 
(µ𝑈/𝑚𝑙) 𝑚𝑖𝑛−2 1 3 -2 
𝑝6 Rate of cellular glucose production 
ability 
𝑚𝑖𝑛−1 0 0 -1 
𝑝7 Rate of excess plasma glucagon 
stimulated glucagon activity 
(𝑝𝑔/𝑚𝑙) 𝑚𝑖𝑛−2 1 3 -2 
𝑝8 Glucagon clearance 𝑚𝑖𝑛
−1 0 0 -1 
𝑝9 Glucose dependent Glucagon secretion (𝑚𝑔/𝑑𝐿) 𝑚𝑖𝑛
−2 0 0 -2 
𝐺𝑏 Baseline plasma glucose concentration mg/dl 1 -3 0 
𝐼𝑏 Baseline plasma insulin concentration µ𝑈/𝑚𝑙 1 -3 0 
𝐸0  = 𝐸𝑏 Baseline plasma glucagon 
concentration 
ng/dl 1 -3 0 
𝐺0 Initial plasma glucose concentration mg/dl 1 -3 0 
𝐼0 Initial plasma insulin concentration µ𝑈/𝑚𝑙 1 -3 0 
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Therefore   in   total   there   are   5   variables   (G,   X,   I,   E,  Y)   and   14   parameters 
(𝑝1, 𝑝2, 𝑝3, 𝑝4, 𝑝5, 𝑝6, 𝑝7, 𝑝8, 𝑝9, 𝐺𝑏, 𝐼𝑏, 𝐸𝑏, 𝐺0, 𝑎𝑛𝑑 𝐼0 ), giving the system a total of 19 
quantities, in 3 fundamental dimension units, and a degree of freedom (DOF) of 11, as 
determined by the Buckingham π theorem taken from Van Groesen and Molenaar 
(2007). 
Since there are more than 4 variables and only 3 dimensional quantities, a unique 
relation between the variables cannot be found. Therefore we are required to refer to 
dimensionless groups of variables, in this case 2 dimensionless groups (number of 
variables – numbers of dimensions). 
There is no unique definition for the procedure of constructing a set of dimensionless 
quantities, however it is beneficial to formulate a set that is meaningful, that 
simplifies the equations (Nittala et al, 2006) and aims to reduce the number of 
parameters (Van Groesen and Molenaar, 2007). 
Therefore an optimal scaling for the plasma concentrations for glucose and the two 
hormones would be  ?̃? =
𝐺
𝐺𝑏
, ?̃? = 𝑋𝜏, 𝐼 =
𝐼
𝐼𝑏
, Ỹ = Yτ and ?̃? =
𝐸
𝐸𝑏 
. 
The rescaling of variables is chosen to simplify the equations, therefore the 
baseline values were chosen for chose the three measurable quantities, whereas 
interstitial insulin and glucagon activity were rescaled by time, consistently 
with the work of Nittala et al. (2006). 
Since interstitial insulin and glucagon activity cannot be measured like the other 
three state variables, they need to be solved. Therefore, the equation can be 
rearranged and solved by the integrating factor method as follows. 
Rewriting the equations (3.17) and (3.19) for interstitial insulin into the form 
 
𝑑𝑦 
+ (𝑡) ∗ (𝑡) = 𝑓(𝑡), (3.19) 
𝑑𝑡 
 
Gives the following 
𝑑𝑋
𝑑𝑡
+ 𝑝2 ∗ 𝑋(𝑡) = 𝑝3 ∗ (𝐼(𝑡) − 𝐼𝑏),                                                (3.20) 
𝑑𝑌
𝑑𝑡
+ 𝑝6 ∗ 𝑌(𝑡) = 𝑝7 ∗ (𝐸(𝑡) − 𝐸𝑏),                                              (3.21) 
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Setting the integrating factors, 𝑚𝑋(𝑡) 𝑎𝑛𝑑 𝑚𝑦(𝑡), as 
 
𝑚𝑥(𝑡) = 𝑒(𝑝2 ∫ 𝑑𝑡)  = 𝑒𝑝2𝑡, (3.22) 
𝑚𝑦(𝑡) = 𝑒(𝑝6 ∫ 𝑑𝑡)  = 𝑒𝑝6𝑡,  (3.23) 
 
The integrating factors are then substituted into the formula (Munkhammar, no date).  
𝑦(𝑡) =
1
𝑚(𝑡)
∗ (∫𝑚(𝑡) ∗ 𝑓(𝑡)𝑑𝑡),                                                         (3.24) 
Resulting in the following solutions for insulin and glucagon activity 
𝑋(𝑡) =  𝑒−𝑝2𝑡 ∗ (𝑝3 ∗ ∫ 𝑒
𝑝2𝜏 ∗ (𝐼(𝜏) − 𝐼𝑏)𝑑𝜏
𝑡
0
),                                (3.25) 
𝑌(𝑡) =  𝑒−𝑝6𝑡 ∗ (𝑝7 ∗ ∫ 𝑒
𝑝6𝜏 ∗ (𝐸(𝜏) − 𝐸𝑏)𝑑𝜏
𝑡
0
),                                (3.26) 
Since this model has been developed to analyse the results of a frequently sampled 
intravenous tolerance test (FSIVGTT) it can be assumed that 𝑋(0) = 𝑌(0) =0, as it is 
assumed that the test is started when the individual is in the basal state. 
The dimensional variables are rescaled to give the following dimensionless variables: 
𝑡 = 𝜏 ∗ 𝑇, 𝐺 = ?̃? ∗ 𝐺𝑏 , 𝐼 = 𝐼 ∗ 𝐼𝑏 , 𝐸 = ?̃? ∗ 𝐸𝑏 𝑎𝑛𝑑 𝑋 =
?̃?
𝜏
   
Given that 
𝑑
𝑑𝑡
=
𝑑
𝑑𝑇
 →
𝑑𝑇
𝑑𝑡
=
1
𝜏
∗
𝑑
𝑑𝑇
, by replacing the variables in the original system (equations 
5.10 – 5.13) with the new variables, the system can now be rewritten in dimensionless form 
as: 
𝑑?̃?
𝑑𝑡
= −𝑝1 ∗ 𝜏 ∗ (?̃? − 1) − ?̃? ∗ (𝐼 − ?̃?),                                                   (3.27) 
𝑑?̃?
𝑑𝑡
= −𝑝2 ∗ 𝜏 ∗ ?̃? + 𝑝3 ∗ 𝜏
2 ∗ 𝐼𝑏 ∗ (𝐼 − 1)
+,                                            (3.28) 
𝑑𝐼
𝑑𝑡
= −𝑝4 ∗ 𝜏 ∗ (𝐼 − 1) +
𝑝5 ∗ 𝐺𝑏 ∗ 𝜏
2 ∗ (?̃? − 1)
+
𝐼𝑏
,                                (3.29) 
𝑑?̃?
𝑑𝑡
= −𝑝6 ∗ 𝜏 ∗ ?̃? + 𝑝7 ∗ 𝜏
2 ∗ 𝐸𝑏 ∗ (?̃? − 1)
+
,                                           (3.30) 
𝑑?̃?
𝑑𝑡
=  −𝑝8 ∗ 𝜏 ∗ (?̃? − 1) +
𝑝9 ∗ 𝐺𝑏 ∗ 𝜏
2 ∗ (1 − 𝐺 ̃)
+
𝐸𝑏
,                              (3.31) 
Nittala et al. (2006) identify the two natural time scales in the minimal model used for the 
FSIVGTT to be glucose disappearance, 
1
 𝑝1
 , and insulin disappearance, 
1
𝑝4
. This suggests that 
from the addition of glucagon into this model there is a third time scaled to be considered in 
this model as glucagon disappearance, 
1
𝑝8
 . 
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Therefore, by using glucagon disappearance to rescale the tie variable such that 𝜏 = 𝑝8𝑡, the 
system now becomes: 
𝑑?̃?
𝑑𝑡
= −𝑝1̃ ∗ (?̃? − 1) + (?̃? − ?̃?) ∗ ?̃?,                                      (3.32) 
𝑑?̃?
𝑑𝑡
= −𝑝2̃ ∗ ?̃? + 𝑝3̃ ∗ (𝐼 − 1)
+,                                                (3.33) 
𝑑𝐼
𝑑𝑡
= −𝑝4̃ ∗ (𝐼 − 1) + 𝑝5̃ ∗ (?̃? − 1)
+
,                                      (3.34) 
𝑑?̃?
𝑑𝑡
= −𝑝6̃ ∗ ?̃? + 𝑝7̃ ∗ (?̃? − 1)
+
,                                                 (3.35) 
𝑑?̃?
𝑑𝑡
=  −(?̃? − 1) + 𝑝9̃ ∗  (1 − ?̃?)
+
,                                           (3.36)  
 
where  ?̃? =
𝐺
𝐺𝑏
, 𝐼 =
𝐼
𝐼𝑏
, ?̃? =
𝐸
𝐸𝑏
, 𝑝1̃ =
𝑝1
𝑝8
, 𝑝2̃ =
𝑝2
𝑝8
, 𝑝3̃ =
𝑝3∗𝐼𝑏
𝑝8
2 , 𝑝4̃ =
𝑝4
𝑝8
, 𝑝5̃ =
𝑝5∗𝐺𝑏
𝑝82∗𝐼𝑏
, 𝑝6̃ =
𝑝6
𝑝8
, 𝑝7̃ =
𝑝7∗𝐸𝑏
𝑝8
2  and 𝑝9̃ =
𝑝9∗𝐺𝑏
𝑝8
2∗𝐸𝑏
. The initial conditions become: ?̃?(0) =
𝐺0
𝐺𝑏
, X̃(0) = 0, 𝐼(0) =
𝐼0
𝐼𝑏
. ?̃? =
0 and ?̃? =
𝐸𝑏
𝐸𝑏
= 1. 
Therefore the free, unitless parameters comprise of: 𝑝1̃, 𝑝2̃, 𝑝3̃, 𝑝4̃, 𝑝5̃, 𝑝6̃, 𝑝7̃, 𝑝9̃, 𝐺0̃ and 𝐼0̃. 
This indicates a DOF of 10, rather than 11 as given by the Buckingham-𝜋 theorem, however 
this quantity is one less due to the assumption that 𝐸0  = 𝐸𝑏. 
The key parameters now change to 𝑆?̃? = 𝑝1̃ =
𝑝1
𝑝8
, 𝑆?̃? =
𝑝3̃
𝑝2̃
=
𝑝3𝐼𝑏
𝑝2𝑝8
 𝑎𝑛𝑑 𝑆?̃? =
𝑝7̃
𝑝6̃
=
𝑝7𝐸𝑏
𝑝6𝑝8
.
Glucose effectiveness now becomes glucose disappearance over glucose independent 
glucagon production, insulin sensitivity now is dependent on insulin sensitivity, basal 
insulin secretion and glucagon clearance, and the glucagon sensitivity index is now 
influenced by basal glucagon and glucose independent production. 
In order to ensure that the system is autonomous, it can clearly be seen that the critical 
point must be (1,0,1,0,1). This refers to when the system is in a resting state, i.e. plasma 
glucose and hormone concentrations are at their basal levels. 
 
In order to determine the stability of the system, the linearized system, given by 
equations (3.32)-(3.36), is analysed. 
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The Jacobian Matrix evaluated at the critical point (1,0,1,0,1), is given by: 
 
𝐽1 = 
(
 
 
 
−𝑝 1̃ −1 0 1 0
0 −𝑝 ̃2 𝑝 ̃3 0 0
0 0 −𝑝 ̃4 0 0
0 0 0 −𝑝 ̃6 𝑝 ̃7
0 0 0 0 −𝑝 ̃8 )
 
 
 
                            (3.37) 
 
Since 𝐽1 is an upper triangular matrix, the eigenvalues are given by the entries on its 
main diagonal and are: 
𝜆1,1  = −𝑝1, 𝜆1,2  = −𝑝2, 𝜆1,3  = −𝑝4, 𝜆1,4  = −𝑝6, 𝜆1,5  = −𝑝8 
 
Note that all roots of the characteristic equation are negative, therefore the system is 
stable. 
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3.4.3. Linear Glucagon Minimal Model 
 
In this section the third model formulated to consider glucose-insulin-glucagon 
dynamics in an IVGTT is non-dimensionalized, in a similar manner to the Glucagon 
Minimal Model in section 3.4.2, in order to investigate the behaviour of the system. 
Non-dimensionalizing the system will enable the system to be described with fewer 
parameters by transforming the variables and parameters to simplify the equations. 
The process reveals the dependence of the system on parameters or groups of 
parameters. 
The following table consists of both the state variables and parameters in the system, 
defining their meanings, range of measurements in the specified units and their 
corresponding dimensions, given in the fundamental units; Mass (M), length (L) and 
time (T). 
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Table 3.5: Values, units and dimensions of variables and parameters in the Linear 
Glucagon Minimal Model. 
 
Symbol Description Unit Dimension 
M L T 
G(t) Plasma Glucose concentration at time t mg/dl 1 -3 0 
I(t) Plasma Insulin concentration at time t µ𝑈/𝑚𝑙 1 -3 0 
X(t) Interstitial Insulin activity at time t 𝑚𝑖𝑛−1 0 0 -1 
E(t) Plasma Glucagon concentration at time t pg/ml 1 -3 0 
𝑝1 𝐺𝑙𝑢𝑐𝑜𝑠𝑒 𝐸𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒𝑛𝑒𝑠𝑠 𝑚𝑖𝑛
−1 0 0 -1 
𝑝2 Decrease of tissue glucose uptake ability 𝑚𝑖𝑛−1 0 0 -1 
𝑝3 Insulin dependent tissue glucose uptake 
ability 
𝑚𝑖𝑛−2 (µ𝑈/𝑚𝑙)−1 - 
1 
3 -2 
𝑝4 Rate of (µ𝑈/𝑚𝑙) 𝑚𝑖𝑛
−2 0 0 -2 
𝑝5 Insulin disappearance 𝑚𝑖𝑛
−1 0 0 -1 
𝑝6 Glucose dependent Glucagon secretion (𝑝𝑔/𝑚𝑙) 𝑚𝑖𝑛
−2 0 0 -2 
𝑝7 Glucagon clearance 𝑚𝑖𝑛
−1 0 0 -1 
𝑝8 Glucagon dependent glucose secretion (𝑝𝑔/𝑚𝑙) 𝑚𝑖𝑛
−2 0 0 -2 
𝐺𝑏 Baseline plasma glucose concentration mg/dl 1 -3 0 
𝐼𝑏 Baseline plasma insulin concentration µ𝑈/𝑚𝑙 1 -3 0 
𝐸0  = 𝐸𝑏 Baseline plasma glucagon concentration pg/ml 1 -3 0 
𝐺0 Initial plasma glucose concentration mg/dl 1 -3 0 
𝐼0 Initial plasma insulin concentration µ𝑈/𝑚𝑙 1 -3 0 
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In total there are 4 variables (G, X,  I, E)  and 13 parameters (𝑝1, 𝑝2, 𝑝3, 𝑝4, 𝑝5, 𝑝6, 𝑝7, 
𝑝8, 𝐺𝑏, 𝐼𝑏, 𝐸𝑏, 𝐺0, 𝑎𝑛𝑑 𝐼0 ), giving the system a total of 17 quantities, in 3 fundamental 
dimension units, and a DOF of 10. From the π-theorem of Buckingham (Van Groesen 
and Molenaar, 2007) it can be determined that the system can be described with 14 
dimensionless quantities: 
(G, X, I, E, 𝑝1, 𝑝2, 𝑝3, 𝑝4, 𝑝5, 𝑝6, 𝑝7, 𝑝8, 𝐺𝑏, 𝐼𝑏, 𝐸𝑏, 𝐺0, 𝐼0  ) (3.38) 
 
Between the variables and parameters of a mathematical model can be replaced with 
the corresponding relation between the dimensionless quantities 𝑞𝑖: 
𝑓∗(𝑞1, … . . , 𝑞14) = 0 (3.39) 
 
In section 3.4.2. it was determined that since interstitial insulin and glucagon activity 
cannot be measured like the other three state variables, they needed to be solved. 
This model does not include glucagon activity; however the same approach will be 
required for interstitial insulin, such that it becomes equation (3.20). 
The dimensional variables are rescaled to give the following dimensionless variables: 
 
𝑡 = 𝜏 ∗ 𝑇, 𝐺 = ?̃? ∗ 𝐺𝑏 , 𝐼 = 𝐼 ∗ 𝐼𝑏 , 𝐸 = ?̃? ∗ 𝐸𝑏 𝑎𝑛𝑑 𝑋 =
?̃?
𝜏
   
Given that 
𝑑
𝑑𝑡
=
𝑑
𝑑𝑇
 →
𝑑𝑇
𝑑𝑡
=
1
𝜏
∗
𝑑
𝑑𝑇
, by replacing the variables in the original system 
5.10 – 5.13) with the new variables, the system can now be rewritten in 
dimensionless form as: 
𝑑?̃?
𝑑𝑇
= −𝑝1 ∗ 𝜏 ∗ (?̃? − 1) − ?̃? ∗ ?̃? +
𝑝8 ∗ 𝐸𝑏 ∗ 𝜏
𝐺𝑏
∗ (?̃? − 1)
+
,                      (3.40) 
𝑑?̃?
𝑑𝑇
= −𝑝2 ∗ 𝜏 ∗ ?̃? + 𝑝3 ∗ 𝜏
2 ∗ 𝐼𝑏 ∗ (𝐼 − 1)
+,                                                   (3.41) 
𝑑𝐼
𝑑𝑇
= −𝑝4 ∗ 𝜏 ∗ (𝐼 − 1) +
𝑝5 ∗ 𝐺𝑏 ∗ 𝜏
2 ∗ 𝑇
𝐼𝑏
∗ (?̃? − 1)
+
,                                (3.42) 
𝑑?̃?
𝑑𝑇
= −𝑝6 ∗ 𝜏 ∗  (?̃? − 1) +
𝑝7 ∗ 𝐺𝑏 ∗ 𝜏
2 ∗ 𝑇
𝐸𝑏
∗ (1 − ?̃?)
+
,                               (3.43) 
?̃?(0) =
𝐺0
𝐺𝑏
= 𝐺0̃, 𝐼(0) =
𝐼0
𝐼𝑏
= 𝐼0̃, ?̃?(0) =
𝐸𝑏
𝐸𝑏
= 1, 𝑋(0) = 0.  
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As discussed in section 3.4.2 there are three natural time scales for this system, each for 
glucose clearance, insulin clearance and glucagon clearance. By setting 𝜏 =
1
𝑝4
, the system is 
rescaled for insulin disappearance and can be rewritten as: 
𝑑?̃?
𝑑𝑇
= −𝑝1̃ ∗ (?̃? − 1) − ?̃? ∗ ?̃? + 𝑝8̃ ∗ (?̃? − 1)
+
,                               (3.44) 
𝑑?̃?
𝑑𝑇
= − 𝑝2̃ ∗ ?̃? + 𝑝3̃ ∗ (𝐼 − 1)
+,                                                            (3.45) 
𝑑𝐼
𝑑𝑇
= −(𝐼 − 1) + 𝑝5̃ ∗ (?̃? − 1)
+
,                                                           (3.46) 
𝑑?̃?
𝑑𝑇
= −𝑝6̃ ∗  (?̃? − 1) + 𝑝7̃ ∗ (1 − ?̃?)
+
,                                                (3.47) 
where the dimensionless parameters are defined as:   
𝑝1̃ =
𝑝1
𝑝4 ,
𝑝2̃ =
𝑝2
𝑝4
 , 𝑝3̃ =
𝑝3
𝑝4 
2 ∗ 𝐼𝑏 ,     𝑝5̃ =
𝑝5 ∗ 𝐺𝑏 ∗ 𝑇
𝐼𝑏 ∗ 𝑝4
2 , 𝑝6̃ =
𝑝6
𝑝4
,
𝑝7̃ =
𝑝7 ∗ 𝐺𝑏 ∗ 𝑇
𝐸𝑏 ∗ 𝑝4
2 ,   and    𝑝8̃ = 
𝑝8 ∗ 𝐸𝑏
𝐺𝑏 ∗ 𝑝4
. 
Therefore the free, unitless parameters comprise of  𝑝1̃,  𝑝2̃,  𝑝3̃,  𝑝5̃,  𝑝6̃,  𝑝7̃,  𝑝8̃, 𝐺0̃ 𝑎𝑛𝑑 𝐼0̃. 
This indicates a DOF of 9, rather than 10 as given by the Buckingham-𝜋 theorem, however 
this quantity is one less due to the assumption that 𝐸0  = 𝐸𝑏. 
The key parameters now change to  𝑆?̃? =  𝑝1̃ 𝑎𝑛𝑑   𝑆?̃? =
𝑝3̃
𝑝2̃
=
𝑝3𝐼𝑏
𝑝2𝑝4.
. Glucose effectiveness now 
becomes glucose disappearance and insulin clearance and insulin sensitivity now is 
dependent on insulin sensitivity, basal insulin secretion and glucose independent insulin 
production. 
It can easily be seen that ?̃?(𝑇) = 1 must be at a critical point to ensure autonomy in the 
system. 
This reduces the remaining equations of the dimensionless system to: 
 
𝑑?̃?
𝑑𝑇
= −𝑝2̃ ∗ ?̃? + 𝑝3̃ ∗ (𝐼 − 1)
+,                                          (3.48) 
𝑑𝐼
𝑑𝑇
=  −𝑝4̃ ∗ (𝐼 − 1),                                                              (3.49) 
𝑑?̃?
𝑑𝑇
=  −𝑝6̃ ∗ (?̃? − 1),                                                            (3.50)  
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Therefore it can be determined that the critical point for the dimensionless system must be: 
?̃?(𝑇) = 1, ?̃?(𝑇) = 0, 𝐼(𝑇) = 1, ?̃?(𝑇) = 1. In physical terms this point represents the 
individual at their basal metabolic rate, i.e. a post-absorptive state at rest and not under any 
form of physiological or mental stress. 
The Jacobian Matrix is evaluated at the critical point for the dimensional system, 
rescaled for insulin disappearance (3.44-3.47), and given as : 
= (
−𝑝1̃ −1 0 𝑝8̃ 
0 −𝑝2̃ 𝑝3̃ 0
𝑝5̃ 0 −𝑝4̃ 0
−𝑝7̃ 0 0 −𝑝6̃
)                                                     (3.51) 
 
det(𝐽2 − 𝐼𝜆) =  (
−𝑝1̃ − 𝜆 −1 0 𝑝8̃
0 −𝑝2̃ − 𝜆 𝑝3̃ 0
𝑝5̃ 0 −𝑝4̃ − 𝜆 0
−𝑝7̃ 0 0 −𝑝6̃ − 𝜆
) = 0                              (3.52) 
Using Mathematica, the characteristic equation was calculated as: 
𝑑𝑒𝑡(𝐽2 − 𝐼𝜆) =  𝑝7̃ (𝑝2̃
2𝑝4̃ + 𝑝2̃
2 𝜆 + 𝑝2̃𝑝4̃ 𝑥 + 𝑝2̃ 𝜆
2) 
+(𝑝6̃ − 𝑥)(−𝑝3̃ 𝑝5̃ + (−𝑝4̃ − 𝜆)(𝑝1̃ 𝑝2̃ + 𝑝1̃ 𝜆 + 𝑝2̃ 𝜆 + 𝜆
2)) = 0          (3.53)  
The roots of the equation (3.53) were solved in Mathematica to give the eigenvalues 
for the matrix (3.51). (See appendix C for an example code). The eigenvalues were all 
negative, confirming the stability of the system. 
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3.5. Model Simulations 
 
The models are solved using the inbuilt MATLAB solver ODE45, based on explicit 
Runge-Kutta methods. The value of the parameters are solved within MATLAB 
using the LSQNONLIN function. Initial parameter values were based on those 
available within literature (Cobelli et al. 1998), (Roy and Parker, 2007), (McDonald 
et al., 2000), Aguilera Gonzalez and Darouach, 2015), the LSQNONLIN solver then 
used these values to determine the optimal set of parameters to fit the data set 
(table 3.2 found in the appendix) of glucose and insulin measurements obtained 
during a frequently sampled intravenous glucose tolerance test (FSIVGTT) from a 
healthy individual (Pacini and Bergman, 1986). 
The initial concentrations for plasma glucose and insulin were estimated using 
starting values and bounds based on Pacini and Bergman’s (1986) MINMOD program. 
Since during a FSIVGTT an individual is considered to be in the fed state, minimal 
glucagon action is assumed, thus set 𝐸0  = 𝐸𝑏. Measurements for basal Insulin, 
Ib, Glucose, Gb, and Glucagon, Eb, were taken from Wolfe et al. (1986). (Ib  = 13.2  ± 
1.4 (µU⁄mL), Gb = 92.5 ± 6.09 (mg⁄dL) and Eb = 142 ± 36 (pg⁄mL).) The 
remaining parameters were constrained with lower and upper bounds based on 
findings in literature where available. The parameters for the models containing 
glucagon activity and/or plasma glucagon were calculated based on the starting 
values for the insulin counterparts; however constraints on the lower and upper 
bounds were decreased due to the limited information available in literature. 
Tables with the parameter values can be found in appendix B. 
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3.5.1. Plasma Glucose 
Figure 3.4 shows the ability of all three proposed models to produce an accurate fit to 
the dataset for plasma glucose measurements. Out of the three models , The Linear 
Model (a) is the poorest to fit the dataset, as it assumes glucose levels to fall slightly 
too quickly in the initial ten minutes and shows glucose levels to gradually decline 
until reaching the basal level. The other two models capture the initial decline and 
manage to account for plasma glucose undershooting the basal level, which are then 
restored by glucagon action. It can be seen that The Glucagon Minimal Model (b) 
provides the most accurate fit.
(a) (b) 
(c) 
Figure 3.4: Simulations of plasma glucose concentrations during an IVGTT: The 
Linear Model (a), The Glucagon Minimal Model (b) and The Linear Glucagon 
Minimal Model (c). 
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3.5.2. Interstitial Insulin 
The predictions for interstitial insulin of both of the models are of a similar 
magnitude to the Minimal Model and follow the behaviour of insulin. The Glucagon 
Minimal Model (a) is much faster to reach a peak of insulin activity and is cleared 
from the system faster than in the Linear Glucagon Minimal Model (b), suggesting a 
slightly greater sensitivity to insulin. 
 
Figure 3.5: Simulations of interstitial insulin activity during an IVGTT: The Glucagon 
Minimal Model (a) and The Linear Glucagon Minimal Model (b). 
(a) (b) 
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3.5.3. Plasma Insulin 
The Linear Glucagon Model does not capture the biphasic release of insulin, plotting a 
smooth curve as the insulin concentration returns to the basal level. This result is 
inadequate for modelling insulin dynamics as it has long been observed that high levels 
of glucose induce a biphasic release of insulin (Taguchi et al., 1995), (Henquin et al., 
2002). 
 
Linear Model (a), The Glucagon Minimal Model (b) and The Linear Glucagon Minimal 
Model (c) 
Both the Glucagon Minimal Model (a) and Linear Glucagon Minimal Model (b) fit the 
data for plasma insulin measurements well and demonstrate the biphasic behaviour 
as observed for insulin release. These results suggest that linear dynamics are not 
sufficient for modelling the glucose-insulin relationship. 
(a) (b) 
Figure 3.6: Simulations of plasma insulin conce 
(c)
ntrations during an IVGTT: The 
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3.5.4. Glucagon Activity 
 
Figure 3.7: Simulation of The Glucagon Minimal Model for glucagon activity during 
an IVGTT. 
The Glucagon Minimal Model is the only model that considers glucagon activity. If 
it is compared with the results for plasma glucagon for the Glucagon Minimal 
Model (figure 3.8.b) it is clearly seen that glucagon activity begins to increases after 
a slight delay of a couple of minutes following the rise in the plasma glucagon 
concentration. By comparing glucagon activity to interstitial insulin (figure 3.5.a) it 
is apparent that the level of glucagon activity following a fall in glucose levels is 
much smaller than the response of interstitial insulin activity to excessive glucose 
in the initial hour of the test.  This result is reasonable due to the magnitude in 
which glucose exceeded the basal level in comparison to the amount it fell below 
the basal level. 
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3.5.5. Plasma Glucagon 
 
Figure 3.8: Simulations for plasma glucagon concentrations during an IVGTT: The 
Linear Glucagon Model (a), The Glucagon Minimal Model (b) and The Linear Glucagon 
Minimal Model (c). 
Since the data set used to validate the model did not contain measurements for 
plasma glucagon, the results have been validated in a more qualitative manner, and 
compared to the results shown by Thomaseth el at. (2014), in which showed an hour 
following the IVGTT plasma glucagon concentrations rose by approximately 30% of 
the basal rate. Clearly the linear model is incapable of predicting such a result, 
showing plasma glucagon not to rise above the basal level at any point. Both the 
Glucagon Minimal Model (b) and the Linear Glucagon Model (c) show the expected 
increase in plasma glucagon concentrations an hour following the intravenous 
glucose administration. However, the magnitude in which the Glucagon Minimal 
(a) 
(b) 
(c) 
46  
Model demonstrates for the increase in glucagon is very minimal, and does not 
correspond with findings in literature. Therefore the Linear Glucagon Minimal Model 
is by far the most accurate model in its ability to predict plasma glucagon 
concentrations during an IVGTT. 
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3.5.6. Dimensionless Glucagon Minimal Model 
 
The dimensionless system was solved in Matlab using ODE45, with the parameters 
fitted to the dimensionless data set of Pacini and Bergman (1986). The system was 
rescaled three times, for each of the recognised time scales; glucose disappearance, 
insulin disappearance and glucagon disappearance. 
The plots in figure 3.9 show the solutions of the dimensionless model rescaled for 
glucagon clearance, given by equations (3.33-3.37). 
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) (c) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(d) (e) 
 
Figure 3.9: Simulations of dimensionless plasma glucose, G(t), against plasma 
glucose measurements (a), plasma insulin, I(t), against plasma insulin 
measurements (b), interstitial insulin, X(t), (c), plasma glucagon, E(t), (e) and 
glucagon activity, Y(t), (d) during an IVGTT. Both data and model have been 
rescaled for glucagon clearance. 
The dimensionless simulation shows similar behaviour to the dimensional model, 
with both insulin (b) and glucose (a) showing a good fit to the dimensionless data. 
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The non-dimensional simulation for plasma glucagon (c) highlights the minimal 
increase in concentrations. 
The dimensional parameter values were calculated from the non-dimensional 
simulation as shown in table 3.6. 
Table 3.6: Comparisons of parameter values for dimensionless Glucagon Minimal 
Model, rescaled for glucose clearance, insulin clearance and glucagon clearance. 
 
Parameter Dimensional 
Value 
Non-Dimensional 
value rescaled by 
𝝉 =  
𝟏 
𝒑𝟏 
Non-Dimensional 
value rescaled by 
𝝉 =  
𝟏 
𝒑𝟒 
Non-Dimensional 
value rescaled by 
𝝉 =  
𝟏 
𝒑𝟖 
𝑆𝐺   = 𝑝1 0.02058 0.01756659 0.0094137 0.00941386 
𝑝2 0.02218 0.11408124 0.0373353 0.037336576 
𝑝3 0.000014 0.00003604 0.0000201 0.000020156 
𝑝4 0.32 0.03563689 0.2783405 0.278343671 
𝑝5 0.0032 0.00630156 0.0033421 0.003342215 
𝑝6 0.142 1.1440989 0.7025258 0.702525919 
𝑝7 0.000217 0.06857451 0.0079650 0.007964075 
𝑝8 0.0494 0.04687327 0.499999 0.5 
𝑝9 0.000018 0.00153339 0.0000245 0.00001 
𝑆𝐼 0.000617 0.00031591 0.0005399 0.00053928 
𝑆𝐸 0.001528 0.0599379 0.0153990 0.0113 
𝐺0 293 292 279 279 
𝐼0 360 366 360 360 
 
 
Rescaling the dimensionless model for both insulin clearance and glucagon clearance 
return similar parameter values for both insulin sensitivity and glucose effectiveness, 
which are slightly less than the dimensional values, whereas the returned values for 
glucagon effectiveness are very close to the dimensional value. 
In comparison, scaling the model for either glucose clearance results in higher values 
for both glucose effectiveness and glucagon sensitivity, but lower values for insulin 
sensitivity than the other two scalings. 
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Table 3.??: Comparisons of parameter values for dimensionless Linear Glucagon 
Minimal Model, rescaled for glucose clearance, insulin clearance and glucagon 
 
 
 
 
3.5.7. Dimensionless Linear Glucagon Minimal Model 
 
The dimensionless system was solved in MATLAB using ODE45, with the parameters 
fitted to the dimensionless data set of Pacini and Bergman (1986). The system was 
rescaled three times, for each of the recognised time scales; glucose disappearance, 
insulin disappearance and glucagon disappearance. 
The plots in figure 3.9 show the solutions of the dimensionless model rescaled for 
insulin clearance, given by equations (3.44-3.47). 
 
 
 
 
 
 
 
 
 
 
 
 
(a) (b) 
 
(c) 
 
(d) 
 
 
Figure 3.10: Simulations of Linear Glucagon Minimal Model during an IVGTT. The 
simulations are plotted as follows: Plasma glucose, G(t), against plasma glucose 
measurements (a), pl sma glucag n, E(t), (b).plasma sulin, I(t), gainst plasma insulin 
measurements (c), and interstitial insulin activity, X(t), (d). 
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The model shows a very good fit to the dimensionless data for glucose (a), but rather 
a poor fit for insulin (c). However the increase in glucagon is as closer to the increase 
expected based on the findings of Thomaseth et al. (2014), as it increases by almost 
20% from its basal value. 
Table 3.7: Comparisons of parameter values for dimensionless Linear Glucagon 
Minimal Model, rescaled for glucose clearance, insulin clearance and glucagon 
clearance. 
 
Parameter Dimensional 
Value 
Non-Dimensional 
value rescaled by 
𝝉 =  
𝟏 
𝒑𝟏 
Non-Dimensional 
value rescaled by 
𝝉 =  
𝟏 
𝒑𝟒 
Non-Dimensional 
value rescaled by 
𝝉 =  
𝟏 
𝒑𝟔 
𝑆𝐺   = 𝑝1 0.02808122 0.01997831 0.0153103 0.0150861 
𝑝2 0.00996122 0.0144932 0.0231139 0.02259839 
𝑝3 7.31888 
∗ 10−6 
0.0000108854 0.00001459 0.000014613 
𝑝4 0.27943170 0.20202604 0.22646731 0.212060508 
𝑝5 0.00290469 0.00197596 0.0023889 0.002129929 
𝑝6 0.19225742 0.485124233 0.1222461 0.221008791 
𝑝7 0.00364470 0.002605806 0.00124715 0.00152487 
𝑝8 0.01530144 0.037376378 0.0116759 0.01809859 
𝑆𝐼 7.34737 
∗ 10−4 
0.000751068 0.00063153 0.000646669 
𝐺0 293 282 279 282 
𝐼0 360 411 406 410 
 
 
Rescaling the dimensionless model for all three parameter values resulted in lower 
values for glucose effectiveness, whereas the values for insulin sensitivity did not 
vary much. Interestingly, the starting values were all considerably different to the 
dimensional model. 
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3.6. Results and Discussion 
 
This section compares the results obtained from the three proposed models for 
glucose-insulin-glucagon dynamics during an IVGTT. The models are assessed based 
on how well they fit the datasets, how the behaviour of glucose and the hormones 
compared to what is supposed from evidence obtained from previous studies and 
how the values for the key parameters compare to the acceptable ranges as specified 
within literature. 
The linear model is the simplest of the three, consisting of 4 less quantities than the 
Glucagon Minimal Model and 3 less than the Linear Glucagon Minimal Model. It is 
beneficial in that it can be solved analytically and also provided a very good fit to the 
plasma measurements for glucose. However, the fit to plasma insulin measurements 
was of a poor quality, and the simulation for plasma glucagon was deemed unrealistic. 
The Glucagon Minimal Model was the best model to fit the data for plasma glucose 
and provided an equally good fit as the Linear Glucagon Minimal Model. Its only 
downfall is the one extra quantity to be considered than the Linear Glucagon Minimal 
Model and the results for plasma glucagon; despite showing the correct behaviour the 
response was of an insufficient magnitude. 
The Linear Glucagon Minimal Model provided a good fit to both of the plasma 
measurements and was able to capture glucagon behaviour. The Glucagon Minimal 
Model did slightly outperform the model for plasma glucose as the Linear Glucagon 
Minimal Model did not capture the levels undershooting the basal value quite as well. 
The reasonable given range of glucose effectiveness is given as 0.8 − 3.8 x 10−2 
(McDonald et al., 2000), which all returned model parameter values are within. It can 
be seen that the more complex the model is and the more non-linear terms a model 
has, the lower the value of glucose effectiveness. This may be due to the effects of the 
terms of glucagon contributing towards hepatic glucose production. 
Insulin sensitivity for a healthy individual is typically around 5 x 10−4 (Pacini and 
Bergman, 1986). The Linear model is not capable of calculating a value for insulin 
sensitivity; however the other models are within reasonable magnitude of the 
stated value. 
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Since there is a limited number of mathematical models for the glucose regulatory 
system that consider glucagon dynamics at present it is not possible to compare the 
value returned by the Glucagon Minimal Model. Since it is within reasonable vicinity 
of insulin sensitivity it is deemed acceptable. 
Table 3.8: Comparisons of key parameter values from the three Glucagon Models. 
 
Parameter Linear Glucagon 
Model 
Glucagon Minimal 
Model 
Linear Glucagon 
Minimal Model 
𝑆𝐺   = 𝑝1 0.02717445 0.02059000 0.02808122 
𝑆𝐼 - 1.78999 x 10−5 7.34737 x 10
−4 
𝑆𝐸 - 6.21902 x 10−4 - 
 
 
Comparing the dimensionless simulations of the model it is noticeable that the Linear 
Glucagon Minimal Model provides a much poorer fit to plasma insulin measurements 
than the Glucagon Minimal Model. Rescaling the Glucagon Minimal Model for 
different parameter values resulted in a larger variation of parameters than for the 
Linear Glucagon Minimal Model. This is likely to be due to the two additional 
quantities of the Glucagon Minimal Model. 
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3.7. Summary 
 
This chapter has covered the development of three mathematical models, capable of 
predicting plasma glucose, insulin and glucagon concentrations following an IVGTT. 
Each model ranged in its complexity, assuming either linear or non-linear 
relationships. The Linear Glucagon Minima Model is the most accurate model for 
predicting blood glucose levels during an IVGTT, and is more simplistic than the 
Glucagon Minimal Model, which required an additional variable and parameter in the 
system. Although the simplest, the Linear Glucagon Model is not acceptable as it 
provides a very poor fit to insulin and an unrealistic prediction for glucagon levels. It 
is possible that the non-linear terms, i.e. equations for hormone activity, are only 
required when there are large fluxes in the hormones. This will be further 
investigated by looking at the system during exercise. 
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Chapter 4 Exercise and the Glucose Regulatory 
System 
4.1. Introduction 
 
Including the effects of glucagon in a model for glucose regulation has allowed for a 
more accurate representation of glycaemic control, and admits a model capable of 
returning to homeostasis after perturbations to the system resulting in either a rise  or 
a fall in plasma glucose concentrations. 
Chapter 3 highlighted the role of glucagon after an IVGTT, i.e. after a period where 
glucose is in what is known as the fed state. The aim of this thesis will now be to model 
glucose-insulin-glucagon dynamics during periods of low glucose availability. 
This chapter examines the major effects had by exercise on the system and reviews the 
key literature that has attempted to model exercise and the glucose regulatory system. 
Understanding the major effects of exercise on glucose homeostasis will allow for the 
identification of both the variables and parameters that will be required in order to 
develop a mathematical model of the system, which will be covered in Chapter 5. 
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4.2. Exercise and the Glucose Regulatory System 
 
Individuals are encouraged to regularly take part in exercise for the numerous 
beneficial effects it has on health, including its ability to positively affect blood 
pressure(Colberg et al. 2010), improve cardio respiratory fitness, and many 
cardiovascular risk factors (Valletta et al., 2014). In addition to the cardiovascular 
system, exercise also promotes metabolic health, and is recognized as a natural, 
inexpensive tool for controlling diabetes and related complications (Derouich and 
Boutayeb, 2002), due to its ability to increase insulin sensitivity. For individuals at 
risk of developing type 2 diabetes, recent studies have shown that the effect of 
physical activity can lower the risk of the onset of the disease by up to 58% (Colberg 
et al., 2010) partly due to its ability to counteract insulin resistance (Costa-Junior et 
al., 2015). Therefore physical exercise is considered as an important factor in the 
treatment of both type 1 and type 2 diabetes (Goodyear and Kahn, 1998). 
4.2.1. Increased Glucose Uptake 
 
During physical activity our bodies expend a greater amount of energy; therefore 
there is an increase in the demand for glucose to be delivered to the working muscles 
as they contract. The increase in the rate of glucose uptake will be greater as exercise 
intensity is amplified (Wasserman and Cherrington, 1991), particularly in scenarios 
of very high intensity exercise, such as at >80% of 𝑉𝑂𝑚 , where glucose is the 
exclusive muscle fuel (Marliss and Vranic, 2002). Exercise is often said to have insulin 
like effect on blood glucose, due to its mechanisms that work to stimulate glucose 
transport independently from insulin (Sternlicht et al., 1989). Additionally, there is an 
increase in the rate of insulin-dependent glucose uptake due to an increase in insulin 
sensitivity (Dalla man et al., 2009) which causes the body to increase its ability to 
absorb glucose with insulin, despite the decreased concentration of the hormone 
within the plasma. 
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4.2.2. Increased Glucose Production 
 
In attempt to maintain homeostasis, the rate of glucose production in the liver 
increases simultaneously. The increase in hepatic glucose production is a 
combination of an increase in the rate of both gluconeogenesis and glycogenolysis, 
stimulated by the increase in plasma glucagon, increased breakdown of ATP, glycogen 
(Jeukendrop and Gleeson, 2010), and a decrease in plasma insulin (Wasserman and 
Cherrington, 1991). Glucose production increases proportionally to the intensity of 
exercise (Petersen et al, 2004), (Hargreaves and Spriet, 2006). Glycogenolysis 
typically contributes the most towards hepatic glucose production and is particularly 
noticed to dominate production early in exercise (Coggan, 1991); however during 
prolonged periods of activity, available glycogen stores are depleted. As the 
availability of glycogen declines so does the rate of hepatic glucose production. The 
amount of available gluconeogenic precursor supplies begins to increase with 
increasing exercise duration; thus the contribution to glucose production from 
gluconeogenesis increases, and soon dominates over glycogenolysis (Kjaer, 1998), 
however is not enough to counterbalance the reduction in glycogenolysis. 
 
 
4.2.3. Decline in Glycogenolysis 
 
Muscle glycogen is the primary fuel for most types of exercise and is able to provide 
immediate energy for the muscles. 
Glycogenolysis typically contributes the most towards hepatic glucose production 
and is particularly noticed to dominate production early in exercise (Coggan, 1991) as 
muscle glycogen is the chief source of energy for contraction (Wasserman and 
Cherrington, 1991). However during prolonged periods of activity, the availability of 
glycogen begins to diminish at a rate that is proportional to exercise intensity, thus 
the rate of glycogenolysis begins to decline (Juekendrup and Gleeson, 2010) until all 
glycogen stores have been used. 
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4.2.4. Decreased Plasma Insulin Concentration 
 
During exercise a decrease in the plasma insulin levels is essential to allow fat release 
for oxidation to occur to enable a sufficient amount of lipids available as a source of 
energy (MacLaren and Morton, 2012). Healthy patients will experience a decline in 
plasma insulin concentrations as a result of insulin secretion being inhibited by β-cell 
α-adrenergic receptor activation (Marliss and Vranic, 2002) and an increase rate of 
insulin-independent glucose uptake, both of which are part of a glucoregulatory 
response to avoid hypoglycaemia. A decrease in insulin removal also occurs, although 
the importance of which during exercise is still unclear, however a decrease in insulin 
clearance has been linked to overcoming insulin resistance, thus delaying type 2 
Diabetes (Costa-Junior et al., 2015). 
 
 
4.2.5. Increased Plasma Glucagon Concentration 
 
Elevated levels of glucagon during exercise allow for an increase in hepatic glucose 
production to avoid hypoglycaemia (Lavoie et al., 1997). Research shows that during 
exercise, signals are sent to the pancreas to increase glucagon secretion. The rate of 
glucagon secretion in exercise is also affected by plasma glucose concentrations, and 
decreases with plasma glucose availability (Luyckx et al., 1978). 
In longer periods of exercise plasma glucose levels begin to fall as glycogen stores are 
depleted (Jeukendrup and Gleeson, 2010), which acts as a potent stimulus for plasma 
glucagon secretion. Typically in prolonged exercise glucagon increases threefold 
(Galbo et al., 1975) (Vranic et al., 1976), however, studies such as that performed by 
Ahlborg et al. (1974) demonstrate glucagon to have risen by as much by as five times 
the resting value. 
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4.3. Critical Review of Existing Exercise Models 
 
4.3.1. Parameter Modification of The Bergman Minimal 
Model 
Derouich and Boutayeb (2002) adapted the minimal model by introducing 
parameters that consider the effects of exercise on glucose regulation. The new 
parameters 𝑞1, 𝑞2 and 𝑞3, mimic the ability of exercise to increase in utilization of 
both glucose and insulin in addition to the increased sensitivity of the muscles and 
liver to insulin, such that the equations for plasma glucose and interstitial insulin 
become: 
𝑑𝐺(𝑡)
𝑑𝑡
= −(1 + 𝑞2) ∗ 𝑋(𝑡) ∗ 𝐺(𝑡) + (𝑝1 + 𝑞1) ∗ (𝐺𝑏 − 𝐺(𝑡)),               (4.1) 
𝑑𝑋(𝑡)
𝑑𝑡
= (𝑝3 + 𝑞3) ∗ (𝐼(𝑡) − 𝐼𝑏) − 𝑝2 ∗ 𝑋(𝑡),                                             (4.2)  
 
The steady state analysis of the model shows that the value given for insulin 
sensitivity is higher with physical activity that the original minimal model which 
confirms the physiological findings that exercise increases insulin sensitivity 
(Borghouts and Keizer, 2000), (Holloszy, 2005). 
Derouich and Boutayeb (2002) ran simulations for healthy individuals and adjusted 
the model so that it was able to consider the diabetic state; both type 1 and type 2. 
Their steady state analysis showed that in the absence of administered insulin both 
profiles would reach a hyperglycaemic state, where as administration of insulin could 
easily be perceived as an excess, thus leading to hypoglycaemia. 
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4.3.2. Introduction of New Variables to The Bergman 
Minimal Model 
Following the work of the Derouich and Boutayeb (2002) was the development of the 
model by Roy and Parker (2007), whose work also used the minimal model as a 
foundation to develop their model. This work introduced new variables to the 
minimal model that account for the physiological changes to the system during 
exercise. 
To quantify the exercise intensity, a term was introduced representing the percentage 
of the maximum rate of oxygen consumption (𝑃𝑉𝑂𝑚𝑎𝑥), and is described
           mathematically as:  
 
𝑑𝑃𝑉𝑂2
𝑚𝑎𝑥
𝑑𝑡
=  −0.8 ∗ 𝑃𝑉𝑂2
𝑚𝑎𝑥(𝑡) + 0.8 ∗ 𝑢3,                                (4.3) 
where 𝑢3 is the exercise intensity. 
 
The exercise induced changes of an increase in the rate of glucose production, 
glucose utilization and decrease in plasma insulin are given by: 
𝑑𝐺𝑝𝑟𝑜𝑑
𝑑𝑡
=  −𝑎1 ∗ 𝐺𝑝𝑟𝑜𝑑(𝑡) + 𝑎2 ∗ 𝑃𝑉𝑂2
𝑚𝑎𝑥(𝑡),                         (4.4) 
𝑑𝐺𝑢𝑝
𝑑𝑡
=  −𝑎3 ∗ 𝐺𝑝𝑟𝑜𝑑(𝑡) + 𝑎4 ∗ 𝑃𝑉𝑂2
𝑚𝑎𝑥(𝑡),                            (4.5) 
𝑑𝐼𝑒
𝑑𝑡
=  −𝑎5 ∗ 𝐼𝑒(𝑡) + 𝑎6 ∗ 𝑃𝑉𝑂2
𝑚𝑎𝑥(𝑡),                                     (4.6) 
 
The model is more sophisticated and physiologically accurate than the parameter 
extension by Derouich and Boutayeb (2002), as it considers the fact that glucose levels 
will decline as muscle glycogen is utilized. The decline in glycogenolysis is modelled by 
creating an energy expenditure threshold and an equation of the integrated exercise 
intensity, given by:  
𝐴𝑇𝐻 = −1.152 ∗ (𝑢3)
2 + 87.471 ∗ 𝑢3,                                      (4.7) 
𝑑𝐴
𝑑𝑡
= 𝑢3(𝑡),                                                                                        (4.8) 
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The rate of glycogenolysis is dependent on whether or not the value of integrated 
exercise intensity (4.8) exceeds the energy expenditure threshold (4.7), and is 
defined as follows: 
𝑑𝐺𝑔𝑙𝑦
𝑑𝑡
=
{
 
 
0,                𝐴(𝑡) < 𝐴𝑇𝐻
𝑘,               𝐴(𝑡) ≥ 𝐴𝑇𝐻
−
𝐺𝑔𝑙𝑦(𝑡)
𝑇1
   𝑢3(𝑡) = 0 
,                                                            (4.8) 
Roy and Parker’s model provides a good fit to the data available for low-moderate 
exercise; however the model is not able to predict higher levels of exercise. 
One explanation could be due to the fact that, the equation for modelling exercise 
intensity is based on the work of Astrand (1960), thus assuming that oxygen 
consumption is approximately linearly proportional to energy expenditure. In more 
recent studies by Barstow and Mole (1991), it was determined that oxygen uptake 
rose linearly only for lower working rates (38 and 54% of 𝑉𝑂𝑚𝑎𝑥), and that the 
increase was significantly greater for exercising at intensities, (85 and 100% of 
𝑉𝑂𝑚𝑎𝑥). Therefore this equation may be inadequate for modelling higher working 
rates. 
 
Another possible reasoning may be due to the fact that the new terms introduced into 
the model are all linear, which, despite the added benefit of simplicity, they may not 
be sufficient to accurately represent the complex behaviour that occurs during 
exercise. Cooper et al. (1989) state that glucose uptake data for exercise at work rates 
between 40 and 60% of 𝑉𝑂2
𝑚𝑎𝑥 suggests a non-linear increase between the two, 
contradicting other research (Katz et al. 1986), (Wahren et al. 1971)  that suggests 
glucose uptake increase in proportion to exercise intensity. 
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4.3.3. Modelling Exercise with Delay Differential Equations 
 
In 2010, Svitra et al. extended the delay differential equation (DDE) model for insulin 
and glucose dynamics proposed by Svitra (1989) to take into account the effects of 
diet and physical activity. Two linear external periodic functions, g(𝑡) and f(𝑡), were 
introduced and defined as: 
 
𝑔𝑖(𝑡) = 𝑔𝑖(𝑡 + 24) = 𝛼𝑖 sin [
𝜋
𝑇𝑖
(𝑡 − 𝑡𝑖1)] , 𝑡𝑖1 ≤ 𝑡 ≤ 𝑡𝑖2,                     (4.9)  
𝑓𝑗(𝑡) = 𝑓𝑗(𝑡 + 24) = 𝛾𝑗 sin [
𝜋
𝑇𝑗
(𝑡 − 𝑡𝑗1)] , 𝑡𝑗1 ≤ 𝑡 ≤ 𝑡𝑗2,                    (4.10)  
where 𝑔(𝑡) is the nutritional intake, 𝑖(𝑡) is the exercise performed, 𝑡𝑖1 and 𝑡𝑗1 are the 
times the effects begin, 𝑡𝑖2 and 𝑡𝑗2 are the times they finish and both 𝑇𝑖 and 𝑇𝑗 are the 
duration of the effects of glucose consumption and exercise. 
The model is easily implemented and allows for an efficient comparison of a number 
of different meals and exercise bouts in both healthy and diabetic individuals. 
Different parameter values are obtained, allowing for an insight into which routine 
may be the most effective in improving the diabetic state, i.e. increasing the ability to 
dispose of excess glucose and respond to insulin secretion. Svitra and co-workers 
performed a thorough mathematical analysis of the model and found a stable 
equilibrium that could be confirmed with physiological reasoning. 
However, there is no detail on how the effect of the meal was quantified; the amount 
of carbohydrates consumed or the glycaemic index of the meal was not discussed, 
making it difficult to apply the model in a physical situation. The same issue remains 
for exercise. It is known that the effects of aerobic exercise on glucose metabolism 
vary with duration and intensity (Adams, 2013), however there is no explicit term 
that quantifies the working rate of the exercise being performed. 
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4.4. Summary 
 
This chapter has given an overview of the fundamental physiological changes that 
affect the glucose regulatory system during exercise. Key literature was reviewed, 
identifying the existing approaches and considerations made to modelling exercise. 
The chapter then went on to examine the major effects of exercise on the system and 
to identify the key considerations for model formulations. 
With this information, the next chapters will introduce proposed models to simulate 
blood glucose regulation during exercise. Each model will be fitted to data and 
analysed mathematically. 
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Chapter 5 Modelling Exercise 
 
5.1. Introduction 
 
Chapter 4 reviewed the importance of exercise for health, its use in both managing 
and preventing diabetes and its effects on glucose homeostasis. New terms are added 
to the models developed in chapter 3 (equations 3.4 – 3.12) to simulate and predict 
the concentrations of glucose and its regulatory hormones in the plasma during 
physical activity. 
Although chapter 3 determined that a non-linear term was not necessary to produce a 
model for glucose -glucagon dynamics during an IVGTT, it is expected that this result 
was due to the fact that there was only a very small increase in plasma glucagon. In 
this chapter both the Glucagon Minimal Model and Linear Glucagon Minimal Model 
will be extended for exercise, and will conclude whether a linear term is sufficient for 
describing glucose-glucagon interactions. 
This chapter considers the glucose regulatory system for a healthy individual and 
does not assume an impaired glucose response. In the presence of T2DM, the effects 
of exercise on the system would expect to remain the same; however it is likely that 
the value for insulin sensitivity would still remain lower than for a healthy individual. 
More research would need to be done to collect datasets from participants with 
T2DM for the effects to become clear. T1DM is considered in the following chapter. 
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5.2. Model Formation 
Exercise is often described as having an insulin like effect on blood glucose due to its 
ability to increase the rate of glucose uptake (Goodyear and Kahn, 1998). Therefore 
the effects of exercise on the system will be modelled in a similar manner to insulin, 
by introducing a compartment to represent the level of exercise induced activity in 
the system. 
5.2.1. Exercise Variables 
 
5.2.1.1. Exercise Activity 
 
Both exercise intensity and the duration of activity have been identified as the primary 
factors determining the effects of exercise on blood glucose levels. To quantify exercise 
intensity, equation (4.3) proposed by Roy and Parker (2007) for the percentage of 𝑉𝑂2
𝑚𝑎𝑥  
(𝑃𝑉𝑂2
𝑚𝑎𝑥), will be incorporated into the model and is given by: 
𝑑𝑃𝑉𝑂2
𝑚𝑎𝑥
𝑑𝑡
= −0.8 ∗  𝑃𝑉𝑂2
𝑚𝑎𝑥(𝑡) + 0.8 ∗ 𝑢3,                                (5.1) 
 
where 𝑢3 defines the exercise intensity (Percentage of 𝑉𝑂
𝑚𝑎𝑥above the basal level) 
and is equal to zero when time, t, is outside of the interval 0 < 𝑡 < 𝑇𝑑𝑢𝑟, where 𝑇𝑑𝑢𝑟 is 
the duration of exercise. It is worth noting that the equation assumes that the basal 
level for 𝑉𝑂𝑚𝑎𝑥 is 8%, which is not entirely accurate, since the value differs based on 
the fitness of an individual (Dalleck and Dalleck, 2008). The equation by Roy and 
Parker is also based on the findings of Astrand (1960) who established that oxygen 
consumption is approximately linearly proportional to energy expenditure. However, 
in more recent studies by Barstow and Mole (1991) it was determined that oxygen 
uptake rose linearly only for lower working rates (38 and 54% of 𝑉𝑂𝑚𝑎𝑥), and that 
the increase was significantly greater for exercising at intensities, (85 and 100% of 
𝑉𝑂𝑚𝑎𝑥). Therefore this equation may be inadequate for modelling higher working 
rates. This will be reviewed at the end of the chapter. 
In this model a new compartment is added (described as cellular exercise activity) to 
account for the effects of exercise on the glucose regulatory system. The equation 
proposed is: 
𝑑𝐴
𝑑𝑡
= −𝑝11 ∗ 𝐴(𝑡) + 𝑝12 ∗ 𝑃𝑉𝑂2
𝑚𝑎𝑥(𝑡),                                    (5.2) 
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where α is the rate clearance of exercise induced activity on the glucose regulatory 
system and β is the increase of activity, proportional to the percentage of an 
individual’s 𝑉𝑂𝑚𝑎𝑥. This new variable will be used to account for the exercise induced 
changes; amplified glucose uptake, decline in plasma insulin and increase in plasma 
glucagon (Goodwin, 2010), as described by the following variables (5.3-5.8). 
5.2.1.2. Increase in Plasma Glucose Uptake 
 
The increased rate of insulin-independent glucose uptake will be modelled by a 
negative non-linear function of both the plasma glucose concentration and the new 
variable for exercise activity 𝐴(𝑡): 
−𝐺𝑢𝑝 = −𝐺(𝑡) ∗ 𝐴(𝑡),                                                                      (5.3) 
The rate will increase with higher plasma glucose concentrations and with higher 
levels of exercise intensity. 
5.2.1.3. Decrease in Plasma Insulin Concentration 
 
A new term is included into the equation for plasma insulin, (𝑡), to represent the 
decrease in plasma insulin concentrations during exercise. The term is similar to 
increased glucose uptake as it will be a negative non-linear function of exercise 
activity and plasma insulin: 
−𝐼𝑑𝑒𝑐 = −𝐴(𝑡) ∗ 𝐼(𝑡),                                                                         (5.4) 
 
5.2.1.4. Increase in Plasma Glucagon Concentration 
 
The term for the exercise induced change in the plasma glucagon concentration is 
similar to plasma insulin, however it will have a positive effect on glucagon 
production. Therefore, the term is given by: 
𝐸𝑖𝑛𝑐 = 𝐴(𝑡) ∗ 𝐸(𝑡),,                                                                             (5.5) 
 
5.2.1.5. Increase in Hepatic Glucose Production 
 
Hepatic glucose production (HGP), the sum of gluconeogenesis and glycogenolysis, 
increases during exercise in attempt to balance the increased glucose uptake by 
muscle to maintain glucose homeostasis (Adams, 2013). 
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Unlike the model of Roy and Parker, this model will not add a term for increased 
glucose production, since this model takes into account muscle glycogenolysis and the 
effects of glucagon to increase (HGP) on the system. In prolonged exercise, it is the 
rise in plasma glucagon and fall in plasma insulin that is essential to ensure an 
increase in hepatic glucose production and gluconeogenesis (Lavoie et al. 1997), 
therefore will not be modelled by an additional term in the model, but indirectly by 
an increase and decrease in both glucagon and insulin activity, caused by an exercise 
induced increase in plasma glucagon and decrease in plasma insulin respectively. 
Note that since skeletal muscle lacks glucose-6-phosphatase (g6p) and consequently 
cannot deliver free glucose to the blood via gluconeogenesis (Gluconeogenesis: 
Endogenous Glucose Synthesis, 2016). Therefore gluconeogenesis is only accounted 
for by the hepatic terms for glucose regulation. 
5.2.1.6. Muscle Glycogen Depletion 
 
Glycogen breakdown and synthesis are reciprocally regulated (Berg et al., 2002), i.e. 
activation of one simultaneously inhibits the other. This suggests that, as during 
exercise there is a significant amount of muscle glycogen utilisation (particularly 
during exercise intensity above 70% of 𝑉𝑜𝑚 ), (Jensen et al., 2011) muscle glycogen 
synthesis becomes obsolete . Since this model is only concerned with the system 
dynamics during exercise, the equation modelling muscle glycogen will focus only on 
the rate of glycogen degradation stimulated by exercise and not give a detailed 
consideration to glycogen synthesis. A term will be included such that the long term 
behaviour corresponds with the physical system, however a simple term will be 
proposed that is proportional to the amount of glycogen below the. This term will be 
omitted in the simulations for exercise. 
In previous work to model the glycogenolysis pathway (Meinke and Edstrom, 1990), 
(Todd, 2008), Michaelis-Menten dynamics are assumed for the rate of glycogen 
depletion. Michaelis-Menten provides a kinetic description of enzyme activity (Berg, 
2002) thus is a good basis for describing the reaction of glycogenolysis, which 
requires different enzymes for the degradation of glycogen (Todd, 2008). 
A Michaelis-Menten term for the velocity of a reaction is of the following structure: 
 
𝑉 =
𝑉𝑚𝑎𝑥 ∗ [𝑆]
𝐾𝑚 + [𝑆]
,                                                                           (5.6) 
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where the 𝑉𝑚𝑎𝑥 represent the maximum velocity and the Michaelis constant, 𝐾𝑚, 
indicates the amount of the substrate for the maximum velocity to be reached 
(Worthington Biochemical Corporation, 2016). 
A simple term for Michaelis-Menten kinetics is proposed, proportional to the amount 
of glycogen in the muscle (𝐺𝑙𝑦(𝑡)) and the exercise intensity (𝑃𝑉𝑂2
𝑚𝑎𝑥(𝑡)), therefore 
the rate will increase as exercise intensity increases and decrease as muscle glycogen 
availability diminishes.  
 
The equation is given by: 
𝑑𝐺𝑙𝑦
𝑑𝑡
=  
−𝛿 ∗ 𝑃𝑉𝑂2
𝑚𝑎𝑥(𝑡) ∗ 𝐺𝑙𝑦(𝑡)
𝐺𝑙𝑦𝑏
2
+ 𝐺𝑙𝑦(𝑡)
− µ ∗ (𝐺𝑙𝑦(𝑡) − 𝐺𝑙𝑦𝑏),                             (5.7)  
where the maximum velocity is given by 𝛿 and the Michaelis constant is fixed to half 
of the amount of basal glycogen, i.e. the amount of glycogen the body will replenish to 
in the fed state, 
𝐺𝑙𝑦𝑏. 
2 
 
The rate of glycogenolysis in muscles is most rapid during the first 5 to 10 minutes of 
exercise (Goldman and Schafer, 2012) and declines as a result of reduced levels of 
muscle glycogen (Blomstrand and Saltin, 1999). Therefore since the 𝐾𝑚 is the 
substrate concentration that gives the enzyme one-half of its 𝑉𝑚𝑎𝑥 (Flynn, 2003), the 
model assumes that the rate the glycogenolysis will reach half of its initial rate when 
the amount of glycogen decreases to half of its initial value. 
5.2.1.7. Glucose Production via Muscle Glycogenolysis 
 
This model will not include an additional term for liver glycogen, since hepatic 
glucose production (HGP) glycogen stored in the muscle is considered as a major 
source of fuel during exercise (Richter et al. 1982), and is stimulated by both muscle 
contractions and epinephrine. Since this model does not account for the effects of 
epinephrine at this stage, the term will be proportional to the amount of available 
glycogen and the level of exercise intensity. The term will not be dependent on the 
concentration of glucagon since it exerts no direct action on muscle cells (Goodwin, 
2010). The increase in the rate of glucose production via muscle glycogenolysis is 
modelled by: 
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𝐺𝑝𝑟𝑜𝑑 =  𝜌 ∗
𝛽 ∗ 𝑃𝑉𝑂2
𝑚𝑎𝑥(𝑡) ∗ 𝐺𝑙𝑦(𝑡)
250 + 𝐺𝑙𝑦(𝑡)
,                                                (5.7) 
where 𝐺𝑙𝑦(𝑡) is the amount of muscle glycogen available. The term is proportional to 
the amount of available muscle glycogen and the amount of energy being expended, 
therefore the rate will decrease over time as glycogen stores become depleted and 
increase with the working rate. 
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5.2.2. The Glucagon Exercise Minimal Model 
 
The relationships and interactions for the first model proposed are shown below in 
figure 5.1: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Compartment Diagram of Glucose-Insulin-Glucagon dynamics during 
exercise, assuming a non-linear relationship between glucose and glucagon 
Table 5.1: Glucagon Exercise Minimal Model Nomenclature of new parameters. 
 
Parameter Description Unit 
𝑝10 
Michaelis constant of maximum velocity, 𝑉𝑚𝑎𝑥, of 
exercise induced glycogen breakdown. 
𝑚𝑖𝑛−1 
𝑝11 
Clearance of exercise induced effects on the glucose 
regulatory system 
𝑚𝑖𝑛−1 
𝑝12 
Increase in exercise induced effects on the glucose 
regulatory system 
𝑚𝑖𝑛−1 
𝑝13 
Rate of glycogen degradation and conversion to 
glucose 
(𝑚𝑔/𝑑𝑙)𝑚𝑖𝑛−2 
𝑝14 Rate of glycogen synthesis 𝑚𝑖𝑛−1 
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Table 5.1 describes the new rates for exercise in the model. It can be seen that in this 
model, exercise increases HGP indirectly, and occurs through the exercise stimulated 
increase in glucagon activity. This is based on the findings of Lavoie et al. (1997) who 
concluded that the increase in glucagon during exercise was essential for the increase 
in HGP and in gluconeogenesis. 
The full system is therefore given by: 
𝑑𝐺
𝑑𝑡
= −𝑝1 ∗ (𝐺(𝑡) − 𝐺𝑏) + 𝐺(𝑡) ∗ (𝑌(𝑡) − 𝑋(𝑡)) + 𝐺𝑝𝑟𝑜𝑑 − 𝐺𝑢𝑝,                           
𝑑𝑋
𝑑𝑡
= −𝑝2 ∗ 𝑋(𝑡) + 𝑝3 ∗ 𝐼(𝑡),   
𝑑𝐼
𝑑𝑡
= −𝑝4 ∗ (𝐼(𝑡) − 𝐼𝑏) + 𝑝5 ∗ (𝐺(𝑡) − 𝐺𝑏)
+ − 𝐼𝑑𝑒𝑐 , 
𝑑𝑌
𝑑𝑡
= −𝑝6 ∗ 𝑌(𝑡) + 𝑝7 ∗ 𝐸(𝑡),                                                                                      
𝑑𝐸
𝑑𝑡
= −𝑝8 ∗ (𝐸(𝑡) − 𝐸𝑏) + 𝑝9 ∗ (𝐺𝑏 − 𝐺(𝑡))
+
+ 𝐸𝑖𝑛𝑐,                                            
𝑑𝐺𝑙𝑦
𝑑𝑡
= −
𝑝10 ∗ 𝑃𝑉𝑂2
𝑚𝑎𝑥(𝑡) ∗ 𝐺𝑙𝑦(𝑡)
250 + 𝐺𝑙𝑦(𝑡)
− 𝑝14 ∗ (𝐺𝑙𝑦(𝑡) − 𝐺𝑙𝑦𝑏),          
𝑑𝑃𝑉𝑂2
𝑚𝑎𝑥
𝑑𝑡
= −0.8 ∗ 𝑃𝑉𝑂2
𝑚𝑎𝑥(𝑡) + 0.8 ∗ 𝑢3,                 
𝑑𝐴
𝑑𝑡
= −𝑝11 ∗ 𝐴(𝑡) + 𝑝12 ∗ 𝑃𝑉𝑂2
𝑚𝑎𝑥(𝑡),                                                  
Subject to the following initial conditions: 
𝐺(0) = 𝐺0, 𝑋(0) = 0, 𝐼(0) = 𝐼0, 𝑌(0) = 0, 𝐸(0) = 𝐸0,    
𝐺𝑙𝑦(0) = 500 (𝐽𝑒𝑛𝑠𝑒𝑛 𝑒𝑡 𝑎𝑙. , 2011), 𝑃𝑉𝑂2
𝑚𝑎𝑥(0) = 0, 𝐴(0) = 0 
(5.9) 
(5.10) 
(5.11) 
(5.12) 
(5.13) 
(5.14) 
(5.15) 
(5.16) 
(5.9) 
(5.10) 
(5.11) 
(5.12) 
(5.13) 
(5.14) 
(5.15) 
(5.16) 
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5.2.3. The Simplified Glucagon Exercise Minimal Model 
 
In chapter 3, it was proven that a reduced model for glucose-insulin-glucagon 
dynamics (Chapter 3, Section 3.3.3) was able to predict the behaviour of the system 
accurately, without an additional compartment for glucagon activity, resulting in two 
less quantities than the Glucagon Minimal Model. 
Therefore a similar approach will be taken for modelling the effects of exercise, 
removing the equation for glucagon activity, (𝑡), and assuming the effects of excess 
glucagon on hepatic glucose production to be a linear term. The rest of the model is as 
given for the Exercise Model 1 (Section 5.1). 
The relationship between variables is as shown in figure 5.2: 
 
Figure 5.2: Compartment Diagram of Glucose-Insulin-Glucagon dynamics during 
exercise, assuming a linear relationship between glucose and glucagon 
Table 5.2 summarises the new rates for exercise in the model. 
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Table 5.2: Linear Glucagon Exercise Minimal Model Nomenclature of new 
parameters. 
 
Parameter Description Unit 
𝑝9 Michaelis constant of maximum velocity, 
𝑉𝑚𝑎𝑥, of exercise induced glycogen 
breakdown. 
𝑚𝑖𝑛−1 
𝑝10 Decrease of exercise induced effects on the 
glucose regulatory system 
𝑚𝑖𝑛−1 
𝑝11 Increase in exercise induced effects on the 
glucose regulatory system 
𝑚𝑖𝑛−1 
𝑝12 Rate of glycogen degradation and 
conversion to glucose 
(𝑚𝑔/𝑑𝑙)𝑚𝑖𝑛−2 
𝑝13 Rate of glycogen synthesis 𝑚𝑖𝑛−1 
 
 
The full system is given by: 
 
𝑑𝐺
𝑑𝑡
= −𝑝1 ∗ (𝐺(𝑡) − 𝐺𝑏) − 𝐺(𝑡) ∗ 𝑋(𝑡) + 𝐺𝑝𝑟𝑜𝑑 − 𝐺𝑢𝑝 + 𝑃8 ∗ (𝐸(𝑡) − 𝐸𝑏)
+,   
𝑑𝑋
𝑑𝑡
= −𝑝2 ∗ 𝑋(𝑡) + 𝑝3 ∗ 𝐼(𝑡),                                                                                                 
𝑑𝐼
𝑑𝑡
= −𝑝4 ∗ (𝐼(𝑡) − 𝐼𝑏) + 𝑝5 ∗ (𝐺(𝑡) − 𝐺𝑏)
+ − 𝐼𝑑𝑒𝑐 ,                                                       
𝑑𝐸
𝑑𝑡
= −𝑝6 ∗ (𝐸(𝑡) − 𝐼𝑏) + 𝑝7 ∗ (𝐺𝑏 − 𝐺(𝑡))
+
+ 𝐸𝑖𝑛𝑐,                                                   
𝑑𝐺𝑙𝑦
𝑑𝑡
= −
𝑝9 ∗ 𝑃𝑉𝑂2
𝑚𝑎𝑥(𝑡) ∗ 𝐺𝑙𝑦(𝑡)
𝐺𝑙𝑦𝑏
2 + 𝐺𝑙𝑦
(𝑡)
− 𝑝13 ∗ (𝐺𝑙𝑦(𝑡) − 𝐺𝑙𝑦𝑏), 
𝑑𝑃𝑉𝑂2
𝑚𝑎𝑥
𝑑𝑡
= −0.8 ∗ 𝑃𝑉𝑂2
𝑚𝑎𝑥(𝑡) + 0.8 ∗ 𝑢3,                                                                        
𝑑𝐴
𝑑𝑡
= −𝑝10 ∗ 𝐴(𝑡) + 𝑝11 ∗ 𝑃𝑉𝑂2
𝑚𝑎𝑥(𝑡),                                                                            
Subject to the following initial conditions:  
𝐺(0) = 𝐺0,   𝑋(0) = 0,   𝐼(0) = 𝐼0,   𝐸(0) = 𝐸0, 𝐺𝑙𝑦(0) = 500 (𝐽𝑒𝑛𝑠𝑒𝑛 𝑒𝑡 𝑎𝑙. , 2011),  
𝑃𝑉𝑂2
𝑚𝑎𝑥(0) = 0,   𝐴(0) = 0. 
(5.17) 
(5.18) 
(5.19) 
(5.20) 
(5.21) 
 (5.22) 
(5.23) 
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2 
2 
5.3. Model Analyses 
 
The system of equations (5.9-5.23) is subject to initials condition that are all greater 
than or equal to zero. The model considers concentrations within the plasma, energy 
stores of glycogen, the working rate of exercise, the activity of exercise to affect 
glucose homeostasis and the activity of the hormones to stimulate glucose production 
and disappearance. Since these are all biological reflections, all variables must be 
positive. Based on the approach of Magombedze et al. (2009) the following theorem is 
given, guaranteeing a well posed system 
Positive-Definitive Theorem 
 
The system of equations (5.9-5.16) is positively invariant, ensuring a positive solution 
existing for all time 0 < 𝑡 < ∞. This can be proved as follows: 
The components of the system 𝐺, 𝑋, 𝐼, 𝑌, 𝐸, 𝐺𝑙𝑦, 𝑃𝑉𝑂𝑚𝑎𝑥 and A under the initial 
conditions are positive for all t > 0. This is proved by assuming the logical negation, i.e. 
proof by contradiction, therefore we assume that there exists a time   such that: 
𝐺(𝑡𝑖) = 0, 𝐺
′(𝑡𝑖) ≤ 0 and 𝐺(𝑡) > 0, 𝑋(𝑡) > 0, 𝐼(𝑡) > 0, 𝑌(𝑡) > 0, 𝐸(𝑡) > 0, 𝐺𝑙𝑦(𝑡) > 0, 
(𝑡) > 0 and 𝑃𝑉𝑂𝑚𝑎(𝑡) > 0, for 0 < 𝑡 <    𝑡𝑖, 
or there exists a time 𝑡𝑗   such that: 
𝑃𝑉𝑂2
𝑚𝑎𝑥(𝑡𝑗) = 0, 𝑃𝑉𝑂2
𝑚𝑎𝑥′(𝑡𝑗) ≤ 0 and 𝑃𝑉𝑂2
𝑚𝑎𝑥(𝑡) > 0, 𝐺(𝑡) > 0, 𝐼(𝑡) > 0, 𝑌(𝑡) >
0, 𝐸(𝑡) > 0, 𝐺𝑙𝑦(𝑡) > 0, 𝐴(𝑡) > 0 and 𝑋(𝑡) > 0, for 0 < 𝑡 < 𝑡𝑗 .  
By substituting in the terms for 𝐺𝑝𝑟𝑜𝑑 and – 𝐺𝑢𝑝 equation (5.9) becomes: 
𝑑𝐺(𝑡𝑖)
𝑑𝑡
= 𝑝1 ∗ 𝐺𝑏 − 𝐺(𝑡𝑖) ∗ (𝑋(𝑡𝑖) − 𝑌(𝑡𝑖) + 𝐴(𝑡𝑖) + 𝑝1) + 𝑝13                              
∗
(𝑝10 ∗ 𝐺𝑙𝑦(𝑡𝑖) ∗ 𝑃𝑉𝑂2
𝑚𝑎𝑥(𝑡𝑖))
250 + 𝐺𝑙𝑦(𝑡𝑖)
,                                                                          (5.24)
which reduces to 
𝑝1 ∗ 𝐺𝑏 + 𝑝13 ∗
(𝑝10 ∗ 𝐺𝑙𝑦(𝑡𝑖) ∗ 𝑃𝑉𝑂2
𝑚𝑎𝑥(𝑡𝑖))
250 + 𝐺𝑙𝑦(𝑡𝑖)
> 0,                                              (5.25) 
At time 𝑡𝑗   equation (5.1) states that 
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𝑑𝑃𝑉𝑂2
𝑚𝑎𝑥(𝑡𝑗)
𝑑𝑡
= −0.8 ∗ 𝑃𝑉𝑂2
𝑚𝑎𝑥(𝑡𝑗) + 0.8 ∗ 𝑢3,                                (5.26) 
which reduces to 
0.8 ∗ 𝑢3 > 0,                                                                        (5.27) 
which are both contradictions. Similarly this holds for the remaining equations, 
which never reach less than zero. Thus it can be concluded that the system of 
equations (5.17-5.23) remains positive for all 𝑡 > 0.  
Note that this theorem holds for both models presented in this chapter. 
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5.3.1 The Glucagon Exercise Minimal Model 
 
This section will consist of a non-dimensional analysis of the equations (5.9-5.16). 
The theory and implications of rescaling and non-dimensionalizing a model is 
described in section 3. 4.3. The first step when non-dimensionalizing a model is to 
identify the dimensions of the variables and parameters in the model (table 5.3) 
Table 5.3: Dimensions of variables in Glucagon Exercise Minimal Model. 
 
Symbol Description Unit Dimension 
M L T 
G(t) Plasma Glucose concentration at time t mg/dl 1 -3 0 
I(t) Plasma Insulin concentration at time t µ𝑈/𝑚𝑙 1 -3 0 
X(t) Interstitial Insulin activity at time t 𝑚𝑖𝑛−1 0 0 -1 
Y(t) Glucagon activity at time t 𝑚𝑖𝑛−1 0 0 -1 
E(t) Plasma Glucagon concentration at time t pg/ml 1 -3 0 
Gly(t) Amount of muscle glycogen at time t G 1 0 0 
𝑃𝑉𝑂2
𝑚𝑎𝑥(𝑡) 
 
Percentage of 𝑉𝑂2
𝑚𝑎𝑥at the time % 0 0 0 
A(t) Exercise activity at time t 𝑚𝑖𝑛−1 0 0 -1 
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Table 5.4: Dimensions of parameters in The Glucagon Exercise Minimal Model. 
 
 
Symbol 
 
Description 
 
Unit 
Dimension 
M L T 
𝑝1 𝐺𝑙𝑢𝑐𝑜𝑠𝑒 𝐸𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒𝑛𝑒𝑠𝑠 𝑚𝑖𝑛−1 0 0 -1 
𝑝2 Rate of tissue glucose uptake ability 𝑚𝑖𝑛−1 0 0 -1 
𝑝3 
Rate of excess plasma insulin 
stimulated insulin activity 
(µ 𝑈⁄𝑚𝑙)−1𝑚𝑖𝑛−2 -1 3 -2 
𝑝4 Insulin disappearance 𝑚𝑖𝑛−1 0 0 -1 
𝑝5 
Rate of second phase insulin secretion 
(glucose dependent) 
(µ𝑈/𝑚𝑙)𝑚𝑖𝑛−1 0 0 -1 
𝑝6 
Rate of cellular glucose production 
ability 
𝑚𝑖𝑛−1 0 0 -1 
𝑝7 
Rate of excess plasma glucagon 
stimulated insulin activity 
(𝑝𝑔 𝑚𝑙)−1𝑚𝑖𝑛−2 -1 3 -2 
𝑝8 Glucagon clearance 𝑚𝑖𝑛−1 0 0 -1 
𝑝9 
Glucose dependent Glucagon 
secretion 
(𝑝𝑔 𝑚𝑙)𝑚𝑖𝑛−1 0 0 -1 
𝑝10 
Maximum velocity for glycogen 
degradation during exercise 
(g) 𝑚𝑖𝑛−1 1 0 -1 
𝑝11 
Rate of clearance of cellular exercise 
stimulated activity 
𝑚𝑖𝑛−1 0 0 -1 
𝑝12 
Rate of increase of 𝑃𝑉𝑂𝑚𝑎𝑥 above 
2 
basal level stimulated exercise 
𝑚𝑖𝑛−2 0 0 -2 
𝑝13 
Rate of glucose production as a result 
of muscle glycogenolysis 
(mg/dl) 𝑚𝑖𝑛−1 1 -3 -1 
𝑝14 Rate of glycogen synthesis 𝑚𝑖𝑛−1 0 0 -1 
𝐺𝑏 
Baseline plasma glucose 
concentration 
mg/dl 1 -3 0 
𝐼𝑏 
Baseline plasma insulin 
concentration 
µ𝑈/𝑚𝑙 1 -3 0 
𝐸𝑏 
Baseline plasma glucagon 
concentration 
pg/ml 1 -3 0 
𝐺𝑙𝑦𝑏 Amount of baseline muscle glycogen g 1 0 0 
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The next step is to convert the original variables to the dimensionless form. Note that all the barred 
variable and parameters are unitless. Let 
𝐺 = 𝐺𝑏 ∗ ?̃?, 𝐼 = 𝐼𝑏 ∗ 𝐼, 𝐸 = 𝐸𝑏 ∗ ?̃?, 𝑋 =
?̃?
𝜏
, 𝑌 =
?̃?
𝜏
,   
𝐺𝑙𝑦 = 𝐺𝑙𝑦𝑏 ∗ 𝐺𝑙?̃?,   𝑃𝑉𝑂2
𝑚𝑎𝑥 =
𝑃𝑉𝑂2
𝑚𝑎?̃?
𝜏
  𝐴 =
?̃?
𝜏
   and  𝑡 = 𝜏 ∗ 𝑇. 
Note that 
 
𝑑
𝑑𝑡
=
𝑑
𝑑𝑇
∗
𝑑𝑇
𝑑𝑡
=
1
𝜏
∗
𝑑
𝑑𝑇
 
The system can now be rewritten in dimensionless form as follows:  
𝑑?̃?
𝑑𝑇
= −𝑝1 ∗ 𝜏 ∗ (?̃? − 1) + ?̃? ∗ (?̃? − ?̃? − ?̃?) +
𝑝13 ∗ 𝑝10 ∗ 𝐺𝑙?̃? ∗ 𝑃𝑉𝑂2
𝑚𝑎?̃?
𝐺𝑏 ∗ (
1
2 + 𝐺𝑙?̃?)
,      
𝑑?̃?
𝑑𝑇
=  −𝑝2 ∗ ?̃? ∗ 𝜏 + 𝑝3 ∗ 𝐼𝑏 ∗ 𝜏
2 ∗ 𝐼,                                                                             
𝑑𝐼
𝑑𝑇
=  −𝑝4 ∗ 𝜏 ∗ (𝐼 − 1) +
𝑝5 ∗ 𝐺𝑏 ∗ 𝜏
𝐼𝑏
∗ (?̃? − 1)
+
− 𝐼 ∗ ?̃?,                                        
𝑑?̃?
𝑑𝑇
=  −𝑝6 ∗ ?̃? ∗ 𝜏 + 𝑝7 ∗ 𝐸𝑏 ∗ 𝜏
2 ∗ ?̃?,                                                                           
𝑑?̃? 
𝑑𝑇
= −𝑝8 ∗ 𝜏 ∗ (?̃? − 1) +
𝑝9 ∗ 𝐺𝑏 ∗ 𝜏
𝐸𝑏
∗ (1 − ?̃?)
+
+ ?̃? ∗ ?̃?,                                    
𝑑𝐺𝑙?̃?
𝑑𝑇
=  −
𝑝10 ∗ 𝐺𝑙?̃? ∗ 𝑃𝑉𝑂2
𝑚𝑎?̃?
𝐺𝑙𝑦𝑏 ∗ (
1
2 + 𝐺𝑙?̃?)
− 𝑝14 ∗ 𝜏 ∗ (𝐺𝑙?̃? − 1),                                             
𝑑𝑃𝑉𝑂2
𝑚𝑎?̃?
𝑑𝑇
= −0.8 ∗ 𝑃𝑉𝑂2
𝑚𝑎?̃? ∗ 𝜏 + 0.8 ∗ 𝜏2 ∗ 𝑢3,                                                      
𝑑?̃?
𝑑𝑇
= −𝑝11 ∗ ?̃? ∗ 𝜏 + 𝑝12 ∗ 𝜏 ∗ 𝑃𝑉𝑂2
𝑚𝑎?̃? ,                                                                     
 
 
 
 
 
 
 
 
 
 
 
 
(5.28) 
 
(5.29) 
(5.30) 
(5.31) 
(5.32) 
(5.33) 
(5.34) 
(5.35) 
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The natural time scales of the minimal were identified as 
1
𝑝1
, the time scale of insulin dependent 
glucose disappearance, and 1/𝑝4, the time scale of insulin disappearance (Nittala et al., 2006). 
The natural time scales of this model also include glucagon disappearance.  
Choosing to rescale the system by 𝜏 =
1
𝑝1
 gives 
𝑑?̃?
𝑑𝑇
= 1 + 𝐺 ̃ ∗ (?̃? − ?̃? − ?̃? − 1) +
𝑝13̃ ∗ 𝐺𝑙?̃? ∗ 𝑃𝑉𝑂2
𝑚𝑎?̃?
(1/2 + 𝐺𝑙?̃?)
                          (5.36) 
𝑑?̃?
𝑑𝑇
=  −𝑝2̃ ∗ ?̃? + 𝑝3̃ ∗ 𝐼,                                                                                     (5.37) 
𝑑𝐼
𝑑𝑇
=  −𝑝4̃ ∗ (𝐼 − 1) + 𝑝5̃ ∗ (?̃? − 1)
+
− 𝐼 ∗ ?̃?,                                                (5.38) 
𝑑?̃?
𝑑𝑇
=  −𝑝6̃ ∗ ?̃? + 𝑝7̃ ∗  ?̃?,                                                                                    (5.39) 
𝑑?̃? 
𝑑𝑇
= −𝑝8̃ ∗ (?̃? − 1) + 𝑝9̃ ∗ (1 − ?̃?)
+
+ ?̃? ∗ ?̃?,                                              (5.40) 
𝑑𝐺𝑙?̃?
𝑑𝑇
=  −
𝑝10̃ ∗ 𝐺𝑙?̃? ∗ 𝑃𝑉𝑂2
𝑚𝑎?̃?
(
1
2 + 𝐺𝑙?̃?)
− 𝑝14̃ ∗ (𝐺𝑙?̃? − 1),                                      (5.41) 
𝑑𝑃𝑉𝑂2
𝑚𝑎?̃?
𝑑𝑇
=  −
0.8 ∗ 𝑃𝑉𝑂2
𝑚𝑎?̃?
𝑝1
+
0.8 ∗ 𝑢3
𝑝1
2 ,                                                       (5.42) 
𝑑?̃?
𝑑𝑇
= −𝑝11̃ ∗ ?̃? + 𝑝12̃ ∗ 𝑃𝑉𝑂2
𝑚𝑎?̃?,                                                                     (5.43) 
Where 
 𝑝2̃ =
𝑝2
𝑝1
, 𝑝3̃ =, 𝑝4̃ =
𝑝4
𝑝1
𝑝5̃ =
𝑝5∗𝐺𝑏
𝑝1∗𝐼𝑏
,  𝑝6̃ =
𝑝6
𝑝1
, 𝑝7̃ =
𝑝7∗𝐸𝑏
𝑝1
2 , 𝑝8̃ =
𝑝8
𝑝1
, 𝑝9̃ =
𝑝9∗𝐺𝑏
𝑝1∗𝐸𝑏
,  
𝑝10̃ =
𝑝10
𝐺𝑙𝑦𝑏
, 𝑝11̃ =
𝑝11
𝑝1
, 𝑝12̃ =
𝑝12
𝑝1
, 𝑝13̃ =
𝑝13.
𝐺𝑏
∗
𝑝10
𝐺𝑙𝑦𝑏
 𝑎𝑛𝑑 𝑝14̃ =
𝑝14
𝑝1
. 
The initial conditions then become  
?̃?(0) =
𝐺𝑏
𝐺𝑏
= 1, ?̃?(0) = 0, 𝐼(0) =
𝐼𝑏
𝐼𝑏
= 1, ?̃?(0) = 0, ?̃?(0) =
𝐸𝑏
𝐸𝑏
= 1, 
𝐺𝑙?̃?(0) =
𝐺𝑙𝑦𝑏
𝐺𝑙𝑦𝑏
= 1, 𝑃𝑉𝑂2
𝑚𝑎𝑥̃ (0) = 0 and ?̃?(0) = 0. 
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The critical points of a system refer to the long term behaviour of the system, in which it is 
assumed that the individual will have stopped exercising, either by choice or exhaustion, i.e. 
𝑢3 = 0. 
By setting the equations (5.27-5.34) equal to zero the system can be rewritten to give the 
following:  
?̃? =
1
?̃? − ?̃?
, 
?̃? =
𝑝3̃
𝑝2̃
∗ 𝐼, 
𝐼 =
𝑝4̃ + 𝑝5̃ ∗ (?̃? − 1)
+
𝑝4̃
, 
?̃? =
𝑝7̃
𝑝6̃
∗ ?̃?, 
?̃? =
𝑝8̃ + 𝑝9̃ ∗ (1 − ?̃?)
+
𝑝8̃
, 
𝐺𝑙?̃? =  1, 
𝑃𝑉𝑂2
𝑚𝑎?̃? = 0, 
?̃? = 0, 
The system reduces to give the critical point of the non-dimensionalized system as  
(
1
𝑝2̃
𝑝2̃
−
𝑝7̃
𝑝6̃
,
𝑝2̃
𝑝2̃
, 1,
𝑝7̃
𝑝6̃
, 1,1,0,0) 
 
The point is the only existing critical point of the system, and refers to the basal state, 
which is the post-absorptive state the individual was in prior to the exercise protocol. 
The critical point of the dimensional system is 
(
𝐺𝑏
𝑝2̃
𝑝2̃
−
𝑝7̃
𝑝6̃
,
𝑝3̃
𝑝2̃
𝐼𝑏 , 𝐼𝑏 ,
𝑝6̃
𝑝7̃
𝐸𝑏 , 𝐸𝑏 , 𝐺𝑙𝑦𝑏 , 0,0) 
 
 
 
 
 
 
 
 
(5.44) 
(5.45) 
(5.46) 
(5.47) 
(5.48) 
(5.49) 
(5.50) 
(5.51) 
 
 
82 
 
The Jacobian matrix evaluated at the critical point is given as: 
𝐽3 = 
[
 
 
 
 
 
 
 
 
 
 −1 −
𝑝2̃
𝑝2̃
+
𝑝7̃
𝑝6̃
−1 0 1 0 0 2 ∗
𝑝13̃
3
−1
0 −𝑝2̃ 𝑝3̃ 0 0 0 0 0
𝑝5̃ 0 −𝑝4̃ 0 0 0 0 −1
0 0 0 −𝑝6̃ 𝑝7̃ 0 0 0
−𝑝9̃ 0 0 0 −𝑝8̃ 0 0 1
0 0 0 0 0 −𝑝14̃ −2 ∗
𝑝10̃
3
0
0 0 0 0 0 0 −
0.8
𝑝1
0
0 0 0 0 0 0 𝑝12̃ −𝑝11̃]
 
 
 
 
 
 
 
 
 
 
            (5.52)                 
 
 
The characteristic polynomial was determined in Mathematica (See appendix) as: 
 
 (𝑑𝑒𝑡 − 𝐽3  𝜆) =  (
0.8
𝑝1
+  𝜆) (−𝑝11̃ − 𝜆)(𝑝14̃ +  𝜆) (−𝑝9̃  ( 𝑝2̃ 𝑝4̃ 𝑝7̃ + (𝑝2̃  +  𝑝4̃ )𝑝7̃ 𝜆 − 𝑝7̃ 𝜆
2 )
+ (𝑝6̃ +  𝜆)(𝑝8̃ +  𝜆)(−𝑝2̃ 𝑝4̃ − 𝑝3̃ 𝑝5̃ − 𝑝2̃  𝜆 − 𝑝4̃  𝜆 − 𝑝2̃ 𝑝4̃  𝜆 − 𝜆
2 − 𝑝2̃  𝜆
2
− 𝑝4̃  𝜆
2 − 𝜆3)) = 0                                                                                        (5.53)  
 
The roots of the system were determined using the Roots function in Mathematica 
and will not be written explicitly in this thesis due to the complexity and length of the 
values, however it is noted that these values are all negative, thus the stability criteria 
for a linearized model holds. 
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5.3.2 The Simplified Glucagon Exercise Minimal Model 
 
This section will involve a mathematical analysis of the second model proposed for 
exercise. It will follow a similar structure to the analysis of the Glucagon Exercise 
Minimal Model in section 5.3.1. 
The variables in the model are listed in table 5.4 along with their units and 
dimensions in terms of mass, length and time. 
Table 5.5: Dimensions of variables in the Simplified Glucagon Exercise Minimal 
Model. 
 
 
Symbol 
 
Description 
 
Unit 
Dimension 
M L T 
G(t) Plasma Glucose concentration at time t mg/dl 1 -3 0 
I(t) Plasma Insulin concentration at time t µ𝑈/𝑚𝑙 1 -3 0 
X(t) Interstitial Insulin activity at time t 𝑚𝑖𝑛−1 0 0 -1 
Y(t) Glucagon activity at time t 𝑚𝑖𝑛−1 0 0 -1 
E(t) 
Plasma Glucagon concentration at 
time t 
pg/ml 1 -3 0 
Gly(t) Amount of muscle glycogen at time t g 1 0 0 
𝑃𝑉𝑂2
𝑚𝑎𝑥  Percentage of 𝑉𝑂2
𝑚𝑎𝑥at time ti % 0 0 0 
A(t) Exercise activity at time t 𝑚𝑖𝑛−1 0 0 -1 
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Table 5.6: Dimensions of parameters in Simplified Glucagon Exercise Minimal Model 
 
Symbol Description Unit 
Dimension 
M L T 
𝑝1 𝐺𝑙𝑢𝑐𝑜𝑠𝑒 𝐸𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒𝑛𝑒𝑠𝑠 𝑚𝑖𝑛
−1 0 0 -1 
𝑝2 Rate of tissue glucose uptake ability 𝑚𝑖𝑛
−1 0 0 -1 
𝑝3 
Rate of excess plasma insulin 
stimulated insulin activity 
(µ 𝑈⁄𝑚𝑙)−1𝑚𝑖𝑛−2 -1 3 -2 
𝑝4 Insulin disappearance 𝑚𝑖𝑛−1 0 0 -1 
𝑝5 
Rate of second phase insulin 
secretion (glucose dependent) 
(µ𝑈/𝑚𝑙)𝑚𝑖𝑛−1 0 0 -1 
𝑝6 Glucagon clearance 𝑚𝑖𝑛−1 0 0 -1 
𝑝7 
Glucose dependent glucagon 
secretion 
(𝑝𝑔 𝑚𝑙)𝑚𝑖𝑛−1 0 0 -1 
𝑃8 
Glucagon stimulated glucose 
production 
(𝑚𝑔/𝑑𝑙)𝑚𝑖𝑛−1 0 0 -1 
 
𝑝9 
Michaelis constant of maximum 
velocity, 𝑉𝑚𝑎𝑥, of exercise induced 
glycogen breakdown. 
 
(g) 𝑚𝑖𝑛−1 
 
1 
 
0 
 
-1 
𝑝10 
Decrease of exercise induced effects 
on the glucose regulatory system 
𝑚𝑖𝑛−1 0 0 -1 
𝑝11 
Increase in exercise induced effects 
on the glucose regulatory system 
𝑚𝑖𝑛−2 0 0 -2 
𝑝12 
Rate of glycogen degradation and 
conversion to glucose 
(mg/dl) 𝑚𝑖𝑛−1 1 -3 -1 
𝑝13 Rate of glycogen synthesis 𝑚𝑖𝑛−1 0 0 -1 
𝐺𝑏 
Baseline plasma glucose 
concentration 
mg/dl 1 -3 0 
𝐼𝑏 
Baseline plasma insulin 
concentration 
µ𝑈/𝑚𝑙 1 -3 0 
𝐸𝑏 
Baseline plasma glucagon 
concentration 
pg/ml 1 -3 0 
𝐺𝑙𝑦𝑏 Amount of baseline muscle glycogen G 1 0 0 
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As shown for the Glucagon Exercise Minimal Model, the original variables are 
converted to give the dimensionless form. Note that all the barred variables and 
parameters are unitless. 
Let 
𝐺 = 𝐺𝑏 ∗ ?̃?, 𝐼 = 𝐼𝑏 ∗ 𝐼, 𝐸 = 𝐸𝑏 ∗ ?̃?, 𝑋 =
?̃?
𝜏
,   
𝐺𝑙𝑦 = 𝐺𝑙𝑦𝑏 ∗ 𝐺𝑙?̃?,   𝑃𝑉𝑂2
𝑚𝑎𝑥 =
𝑃𝑉𝑂2
𝑚𝑎?̃?
𝜏
  𝐴 =
?̃?
𝜏
   and  𝑡 = 𝜏 ∗ 𝑇. 
Note that 
𝑑
𝑑𝑡
=
𝑑
𝑑𝑇
∗
𝑑𝑇
𝑑𝑡
=
1
𝜏
∗
𝑑
𝑑𝑇
 
The system can now be rewritten in the dimensionless form as follows: 
𝑑?̃?
𝑑𝑇
= −𝑝1 ∗ 𝜏 ∗ (?̃? − 1) − ?̃? ∗ (?̃? + ?̃?) +
𝑝12 ∗ 𝑝9 ∗ 𝜏 ∗ 𝐺𝑙?̃? ∗ 𝑃𝑉𝑂2
𝑚𝑎?̃?
𝐺𝑏 ∗ (
1
2 + 𝐺𝑙?̃?)
                                  
+
𝑝8 ∗ 𝐸𝑏 ∗ 𝜏
𝐺𝑏
∗ (?̃? − 1),                       , 
𝑑?̃?
𝑑𝑇
=  −𝑝2 ∗ ?̃? ∗ 𝜏 + 𝑝3 ∗ 𝐼𝑏 ∗ 𝜏
2 ∗ 𝐼,   
𝑑𝐼
𝑑𝑇
=  −𝑝4 ∗ 𝜏 ∗ (𝐼 − 1) +
𝑝5 ∗ 𝐺𝑏 ∗ 𝜏
𝐼𝑏
∗ (?̃? − 1) − 𝐼 ∗ ?̃?,  
𝑑?̃? 
𝑑𝑇
= −𝑝6 ∗ 𝜏 ∗ (?̃? − 1) +
𝑝7 ∗ 𝐺𝑏 ∗ 𝜏
𝐸𝑏
∗ (1 − ?̃?) + ?̃? ∗ ?̃?,         
𝑑𝐺𝑙?̃?
𝑑𝑇
=  −
𝑝9 ∗ 𝐺𝑙?̃? ∗ 𝑃𝑉𝑂2
𝑚𝑎?̃?
𝐺𝑙𝑦𝑏 ∗ (
1
2 + 𝐺𝑙?̃?)
− 𝑝13 ∗ 𝜏 ∗ (𝐺𝑙?̃? − 1) ∗ (1 −
𝑢3
𝑢3
),                    
𝑑𝑃𝑉𝑂2
𝑚𝑎?̃?
𝑑𝑇
=  −0.8 ∗ 𝑃𝑉𝑂2
𝑚𝑎?̃? ∗ 𝜏 + 0.8 ∗ 𝜏2 ∗ 𝑢3,                                              
 
𝑑?̃?
𝑑𝑇
= −𝑝10 ∗ ?̃? ∗ 𝜏 + 𝑝11 ∗ 𝜏 ∗ 𝑃𝑉𝑂2
𝑚𝑎?̃? ,                                                        
 
 
 
 
 
 
(5.54) 
 
(5.54) 
 
(5.55) 
 
(5.56) 
 
(5.57) 
 
(5.58) 
 
(5.59) 
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As discussed in section 5.3.1, there are three natural timescales in the system. 
Choosing to rescale for glucagon clearance, let 𝜏 =
1
𝑝6
: 
𝑑?̃?
𝑑𝑇
= −𝑝1̃ ∗ (?̃? − 1) − ?̃? ∗ (?̃? + ?̃?) +
𝑝12̃ ∗ 𝑝10̃ ∗ 𝐺𝑙?̃? ∗ 𝑃𝑉𝑂2
𝑚𝑎?̃?
(
1
2 + 𝐺𝑙?̃?)
+ 𝑃8̃ ∗ (?̃? − 1), 
𝑑?̃?
𝑑𝑇
=  −𝑝2̃ ∗ ?̃? + 𝑝3̃ ∗ 𝐼,                                                                                                            
𝑑𝐼
𝑑𝑇
=  −𝑝4̃ ∗ (𝐼 − 1) + 𝑝5̃ ∗ (?̃? − 1) − 𝐼 ∗ ?̃?,                                                                       
𝑑?̃? 
𝑑𝑇
= −(?̃? − 1) + 𝑝7̃ ∗ (1 − ?̃?) + ?̃? ∗ ?̃?,                                                                           
𝑑𝐺𝑙?̃?
𝑑𝑇
=  −
𝑝9̃ ∗ 𝐺𝑙?̃? ∗ 𝑃𝑉𝑂2
𝑚𝑎?̃?
(
1
2 + 𝐺𝑙?̃?)
− 𝑝13̃ ∗ (𝐺𝑙?̃? − 1),                                    
   
𝑑𝑃𝑉𝑂2
𝑚𝑎?̃?
𝑑𝑇
=  −0.8 ∗
𝑃𝑉𝑂2
𝑚𝑎?̃?
𝑝6
+
0.8
𝑝6
2 ∗ 𝑢3,                                                                           
𝑑?̃?
𝑑𝑇
= −𝑝10̃ ∗ ?̃? + 𝑝11̃ ∗ 𝑃𝑉𝑂2
𝑚𝑎?̃? ,                                                                                             
Where  
𝑝1̃ =
𝑝1
𝑝6
, 𝑝2̃ =
𝑝2
𝑝6
, 𝑝3̃ = 𝑝3 ∗
𝐼𝑏
𝑝6
2 , 𝑝4̃ =
𝑝4
𝑝6
, 𝑝5̃ =
𝑝5 ∗ 𝐺𝑏
𝐼𝑏 ∗ 𝑝6
, 𝑝7̃ =
𝑝7 ∗ 𝐺𝑏
𝐸𝑏 ∗ 𝑝6
, 𝑝8̃ =
𝑝8 ∗ 𝐸𝑏
𝐺𝑏 ∗ 𝑝6
̃
, 
𝑝9̃ =
𝑝9
𝐺𝑙𝑦𝑏
, 𝑝10̃ =
𝑝10
𝑝6
, 𝑝11̃ =
𝑝11
𝑝6
, 𝑝12̃ =
𝑝12
𝐺𝑏
 and 𝑝13̃ =
𝑝13
𝑝6
. 
where 
𝑝1̃ =
𝑝1
𝑝6
, 𝑝2̃ =
𝑝2
𝑝6
, 𝑝3̃ = 𝑝3 ∗
𝐼𝑏
𝑝6
2 , 𝑝4̃ =
𝑝4
𝑝6
, 𝑝5̃ =
𝑝5 ∗ 𝐺𝑏
𝐼𝑏 ∗ 𝑝6
, 𝑝7̃ =
𝑝7 ∗ 𝐺𝑏
𝐸𝑏 ∗ 𝑝6
, 𝑝8̃ =
𝑝8 ∗ 𝐸𝑏
𝐺𝑏 ∗ 𝑝6
̃
,
𝑝9̃ =
𝑝9
𝐺𝑙𝑦𝑏
, 𝑝10̃ =
𝑝10
𝑝6
, 𝑝11̃ =
𝑝11
𝑝6
, 𝑝12̃ =
𝑝12
𝐺𝑏
 and 𝑝13̃ =
𝑝13
𝑝6
 
The initial conditions then become 
?̃?(0) = 1, ?̃?(0) = 0, 𝐼(0) = 1, ?̃?(0) = 1, 𝐺𝑙?̃?(0) = 1, 𝑃𝑉𝑂2
𝑚𝑎𝑥̃ (0) = 0 and ?̃?(0) = 0. 
 
 
 
 
 
 
 
(5.60) 
(5.61) 
(5.62) 
(5.63) 
(5.64) 
(5.65) 
(5.66) 
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The critical points of a system refer to the long term behaviour of the system, in 
which it is assumed that the individual will have stopped exercising. 
By setting the system of equations (5.61-5.67) equal to zero and 
rearranging gives the non-dimensional system as follows: 
?̃? =
 𝑝1̃ ∗ 𝑝2̃
𝑝3  ̃
, 
?̃? =
𝑝3̃
𝑝2̃
, 
𝐼 = 𝑝4̃ + 𝑝5̃ ∗
(?̃? − 1)
+
𝑝4̃
, 
?̃? = 1 + 𝑝7̃ ∗ (1 − ?̃?)
+
,  
𝐺𝑙?̃? =  1, 
𝑃𝑉𝑂2
𝑚𝑎𝑥̃ = 0, 
?̃? = 0,   
Therefore it can be seen that, over time, both insulin and glucagon ensure glucose 
returns to the basal state, resulting  in the critical point of the system to be at 
 
(1, 
𝑝3̃
𝑝2̃
,1,1,1,0,0). The point is the only existing critical point of the system, and refers 
to the same state of the system at the beginning of the exercise protocol. 
The Jacobian matrix evaluated at the critical point is given as: 
𝐽4
= 
[
 
 
 
 
 
 
 
 
 
 −𝑝1̃ −
𝑝3̃
𝑝2̃
 −1 0 𝑃8̃ 0 2 ∗ 𝑝10̃ ∗
𝑝12̃
3
−1
0 −𝑝2̃ 𝑝3̃ 0 0 0 0
𝑝5̃ 0 𝑝4̃ 0 0 0 −1
−𝑝7̃ 0 0 −1 0 0 1
0 0 0 0 −𝑝13̃ −2 ∗
𝑝10̃
3
0
0 0 0 0 0 −
0.8
𝑝6
0
0 0 0 0 0 𝑝11 ̃ −𝑝10̃]
 
 
 
 
 
 
 
 
 
 
 
 
 
Therefore the characteristic equation is given 
by: 
 
The characteristic equation and roots were calculated in Mathematica,. The roots are 
all negative, thus the system is stable. 
(5.75) 
 
(5.68) 
(5.69) 
(5.70) 
(5.71) 
(5.72) 
(5.73) 
(5.74) 
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5.4. Model Simulations 
 
Both models are implemented in MATLAB to simulate the components within the 
glucose regulatory system for various exercise intensities and durations. The model 
parameters 𝑢3 and 𝑇𝑑𝑢𝑟 are fixed to adjust the simulations for various exercise 
intensities and durations respectively, replicating the protocols to the data obtained 
from the various studies used to validate the models. 
The datasets used to validate the models are obtained from Ahlborg et al. (1974), 
Wolfe et al. (1984), Ahlborg and Felig (1982) and Campbell et al. (2014). Each dataset 
consists of plasma measurements of glucose, insulin and glucagon, all taken at regular 
intervals. There are approximately 5 measurements of each concentration for each 
data set. Although this is a sufficient amount of data to be able to understand the 
behaviour of glucose and the hormones during exercise, given the scale of the models 
it is an insufficient number of points to return an individual set of parameters, and 
results in large confidence intervals for the individual parameters (see appendix). 
It is expected that the amount of physiological exercise induced effects ought to 
increase with increasing energy expenditure, which is reflected by the level of 
exercise activity, (𝑡). The total amount of energy expenditure is a function of the 
duration of exercise, the intensity, the weight of the individual and the activity 
(Moore, 2011). This presents some difficulty in determining the value of energy 
expenditure for each of the simulations, given that the data used has not been 
obtained from the same individual, and not all of the studies consisted of the same 
activity. It can be seen from Moore (2011) that running and cycling have very similar 
energy expenditure values, therefore it will be assumed that the activities of the 
datasets consist of the same energy expenditure value. All participants in the four 
studies were male, and of a healthy weight, therefore for simplicity body weight will 
not be considered at this stage. 
The models are solved using the inbuilt MATLAB solver ODE45, based on explicit 
Runge-Kutta methods. The parameters are solved within MATLAB using the 
LSQNONLIN function. Initial parameter guesses are inputted into the function based 
on parameter values obtained in chapter 3, existing literature (Roy and Parker, 2007), 
(Cobelli et al., 1998), (Cobelli et al., 1982) and adjusted to allow for exercise induced 
effects. 
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5.4.1. Exercise at 30% of 𝑽𝑶𝒎𝒂𝒙 
 
In this section the models are implemented in MATLAB, setting 𝑢3  = 30 and 
𝑇𝑑  = 240 to represent the individual working at 30% of their 𝑉𝑂
𝑚𝑎𝑥for 240 minutes. 
The models are fitted to the data set obtained by Ahlborg et al. (1974), where 
individuals performed exercise following an overnight fast in a post-absorptive state. 
The data set includes measurements for plasma glucose, insulin and glucagon, taken 
at 5 different time points, including the resting values, giving a total of 15 data points. 
Since the system consists of 13 unknown parameters a much greater number of data 
points would be required in order to give an accurate set of parameters for the model. 
This result is discussed later in the chapter. 
Since the initial measurements from the study performed by Ahlborg et al. (1974) are 
taken after an overnight fast, the initial measurements from the data will be used for 
the model’s initial and basal values for glucose, insulin and glucagon, i.e. 𝐺0  = 𝐺𝑏, 
𝐸0  = 𝐸𝑏  and 𝐼0   = 𝐼𝑏. 
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Figure 5.3: Exercise at 30% of PVOmax : G(t) against plasma glucose measurements, 
(a), Gly(t), (b),  PVOmax(t), (c) and A(t), (d). 
Figure 5.3 shows both models providing a good fit to the data set for plasma glucose 
(a), however the models show very different behaviour in the first 50 minutes of 
activity. The simulation for glucose in the Glucagon Exercise Minimal Model shows an 
initial fall in glucose levels, as the rate of glucose uptake increase to meet the 
increased demand for energy by the muscles, which is then met by an increase in HGP 
and glycogenolysis. Plasma glucose concentrations then gradually decrease with 
glycogen stores. In contrast, the Simplified Glucagon Exercise Minimal Model assumes 
an immediate increase in the concentration of glucose in the plasma, suggesting the 
onset of exercise is instantly met by an increase in glucose production, which then 
returns to basal and begins to decline as energy stores are depleted. 
(a) (b) 
(c) (d) 
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Both models predict a similar decrease in the amount of glycogen available 
throughout the duration of exercise. The models predict glycogen stores to decline to 
20% of their starting values, which is very close to the physical actuality, as glycogen 
stores were depleted by approximately 75%, according to Ahlborg et al. (1974). 
Both models show exercise activity increasing linearly as a function of exercise 
intensity and time (d). The Simplified Glucagon Exercise Minimal Model shows almost 
twice the amount of activity than the Glucagon Exercise Minimal Model, predicting 
the individual to be more sensitive to the effects of exercise. 
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Figure 5.4: Exercise at 30% of PVOmax: I(t) against plasma insulin concentrations, 
(a), X(t), (b), E(t) against plasma glucagon concentrations, (c) and Y(t), (d). 
Both models are capable of capturing the magnitude of the decline of plasma insulin 
concentrations (b); however, visually, the Simplified Glucagon Exercise Minimal 
Model provides a slightly better fit to the dataset. The Simplified Glucagon Exercise 
Minimal Model shows a greater amount of interstitial insulin activity than the 
Glucagon Exercise Minimal Model (b), suggesting a greater responsivity of the liver to 
insulin. Figure 5.4 (c) displays the accuracy of both models to fit the dataset of 
glucagon. 
(a) (b) 
(c) (d) 
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Table 5.7: Parameter results from simulations ran for both the Glucagon Exercise 
Minimal Model and the Linear Glucagon Exercise Minimal Model for 240 minutes of 
exercise at 30% of 𝑉𝑂𝑚𝑎𝑥 
 
Parameter GEMM GEMM Parameter SGEMM SGEMM 
𝑆𝐺   = 𝑝1 0.017553609 𝑝1 0.00150000 
𝑝2 2.239076769 𝑝2 0.30089987 
𝑝3 0.003716462 𝑝3 0.00142961 
𝑝4 0.018928669 𝑝4 0.03692484 
𝑝5 7.17288309 ∗ 10
−5 𝑝5 4.1464406 ∗ 10
−4 
𝑝6 0.98138568 - - 
𝑝7 3.31033229 ∗ 10
−5 - - 
𝑝8 0.01758642 𝑝6 0.04036082 
𝑝9 2.56707631 ∗ 10
−6 𝑝7 2.811859 ∗ 10
−12 
- - 𝑃8 0.10928015 
𝑝10 0.10927865 𝑝9 4.360198 ∗ 10
−14 
𝑝11 6.66091373 ∗ 10
−4 𝑝10 6.4258065 ∗ 10
−6 
𝑝12 4.13286068 ∗ 10
−6 𝑝11 2.65330416 
𝑝13 0.93794325 𝑝12 0.00503468 
𝑆𝐼 =
𝑝3
𝑝2
 0.00165982 𝑆   = 
𝑝3 
𝐼 𝑝2
 
0.00475113 
𝑆𝐸 =
𝑝7
𝑝6
 
3.37312064 ∗ 10−5 - - 
𝑆𝐴 =
𝑝12
𝑝11
 0.006204645 𝑆   =  
𝑝10 
𝐴 𝑝9
 
1.49667911∗ 108 
 
In the both Glucagon Exercise Minimal Model and the Simplified Glucagon Exercise 
Minimal Model, the parameter values for glucose effectiveness, 𝑆𝐺, are lower than for 
the values obtained for the IVGTT models (tables 3.7 and 3.8). Exercise is typically 
reported to increase glucose effectiveness (Nishida et al., 2001) however there are a 
number of factors that may have influenced this result which will be further 
94  
discussed in section 5.5. 
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Table 5.7 shows higher values for both models in comparison to their values for 
insulin sensitivity, 𝑆𝐼, when simulated for an IVGTT (tables 3.7 and 3.8), which is 
confirmed by studies that have established that exercise increases insulin sensitivity 
(Richter et al., 1985), (Ross, 2003). 
According to research, during exercise, there is an increase in sensitivity of the liver 
to glucagon during exercise (Bonjorn et al. 2002), (Adams, 2003). In comparison with 
the result from the IVGTT (table 3.7) the result from glucagon sensitivity, 𝑆𝐸, has in 
fact decreased. Despite this, comparing figures 5.4 and 3.7 it can be seen that the 
exercise model shows a much greater amount of glucagon activity acting on the 
system than in the IVGTT model. Therefore the likely cause for the exercise 
parameter value being lower than that of the IVGTT is that the term in Y(t) 
representing the increase in hepatic glucose production ability (𝑝7) is proportional to 
per unit of glucagon above baseline within the IVGTT Glucagon Minimal Model, 
whereas the exercise model is proportional to the total concentration of glucagon. 
The new parameter exercise sensitivity, 𝑆𝐴, is introduced and is defined as the ability 
of the system to respond accordingly to the onset of exercise. The glucose regulatory 
system response in this model consists of the system’s ability to decrease the 
concentration of insulin in the plasma, increase the concentration of plasma glucagon, 
increased muscle glucose uptake and glucose production (Goodwin, 2010). This value 
is expected to increase with exercise intensity and duration. 
The Glucagon Exercise Minimal Model returns a value within a reasonable magnitude 
of the other key parameters listed, whereas the Glucagon Exercise Linear Minimal 
Model returns a significantly higher value, which appears mismatched in comparison 
with the other parameters. 
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5.4.2. Exercise at 40% of 𝐕𝐎𝐦𝐚𝐱 
 
The second dataset used to validate the models is from the experiment by Wolfe et al. 
(1984) where a group of healthy men took part in exercise at 40% of their 𝑉𝑂𝑚𝑎𝑥 for 
60 minutes, following an overnight fast. Therefore the basal values will be fixed as the 
initial measurements, given the fact that the individuals were in the post absorptive 
state, and the exercise parameters will be fixed as 𝑢3  = 40 and 𝑇𝑑𝑢𝑟  = 60. 
As when fitting the models to the dataset in section 5.4.1, there are only 5 
measurements taken for each of the physical quantities in the plasma to fit the models 
to, posing an issue with obtaining a good quality fit for the models and a unique set of 
parameter values. 
Although the exercise intensity is slightly higher than the previous simulation in 
section 5.4.1, the exercise duration is significantly less. By estimating the total energy 
expenditure of both activities by calculating the products of the exercise activity and 
duration, it is presumed that the effects of exercise on the system will be significantly 
less than in the previous simulation. 
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(c) (d) 
Figure 5.5: Exercise at 40% of 𝑉𝑂𝑚 : G(t) against plasma glucose measurements,  
G(t) (a), Gly(t), (b),  𝑃𝑉𝑂2
𝑚𝑎𝑥(t), (c) and A(t), (d). 
Despite both models providing a fairly good fit to the dataset for plasma glucose 
levels, both anticipate a rapid fall in glucose levels within the first ten minutes of 
exercise. 
Although quite often blood glucose concentrations fall as a result of a delay in the 
response of the glucose regulatory system to the onset of exercise, it is unlikely for 
levels to fall by such a significant amount. This is particularly true for the Simplified 
Glucagon Exercise Minimal Model, with predicts the individual to become severely 
hypoglycaemic and unlikely to be able to sustain exercise, thus making the Glucagon 
Exercise Minimal Model the preferred choice for glucose levels. 
Both models predict the same amount of decline for muscle glycogen, show stores to 
only deplete by a quarter of the starting amount. Since the total energy expenditure is 
low it would be unlikely that a great amount would be utilised. 
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Both models demonstrate a greater amount of exercise activity than in comparison to 
the simulation for exercise at a lower intensity (see figure 5.3). For the simulation at 
30% of 𝑉𝑂𝑚𝑎𝑥 exercise activity appeared to increase linearly with exercise intensity 
at time, where as in this simulation the level appears to reach a peak level 
corresponding to the activity of  𝑃𝑉𝑂𝑚𝑎𝑥(𝑡). 
99  
2 
2 
 
 
Figure 5.6: Exercise at 40% of 𝑉𝑂𝑚 : I(t) against plasma insulin concentrations, (a), 
X(t), (b), E(t) against plasma glucagon concentrations, (c) and Y(t), (d). 
Both of the models predict plasma insulin levels (figure 5.6.a) to fall a little too 
quickly until it stabilises at what appears to be the minimum value. This 
behaviour correlates with exercise action, A(t), which ceases to increase as it 
reaches its ultimate level. 
Neither of the models serve a good fit to the data set for plasma insulin, predicting the 
concentration falls much quicker in the initial 15 minutes and then assuming levels 
level out around 9.5 µU/ml rather than continuing to fall. In comparison with the 
model simulations for individuals exercising at 30% of their 𝑉𝑂𝑚𝑎𝑥 , both models 
show an increase in the amount of insulin activity, which is to be expected given the 
combination of the slightly higher intensity of the exercise being and performed and 
greater availability of insulin in the plasma. 
(a) (b) 
(c) (d) 
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The Glucagon Exercise Minimal Model provides an excellent fit to the data for 
glucagon, whereas the Simplified Glucagon Exercise Minimal Model still fits the data 
well, it misses the third and fourth points. Although the Simplified Glucagon Exercise 
Minimal Model fits the data well, it shows a very large spike in the first ten minutes, 
which is in response to the exaggerated fall in glucose seen in figure 5.5.a. The 
glucagon activity matches the behaviour of glucagon and is of a greater magnitude 
than at exercising at a lower intensity (figure 5.6.d), since the sensitivity of the liver to 
glucagon is magnified with increasing intensity. 
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Table 5.8: Parameter results from the simulations for both the Glucagon Exercise 
Minimal Model and the Simplified Glucagon Exercise Minimal Model for 60 minutes of 
exercise at 40% of 𝑉𝑂𝑚 . 
 
Parameter 
GEMM 
Value 
Parameter 
SGEMM 
Value 
𝑝1 9.82210456 ∗ 10−7 𝑝1 1.294901545 ∗ 10−4 
𝑝2 2.174472150 𝑝2 3.046685906 
𝑝3 0.030060071 𝑝3 0.026127559 
𝑝4 0.427363226 𝑝4 0.155124835 
𝑝5 3.10209295 ∗ 10
−7 𝑝5 2.03958405 ∗ 10
−7 
𝑝6 0.351946257 - - 
𝑝7 5.50234639 ∗ 10−4 - - 
𝑝8 0.710810527 𝑝6 0.238400979 
𝑝9 1.374827718 𝑝7 1.374827718 
- - 𝑃8 0.223552393 
𝑝10 0.061870951 𝑝9 0.061870951 
𝑝11 0.183857888 𝑝10 0.814572420 
𝑝12 8.78558488 ∗ 10−4 𝑝11 0.001336112 
𝑝13 0.314711184 𝑝12 0.362639165 
𝑆𝐼 =
𝑝3
𝑝2
 0.013824077 𝑆   = 
𝑝3 
𝐼 𝑝2
 
0.008575731 
𝑆𝐸 =
𝑝7
𝑝6
 0.001563405 - - 
𝑆𝐴 =
𝑝12
𝑝11
 0.004778465 𝑆   =  
𝑝10 
𝐴 𝑝9
 13.16566828 
 
Both models return very low values for glucose effectiveness in comparison to the 
IVGTT models and the exercise simulations where 𝑢3 = 30 (see tables 3.7, 3.10 and 
5.6). This result was unexpected, given the extent of research that has found glucose 
effectiveness to increase with exercise (Nishida et al., 2001). For the Glucagon 
Exercise Minimal Model it is possible that the low value of glucose is due to the 
marked increase in both glucagon and insulin sensitivity.  These outcomes are 
discussed fully with the other parameter results in section 5.5. 
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The increase in insulin sensitivity for both models in comparison to the previous 
results for the 𝑃𝑉𝑂𝑚𝑎𝑥 = 30 indicate a higher level of insulin dependent glucose 
uptake and generally better health (Insulin Sensitivity, no date), which, in view of the 
measurements being taken from multiple people, could be down to individual 
variation. 
The result for insulin sensitivity, 𝑆𝐼, also deviates from expectations. It has been 
established that the greater the amount of glycogen depleted in a bout of exercise, the 
greater the increase in insulin sensitivity (Colberg, 2007). Therefore since more 
glycogen was depleted for the simulation where an individual was exercising at 30% 
of their 𝑉𝑂𝑚𝑎𝑥, the result would suggest that insulin sensitivity ought to be lower in 
this simulation. Due to the fact that the two datasets were from different individuals, 
it is likely that the participants in the study by Wolfe et al. (1984) had a higher 
sensitivity to insulin than those of the study performed by Ahlborg et al. (1974). 
Exercise sensitivity has slightly decreased in value for the Glucagon Exercise Minimal 
Model, which, despite an increased exercise intensity, seems reasonable given that 
the duration of exercise for this dataset was a quarter of that for the measurements 
taken during exercise where 𝑃𝑉𝑂𝑚𝑎𝑥 = 30. The value for the Linear Glucagon 
Exercise Minimal Model has also decreased, and is of a significantly lower magnitude 
than of the previous simulation. 
102  
𝟐 
2 
5.4.3. Exercise at 58% of 𝑽𝑶𝒎𝒂𝒙 
 
The third data set the models are validated against is taken from the results from 
Ahlborg and Felig (1982). In this experiment a group of healthy, non-diabetic men 
took part in 210 minutes of exercise at 58% of their 𝑉𝑂𝑚𝑎𝑥 following a 12-14 hour 
overnight fast. Thus the initial measurements for glucose, insulin and glucagon were 
fixed as the basal values, with the exercise parameters set as 𝑢3  = 58 and 𝑇𝑑𝑢𝑟  = 210. 
This dataset consists of 6 data points available for each concentration within the 
plasma, which, although is three more points than offered by the previous datasets, is 
still an insufficient number to obtain a parameter set with narrow confidence 
intervals. 
Since this simulation is of a higher intensity than both of the previous simulations and 
is for a considerable duration, the effects of exercise on the system are expected to be 
considerably greater than previously seen. 
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Figure 5.7: Exercise at 58% of VOmax: G(t) against plasma glucose measurements, 
G(t) (a), Gly(t) (b), 𝑃𝑉𝑂2
𝑚𝑎𝑥 (c), and A(t) (d).  
The two models show different behaviour for plasma glucose levels. The Simplified 
Glucagon Exercise Minimal Model shows more continuous behaviour, predicting 
levels to increase rapidly as a result of the model’s overestimation of glucagon levels, 
then decline too quickly, overestimating the glucose concentration for a large part of 
the exercise duration. The Glucagon Exercise Minimal Model shows unstable as the 
hormones adjust to the onset of exercise, before settling into a gradual decline as 
glycogen stores become depleted. 
Both models predict a fast decline in glycogen stores, which become entirely depleted 
by the end of the duration of activity. This suggests that, out of the three exercise 
protocols so far, this is the most effective for improving the diabetic state. This verdict 
is based on the results of the research by Colberg (2007) and Kang et al. (1996) who 
(a) 
(c) 
(b) 
(d) 
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found a longer improvement in insulin sensitivity was related to the greater the 
amount of glycogen burned during a bout of activity. 
The Glucagon Exercise Minimal Model shows significantly greater levels of exercise 
activity out of the two. It displays a greater amount of activity than the protocol for 
30% as expected but less than 40% which appears quite unconventional, given the 
increase in intensity and exercise duration. The Simplified Glucagon Exercise 
Minimal Model shows less exercise activity than both of the previous simulations, a 
result that deviates from the predicted outcome based on research, thus giving some 
doubt to the reliability of the model. 
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Figure 5.8: Exercise at 58% of VOmax: I(t) against plasma insulin concentrations, (a), 
X(t), (b), E(t) against plasma glucagon concentrations, (c) and Y(t), (d). 
The results for plasma insulin clearly show the Simplified Glucagon Exercise Minimal 
Model to provide the better fit to the data of the two, since the Glucagon Exercise 
Minimal Model underestimates the rate of decline in plasma insulin levels. 
However the Simplified Glucagon Exercise Minimal Model has a very low level of 
insulin activity in comparison with the simulations for exercise of 30% and 40% 
of 𝑉𝑂2
𝑚𝑎𝑥  than at 58% of  𝑉𝑂2
𝑚𝑎𝑥 , which is not expected, since, as previously 
  
mentioned, insulin sensitivity has been observed to increase with decreasing 
glycogen levels and increased energy expenditure (Verkerke et al., 2015). This 
simulation has shown glycogen levels to deplete at a faster rate than previous 
simulations; therefore insulin activity should follow insulin sensitivity be the greatest 
(a) 
(c) 
(b) 
(d) 
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for this simulation. The Glucagon Exercise Minimal Model however does meet this 
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expectation, as there is a slightly higher amount of activity than demonstrated at 
30% of  and significantly more than at 40%. 
The Glucagon Exercise Minimal Model provides a notably better fit to the plasma 
glucagon measurements than the Simplifed Glucagon Exercise Minimal Model, which 
rises too quickly and is responsible for the initial increment in plasma glucose. 
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Table 5.9: Parameter results from simulations for both the Glucagon Exercise 
Minimal Model and the Simplified Glucagon Exercise Minimal Model for 210 minutes 
of exercise at 58% of 𝑉𝑂𝑚𝑎𝑥. 
 
Parameter 
GEMM 
Value 
Parameter 
SGEMM 
Value 
𝑆𝐺   = 𝑝1 0.20550317 𝑝1 0.016411558 
𝑝2 1.13046419 𝑝2 0.963873328 
𝑝3 0.02299561 𝑝3 0.000679837 
𝑝4 0.09800001 𝑝4 0.010277818 
𝑝5 0.05600000 𝑝5 7.87208 ∗ 10
−14 
𝑝6 5.37961561 - - 
𝑝7 0.00015838 - - 
𝑝8 1.59847556 𝑝6 0.161251435 
𝑝9 9.20837923 𝑝7 0.016193108 
𝑝10 0.09947311 𝑝8 0.001037968 
𝑝11 0.00000188 𝑝9 0.099488025 
𝑝12 0.00001003 𝑝10 0.010979608 
𝑝13 6.40031140 𝑝11 0.000003678 
- 0.02034174 𝑝12 2.681901231 
𝑆𝐼 =
𝑝3
𝑝2
 0.00002944 𝑆𝐼 =
𝑝3
𝑝2
 0.000705317 
𝑆𝐸 =
𝑝7
𝑝6
 5.32583804 - - 
𝑆𝐴 =
𝑝12
𝑝11
 0.20550317 𝑆𝐴 =
𝑝12
𝑝11
 0.110361102 
 
The values for glucose effectiveness for both the Glucagon Exercise Minimal Model 
and the Simplified Glucagon Exercise Minimal Model have increased significantly in 
comparison to the values returned for the models by any of the other simulations for 
exercise or the IVGTT. This result suggests long durations of exercise at a moderate 
exercise intensity significantly increase glucose effectiveness. 
The value of insulin sensitivity for both of the models has decreased in comparison to 
the values for the models from the previous simulations of exercise at lower 
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intensities. This is an unexpected result, given the greater amount of energy 
expenditure in this simulation. This result suggests that the data obtained from this 
study was from an individual with a higher insulin resistance than the previous two. 
Glucagon sensitivity has increased a considerable amount from the previous 
simulations, a result which is expected given the high intensity and prolonged 
duration of the exercise. This result is likely to be an adaptation of the liver to 
prolonged exercise in order to avoid hypoglycaemia. If this value did not decrease 
post workout, combined with the low value for insulin sensitivity the individual 
would be at a risk of experiencing hyperglycaemia. 
For the Glucagon Exercise Minimal Model, exercise sensitivity is at its highest value, 
and shows a trend of increasing with total energy expenditure. This is a positive 
result, as it is what would have been expected for if all of the data had been obtained 
from the same individual. The Simplified Glucagon Exercise Minimal Model shows a 
lower value for exercise activity, particularly in comparison to the previous 
simulation (see table 5.8). At present there appears to be no relationship between 
exercise sensitivity and energy expenditure, intensity or duration. 
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5.4.4. Exercise at 70% of 𝐕𝐎𝐦𝐚𝐱 
 
The final dataset used to validate the model is from Campbell et al. (2014) and consist 
of the glucose and hormone concentrations within the plasma being measured four 
times over 45 minutes whilst the patients are exercising at approximately 70% of 
their VOmax. The individuals all had type 1 diabetes, however they had received 
insulin treatments, and therefore the model will not be changed and it will be 
assumed that the insulin present in the blood was the result of pancreatic secretion. 
Patients took part in the evening, and were not in the fasted state; therefore the initial 
conditions will not be starting at the basal levels. 
Since the dataset was obtained from individuals with type 1 diabetes, it is unlikely 
that the two models in this chapter will present a good fit to the plasma insulin 
measurements, as the equations for insulin (5.11 and 5.19) assumes insulin 
production and normal beta cell functionality. A model is introduced in chapter 6 that 
assumes type 1 diabetes and requires an input function for exogenous insulin, thus is 
expected to give a better fit to the data. 
The patients who took part in the study by Campbell at el. (2014) were considered to 
be healthy and not known to have any diabetes related complications normal gluco- 
regulatory responses will be assumed and no changes will be made to the models. 
Despite the exercise duration being shorter than the previous simulations, since the 
exercise intensity is fairly high it is expected that this exercise protocol ought to have 
a significant impact on the glucose regulatory system. 
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Figure 5.9: Exercise at 70% of  VOmax: G(t) against plasma insulin concentrations,  (a), 
PVOmax(t), (b), E(t) against plasma glucagon concentrations, (c) and A(t), (d). 
 
The Glucagon Exercise Minimal Model provides the better fit of the two models to the 
dataset. It predicts an initial fall in glucose concentrations as the onset of exercise 
increases the demand for glucose as fuel by the working muscles. Research shows 
that, during the first fifteen minutes of exercise, fuel for the working muscles mostly 
comes from glucose within either the blood stream or stored as muscle glycogen 
(Giles, 2016). Glucose levels then rise as the glucagon concentration increases and 
subsequently cause an increase in the rate HGP. The Simplified Glucagon Exercise 
Minimal Model predicts that glucose production will rise immediately, which is likely 
to be a result of the exaggerated rise it anticipates for plasma glucagon levels, as 
shown in figure 5.10.a. 
(a) (b) 
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Both models show a similar rate for the depletions of glycogen stores, with the 
Simplified Glucagon Exercise Minimal Model falling slightly lower. 
The Simplified Glucagon Exercise Minimal shows a much greater level of exercise 
activity than the Glucagon Exercise Minimal Model. Although it is not unlikely that 
this simulation would result in the highest levels of exercise activity, the result given 
by the Simplified Glucagon Exercise Minimal is of a far greater magnitude than any of 
the previous simulations, making its physiological accuracy questionable. 
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Figure 5.10: Exercise at 70% of VOmax: E(t) against plasma glucagon concentrations, 
(a), Y(t), (b), I(t) against plasma insulin concentrations, (c) and X(t), (d). 
The Glucagon Exercise Minimal Model provides a much better fit to the dataset for 
plasma glucagon measurements than the Simplified Glucagon Exercise Minimal Model. 
It shows levels rise quickly accordingly with the onset of exercise and fall in glucose 
levels (figure 5.9.a) and then remain at a consistent elevated level for the remaining 
duration of exercise. The Simplified Glucagon Exercise Minimal Model predicts 
unusual behaviour, show a sharp rise then fall in levels before continually rising, 
overshooting all data points. From figure 5.9.d it is clear to see that the elevated level 
of exercise activity for the Simplified Glucagon Exercise Minimal Model is responsible 
for the excess of glucagon in the plasma. 
Although neither of the models provides a good fit to the insulin data, clearly the 
Glucagon Exercise Minimal Model is the better of the two. The models were not 
(a) (b) 
(c) (d) 
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expected to fit the data well, since they both simulate a healthy patient, whereas this 
data was collect from type 1 diabetic individuals, administering exogenous insulin. It 
is known that exogenously delivered insulin is not subject to normal physiological 
feedback regulation (McCrimmon and Sherwin, 2010) as is assumed by equation 
(5.11) in the model, which is likely to be the cause of the poor data fit. 
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Table 5.10: Parameter results from simulations for both the Glucagon Exercise 
Minimal Model and the Simplified Glucagon Exercise Minimal Model for 45 minutes of 
exercise at 70% of 𝑉𝑂𝑚 . 
 
Parameter 
GEMM 
Value 
Parameter 
SGEMM 
Value 
𝑆𝐺   = 𝑝1 0.21299553 𝑝1 0.346341523 
𝑝2 1.29778516 𝑝2 9.633789789 
𝑝3 0.03443631 𝑝3 1.173031 ∗ 10−4 
𝑝4 0.24788057 𝑝4 14.231816526 
𝑝5 0.01799555 𝑝5 8.603068353 
𝑝6 0.09630926 - - 
𝑝7 0.00004806 - - 
𝑝8 1.43637670 𝑝6 0.001000000 
𝑝9 0.22328702 𝑝7 23.707465199 
- - 𝑃8 3.124506262 
𝑝10 0.30186851 𝑝9 0.953347919 
𝑝11 0.07182015 𝑝10 4.189026 ∗ 10−6 
𝑝12 0.00009171 𝑝11 8.169374 ∗ 10−4 
𝑝13 1.73064711 𝑝12 4.454932251 
𝑆𝐼 =
𝑝3
𝑝2
 0.02653468 𝑆𝐼 =
𝑝3
𝑝2
 1.217621 ∗ 10−5 
𝑆𝐸 =
𝑝7
𝑝6
 4.989975 ∗ 10
−4 - - 
𝑆𝐴 =
𝑝12
𝑝11
 0.00127690 𝑆𝐴 =
𝑝12
𝑝11
 4.394016 ∗ 10−6 
 
Both models return a high value for glucose effectiveness, which is to be expected 
given the high intensity and duration of exercise, resulting in an overall reasonably 
high level of energy expenditure. 
The Glucagon Exercise Minimal Model returns a higher value for insulin sensitivity 
than all other simulations. Some evidence suggests that exercising at higher 
intensities achieve greater improvements in insulin sensitivity (Seals et al., 1984), 
(DiPietro et al., 2006). The result from the Glucagon Exercise Minimal Model confirms 
this finding; however more datasets will need to be collected for the model to be 
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fitted to in order to validate this conjecture with certainty. On the other hand the 
Simplified Glucagon Exercise Minimal Model returns a very low value for insulin 
sensitivity. 
The Glucagon Exercise Minimal Model returns a lower value for glucagon sensitivity  
in comparison to the results from the IVGTT model and the simulations for exercise at 
both 40% and 58% of 𝑃𝑉𝑂𝑚𝑎𝑥. One aspect that may have influenced this result is that, 
research has shown that within a few years of diagnosis individuals with T1DM tend 
to fail to generate an adequate glucagon response (McCrimmon and Sherwin, 2010), 
which, since this dataset was obtained from participants with T1DM, may explain this 
result. Additionally, and most likely to be the case, is that this model assumes the 
increase of glucagon activity to be proportional to the total concentration of plasma 
glucagon, as opposed to the increase above the basal level as is assumed in the IVGTT 
model. The plasma measurements for glucagon in this data set are also markedly 
higher than in the previous data sets. Therefore with a greater amount of glucagon, a 
lower value of sensitivity will still have the same, if not larger, effects to the glucose 
regulatory system. 
The Glucagon Exercise Minimal Model returns a moderately high value for exercise 
sensitivity in comparison to the other simulations whereas the Simplified Glucagon 
Exercise Minimal Model does not, returning an unexpectedly low value. 
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5.5. Discussion 
 
In section 5.4 both of the models proposed in section 5.2 were simulated and fitted to 
the datasets obtained from four different studies on exercise, consisting of varying 
exercise intensities and durations. The parameter expectations and actual parameter 
results were briefly discussed and compared with the results for the IVGTT models in 
section 5.4. In this section an analysis of the parameters is given, comparing the 
values obtained from the simulations with each other, what the physiological 
implications of the values are in addition to possible factors that may have influenced 
the results. A comparison of the results for the key parameters is shown in table 5.12. 
Before comparing the parameter values and discussing the implications it is to be 
noted that, since the datasets are not measurements all from the same individual, 
there is likely to be intra-individual variation in glucose regulation. This may have 
been the cause of some results differing from what was hypothesised. 
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Table 5.11: Comparison of the key parameters from the two exercise models for the 
four different exercise protocols. 
 
Parameter GEMM SGEMM 
30% of 𝑽𝑶𝒎𝒂𝒙 
𝟐 
𝑆𝐺 0.017553 0.001500 
𝑆𝐼 0.001659 0.004751 
𝑆𝐸 3.3*10−5 - 
𝑆𝐴 0.017553 0.001500 
40% of 𝑽𝑶𝒎𝒂𝒙 
𝟐 
𝑆𝐺 9.82*10−7 1.2949010
−4 
𝑆𝐼 0.01382407 0.0085757 
𝑆𝐸 0.00156340 - 
𝑆𝐴 0.00477846 13.165668 
58% of 𝑽𝑶𝒎𝒂𝒙 
𝟐 
𝑆𝐺 0.205503 0.0164115 
𝑆𝐼 2.944∗ 10−5 0.0007053 
𝑆𝐸 5.325838 - 
𝑆𝐴 0.205503 0.1103611 
70% of 𝑽𝑶𝒎𝒂𝒙 
𝟐 
𝑆𝐺 0.2129955 0.346341 
𝑆𝐼 0.0265346 1.2176 ∗ 10−5 
𝑆𝐸 0.0004990 - 
𝑆𝐴 0.0012769 4.39 ∗ 10−6 
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5.5.1. Glucose Effectiveness 
 
In chapter 3 the acceptable range for glucose effectivenes, 𝑆𝐺   = 𝑝1, from an IVGTT 
was identified as [0.8 − 3.8 ∗ 10−2], as defined by McDonald and co-workers (2000). 
All model simulations with the exception of where 𝑃𝑉𝑂𝑚  = 40 lie within 
reasonable vicinity to this range, and typically increase with energy expenditure. 
 
Exercise has been reported to increase glucose effectiveness (Nishida et al., 2001), 
(Sakamoto et al., 1999), as studies have found that, following a bout of exercise, 
glucose effectiveness would increase during an IVGTT in comparison to if individuals 
had been sedentary. However there are few studies that consider or attempt to 
measure glucose effectiveness during exercise. 
Epinephrine is one of the main hormones whose concentrations markedly increase 
during exercise (Zouhal et al., 2008), and has been found to decreased glucose 
effectiveness significantly (Avagaro et al., 1996), It is possible that this may be an 
underlying cause of some values for glucose effectiveness being lower than expected. 
It is difficult to assess the effect of epinephrine without further study. This will be 
further discussed in chapter 7. 
Glucose effectiveness is defined as the ability of hyperglycemia to promote glucose 
disposal at basal insulin (Nishida et al., 2001). Throughout the entire duration of 
exercise for all simulations, with the exception of where 𝑃𝑉𝑂𝑚𝑎𝑥 = 70, the patients’ 
plasma glucose concentrations remain fairly close to the basal levels and therefore 
disposal of excess glucose is not required. Given that the individual is not in a fed 
state it is difficult to evaluate of the ability of glucose to stimulate glucose uptake 
(Tonelli et al., 2005). Thus it is unlikely that the values of 𝑆𝐺 during exercise give a 
true insight into the ability to dispose of glucose without the presence of insulin. 
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Figure 5.11: Comparison of Glucose Effectiveness for both exercise models for 
different durations and exercise intensities. 
Figure 5.11 shows the relationship between glucose effectiveness and the four 
exercise protocols for both of the models. The Glucagon Exercise Minimal Model 
shows the value for the parameter to increase with intensity except for where 
𝑃𝑉𝑂𝑚  = 40, which is to be expected given the duration is much shorter than the 
simulations where 𝑃𝑉𝑂𝑚𝑎𝑥  = 30, thus resulting in the lowest energy expenditure.  
The Simplified Glucagon Exercise Minimal Model does not predict this behaviour, and 
shows the value to continually rise with increasing intensity despite the differences in 
exercise duration. 
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5.5.2. Insulin Sensitivity 
 
Referring to the ability of insulin stimulated glucose uptake (Lakshmi Kiran et al. 
2010), insulin sensitivity, 𝑆𝐼, is a key parameter for analysing the diabetic state. The 
acceptable value for insulin sensitivity for a healthy person undertaking an IVGTT is 
given as approximately 5 ∗ 10−4  (Pacini and Bergman, 1986). 
One of the many benefits of exercise includes the fact that it increases insulin 
sensitivity (Richter et al., 1985), (Ross, 2003), (Borghouts and Keizer, 2000), 
(Holloszy, 2005). However, since the exercise models assume insulin activity to 
increase proportionally to the total amount of insulin in the plasma rather than the 
excess above the basal level, as is assumed in the IVGTT model, it is quite reasonable 
that the exercise models should return values that are lower than would have been 
expected. This change was made to the model as, if it had remained the same as in the 
IVGTT model, since there are low levels of insulin the model would assume that there 
was no insulin activity, which physiological is not true. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12: Comparison of Insulin Sensitivity for both exercise models for different 
durations and exercise intensities. 
In figure 5.12 it can be seen that for Simplified Glucagon Exercise Minimal Model 
there is no trend for insulin sensitivity, giving the lowest values for the two protocols 
with the highest intensities and the highest value for the protocol with the lowest 
amount of energy expenditure, which is very unlikely. The Glucagon Exercise Minimal 
Model shows a much clearer trend, showing insulin sensitivity to increase with 
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2 intensity, as would be expected. The only anomaly is for 𝑃𝑉𝑂
𝑚  = 58, where for  both 
models the value for insulin sensitivity is extremely low. It would suggest that the 
individual exercising was significantly more insulin resistant in comparison to the 
individuals of whom the other measurements were obtained from. 
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5.5.3. Glucagon Sensitivity 
 
In 1985 Bonjorn et al. suggested that exercise was responsible for an increased 
sensitivity of the liver to glucagon. This has later been confirmed by Lavoie (2005), 
who found that an increase in glucagon receptor density occurred during both 
endurance exercise and periods of fasting, which appears to be an adaptation of the 
liver to enhance HGP responsiveness to glucagon, i.e. to increase glucagon sensitivity. 
In chapter 3 the Glucagon Minimal Model gave a value for glucagon sensitivity during 
the IVGTT to be 𝑆𝐸 = 0.001528. Despite the fact that fasting increases glucagon 
sensitivity, it would be expected that, since at the beginning of the protocol the 
patient receives a large glucose bolus, thus inducing a fed state, glucagon sensitivity 
would be significantly lower than it would be for any of the exercise protocols. 
However since in the exercise models glucagon activity increases proportionally to 
the plasma glucagon concentration rather than the excess above the basal level, it is 
expected that the values may be slightly lower. 
Often the effect of diabetes on glucagon regulation is overlooked, with treatment 
namely focusing on the insulin secretion abnormalities (Godoy-Matos, 2014). 
Individuals with T2DM may experience hyper secretion in the postprandial state and 
dysfunctional secretion in the fasting state (Khardori, 2013), therefore an abnormally 
low value for glucagon sensitivity during exercise may be seen as an indication of an 
impairment within the glucose regulatory system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13: Comparison of Glucagon Sensitivity for the Glucagon Exercise Minimal 
Model for different durations and exercise intensities. 
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The Glucagon Exercise Minimal Model shows all values to be of a similar magnitude, 
with the exception of where 𝑃𝑉𝑂𝑚𝑎𝑥 = 58, which returns a much higher value than 
the other three simulations. It is expected that glucagon sensitivity increases with 
increasing exercise duration and intensity, therefore since 𝑃𝑉𝑂𝑚𝑎𝑥 = 58 resulted in 
the largest energy expenditure (produce of exercise intensity and duration), the 
parameter results are in keeping with the findings in literature. 
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5.5.4. Exercise Sensitivity 
 
In this chapter a new parameter has been introduced referred to as exercise 
sensitivity, 
𝑆𝐴. This parameter is defined as the ability of the glucose regulatory system to 
respond and to act accordingly to the onset of exercise, i.e. to maintain homeostasis 
whilst meeting the increased demand for energy. 
Since this is the first mathematical model to represent the effects of exercise in this 
manner, there are no existing values to compare the parameters to, however they 
should be within reasonable magnitude of the values for the other key parameters 
as listed in table 5.12. 
It is not anticipated that a diabetic state ought to affect the individual’s ability to 
respond directly to exercise. Since exercise stimulated glucose uptake acts through a 
separate signalling pathway to insulin dependent glucose uptake (Hayashi et al., 
1997), it is considered to be normal even in those who suffer from insulin resistance 
and diabetes (Merry and McConell, 2009). Therefore, although some abnormalities 
are expected to occur during exercise, e.g. hyper- or hypoglycaemia, the value for 
exercise sensitivity is not expected to change significantly given the presence of the 
disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14: Comparison of the values for Exercise Sensitivity from both models for 
different durations and exercise intensities. 
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Figure 5.14 does not consider two of the parameter results for the Simplified 
Glucagon Exercise Minimal Model since the values are of a much larger magnitude 
than any of the other parameter values in these models, thus deemed unrealistic and 
inaccurate. 
The Glucagon Exercise Minimal Model returns the highest value for where 
𝑃𝑉𝑂𝑚𝑎𝑥 = 58, which corresponds with expectations given that the individual was 
exercising for a long duration at a moderately high intensity, thus was most likely to 
have resulted in the highest amount of energy expenditure, confirming the models 
accuracy. 
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5.6. Summary 
 
In this chapter two mathematical models have been proposed that are capable of 
accounting for the key processes responsible for blood glucose regulation during 
exercise. 
The first model proposed, the Glucagon Exercise Minimal Model, modelled the effects 
of glucagon on glucose levels indirectly by introducing a non-linear variable that 
accounts of the level of glucagon induced activity within the system. The key 
parameter values, as shown in table 5.12 are all within physiological reasoning, with 
the values for both glucose effectiveness and insulin sensitivity lying within justifiable 
magnitude to the parameter values deemed acceptable for the IVGTT minimal model. 
Typically, the key parameters increased with increasing energy expenditure, which is 
estimated based on the work of Moore (2011) as a product of exercise duration and 
intensity. 
The second model proposed, the Simplified Glucagon Exercise Minimal Model, 
assumed a linear relationship between the amount of glucagon in the plasma above 
baseline value and glucose. Although the model is advantageous in the sense it has a 
parameter and variable less than the Glucagon Exercise Minimal Model, the returned 
values for the key parameters do not correlate with each other, the hypotheses from 
literature nor are deemed as physiologically realistic. 
Overall, the Glucagon Exercise Minimal Model provided the best fit to the data and the 
most physiologically accurate behaviour for concentrations of glucose and the two 
hormones in the plasma. Although it consistently provide a good fit, this is to be 
expected given the limited amount of data points available for the studies. 
Research shows that the greater the amount of glycogen burned during a single 
exercise session, the greater the improvement for insulin sensitivity (Colberg, 2008), 
(Kang et al. 1996). The models show that the exercise protocol where 𝑃𝑉𝑂𝑚𝑎𝑥 = 70 
and 𝑃𝑉𝑂𝑚𝑎𝑥 = 58 to be the best options for improving insulin sensitivity as they 
utilised the most glycogen. This is confirmed by the results of the Glucagon Exercise 
Minimal Model, which returned the highest value for insulin sensitivity of all of the 
simulations when 𝑃𝑉𝑂𝑚  = 70. The model returns an unusually low value for 
𝑉𝑂𝑚𝑎𝑥 = 58, however without further data to validate it is impossible to identify the 
cause of this result, and could simply due to individual variability. 
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Therefore the Glucagon Exercise Minimal Model was the best performing of the two 
models and will be extended in chapter 6 to consider an individual with T1DM 
diabetes. 
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Chapter 6 Insulin Infusion and Exercise 
 
6.1. Introduction to Insulin Treatments for T1DM 
 
As discussed in chapter 1, T1DM occurs when the pancreas is unable to produce any 
insulin; therefore patients are dependent on an exogenous supply to maintain glucose 
homeostasis. The aim of this chapter is to introduce a term into the models proposed 
to replicate insulin treatments. The response of plasma insulin concentrations to an 
exogenous supply varies, depending on the type of insulin treatment used. Figure 6.1 
summarises the effect of varying treatments on insulin. 
 
 
Figure 6.1: Different durations and onsets of various insulin treatments taken from 
Latif (2007). 
Typically insulin treatments are classified as short, medium or long according on 
their action in time (Basov et al., 1999), as shown in table 6.1, adapted from Donner 
(2015), describing the pharmacokinetics of available insulins. 
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Table 6.1. Pharmacokinetics of insulins (Donner, 2015) 
 
Insulin Onset Peak Duration 
Lispro 5-15 minutes 30-90 minutes 3-5 hours 
Aspart 10-20 minutes 1-3 hours 3-5 hours 
Regular Insulin 30-60 minutes 1-5 hours 6-10 hours 
Buffered Regular 
Insulin 
30-60 minutes 1-3 hours 8 hours 
Lente 1-3 hours 6-14 hours 16-24 hours 
NPH 1-2 hours 6-14 hours 16-24+ hours 
Glargine 1.1 hours None 24 hours 
Ultralente 4-6 hours 8-20 hours >24 hours 
 
 
Therefore in order to develop a model capable of considering exogenous insulin, the 
mathematical term needs to be adaptable to allow for the different characteristics 
belonging to the various types of insulins, including different durations of the 
treatment, the size of the insulin dosage and the frequency of the administration. 
Knowledge of the time action of insulins can help clinicians and patients to determine 
a suitable treatment plan and predict the effect of the treatment on the plasma over 
time. However, as for most aspects within the glucose regulatory system, insulin 
administration varies between patients and can be affected by a number of factors. 
McCulloch et al. (2016) list the external affecting factors to be the dose of insulin, the 
injection technique, the injection site and the time passed since opening the bottle, 
since the potency of insulin is noted to decrease over the following 30 days. In 
addition to the external factors relating to the administration of insulin, each 
individual will react differently to the treatments, due to variations in subcutaneous 
blood flow and levels of physical activity, which affect the diffusion conditions in the 
subcutaneous tissue (Hildebrandt, 1991).Developing a model that can account for and 
analyse the effects of such factors can assist the understanding and implementation of 
an effective treatment plan for individuals with  T1DM. 
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6.2. Critical Review of Insulin Infusion Models 
 
Basov et al. (1999) proposed a model that considers the effect of self-administered 
insulin, in order to help determine the required dosage and corresponding effects on 
glycaemia. 
The term for insulin infusion is given mathematically as the following: 
 
𝐼𝑒𝑥𝑔 = {
0, 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒,
𝐵 ∗ sin (𝜋 ∗
𝑡
𝑇
), 𝑡0 ≤ 𝑡 ≤ 𝑡0 +  𝑇,
                                        (6.1) 
 
Where the constants have been defined by Sulston et al. (2007) as can be seen in table 
6.2. 
Table 6.2. Nomenclature for Basov’s insulin infusion term 
 
 
 
 
 
 
 
 
 
 
 
 
 
Although the model is simple to use and allows for the parameters to be adjusted for various 
insulin treatments there are drawbacks to the model proposed by Basov et al. (1999). The 
sine function is a continuous function that does not reach a natural end; therefore the 
function is forced to discontinue, which does not provide an accurate physiological 
representation and encounters issues when determining the long term behaviour of the 
system, since sine functions have no limit but simply oscillate between their minimum and 
maximum values. 
Additionally, the model does not allow for different onset and clearance times, assuming that 
the insulin leaves the blood at the same rate at which it enters. This is demonstrated by a 
simulation of the minimal model, where the equation for insulin has been adapted to consider 
the sine term for exogenous insulin and the parameter values are set to those provided by 
Roy and Parker (2007) for a type 1 diabetic individual. 
 
Parameter Description 
𝐼𝑇𝑜𝑡𝑎𝑙 Size of insulin dosage. 
𝑇 Duration of effectiveness of treatment, 
i.e. time taken for insulin treatment to 
reach its peak 𝑡0 Time of administration 
            𝐵 
𝜋 ∗
𝐼𝑇𝑜𝑡𝑎𝑙
2 ∗ 𝑇
 
 sin (𝜋 ∗
𝑡
𝑇
) 
Representation of the behaviour of the 
infused insulin entering the plasma. 
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Figure 6.2. Simulation of the minimal model with the term proposed by Basov and 
co-workers for rapid (a) and long (b) acting exogenous insulin. 
Other models to describe exogenous insulin administration include the model 
proposed by Li and Kuang (2009). Li and Kuang developed a system of differential 
equations to mimic the effects of rapid acting insulin, administered in hexameric form, 
which is then broken down into dimers, which are then broken down into monomers 
and absorbed into the bloodstream (Wuang et al. 2013). Their proposed system is as 
follows:  
𝑑𝐻
𝑑𝑡
=  −𝑝 ∗ (𝐻(𝑡) − 𝑞 ∗ 𝐷3(𝑡)),                                                       (6.2) 
𝑑𝐷
𝑑𝑡
= 𝑝 ∗ (𝐻(𝑡) − 𝑞 ∗ 𝐷3(𝑡)) − 𝑏 ∗
𝐷(𝑡)
1 + 𝐼(𝑡)
,                               (6.3) 
𝑑𝐼
𝑑𝑡
=  𝑟 ∗ 𝑏 ∗
𝐷(𝑡)
1 + 𝐼(𝑡)
− 𝑑𝑖 ∗ 𝐼(𝑡),                                                     (6.4) 
where H is insulin analogue in hexameric form, D is insulin analogue in dimeric form 
and I is the plasma insulin concentration. 
The model provided a good fit to experimental data and it possesses a unique globally 
asymptotically stable equilibrium. However, the system is significantly more complex 
in comparison to the term proposed by Basov et al. (1999), introducing 6 new 
quantities to model the effects in the system. 
 
 
 
 
(a) (b) 
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6.3. Model Formulation for Insulin Infusion 
 
Since the aim of this thesis is to develop a mathematical model to predict blood 
glucose levels during exercise, the term for insulin administration will not go into the 
level of detail and complexity as Li and Kuang (2009) but will take a more simplified 
approach. 
A term is proposed is designed to mimic the effects of administering insulin 
treatments: 
𝐼𝑒𝑥𝑔 = 𝛼 ∗ (−e
−π∗
t
ton + 𝑒
−𝜋∗
𝑡
𝑡𝑑𝑒𝑔),                                                          (6.5) 
where 𝑡𝑜𝑛 is the duration of the onset of the insulin treatment, tdegis the duration of 
the clearance from the plasma and α is the parameter that controls how the amount 
by which the treatment will increase the plasma insulin concentration. 
6.3.1. Minimal Model and Insulin Infusion 
 
The Minimal Model, equations (2.3-2.5), was adapted to simulate a type 1 diabetic 
patient. The first and second phase insulin secretion terms were removed and replaced 
with the term for insulin administration, 𝐼𝑒𝑥𝑔, changing equation (2.5) to be the 
following: 
𝑑𝐼
𝑑𝑡
= −𝑝4 ∗ 𝐼(𝑡) + 𝐼𝑒𝑥𝑔,                                                           (6.6) 
Notice that this new equation assumes no insulin secretion, implying a severe state of 
diabetes where the individual is entirely dependent on insulin treatments. 
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6.3.2. Exercise and Insulin Infusion 
 
In chapter 5 two models were proposed to model the effects of exercise on the 
glucose regulatory system. Since the Exercise Glucagon Minimal Model provide the 
most accurate fit to the datasets it will be chosen to simulate exercise for type 1 
diabetic patients. 
Three of the datasets for exercise used to validate the models in this thesis (Ahlborg 
et al., 1974), (Ahlborg and Felig, 1984), (Wolfe et al., 1982) consider subjects 
exercising in the post absorptive state, following an overnight fast, therefore it is 
assumed that no rapid acting insulin is administered, as it is typically administered to 
accompany meals. Since a popular choice is to take long acting insulin (known as 
basal insulin) before a patient’s bedtime (Diabetes.co.uk, 2012), it will be assumed for 
these three cases that the injection will have been administered tdel minutes before 
the individual started exercising. Therefore equation (6.5) will now become: 
𝐼𝑒𝑥𝑔 = 𝛼 ∗ (−e
−π∗
t+tdel 
ton + 𝑒
−𝜋∗
𝑡+tdel
𝑡𝑑𝑒𝑔 ),                                                          (6.7) 
Adjusting equation (5.9) (see section 5.2) to mimic a type 1 diabetic patient 
exercising, the equation now becomes: 
𝑑𝐼
𝑑𝑡
= −𝑝4 ∗ 𝐼(𝑡) + 𝐼𝑒𝑥𝑔𝐿 − 𝐼(𝑡) ∗ 𝐴(𝑡),                                                           (6.8) 
Note that this equation also assumes an extreme form of diabetes where the pancreas 
secretes no insulin. This equation will be used for plasma insulin in the exercise 
model. For the dataset obtained by Campbell et al. (2014), the patients took part in 
exercise in the evening, in which they started 60 minutes after consuming a meal with 
a dose of rapid acting insulin. Therefore in order to replicate this protocol two insulin 
administrations will need to be considered; the long acting insulin that would have 
been administered the previous night, and the reduced rapid acting insulin that 
would have been administered 60 minutes prior to the exercise. Therefore the new 
equation for insulin becomes: 
𝑑𝐼
𝑑𝑡
= −𝑝4 ∗ 𝐼(𝑡) + 𝐼𝑒𝑥𝑔𝐿 + 𝐼𝑒𝑥𝑔𝑅 − 𝐼(𝑡) ∗ 𝐴(𝑡),                                                     (6.9) 
 
where 𝐼𝑒𝑥𝑔 represents that long acting insulin and 𝐼𝑒𝑥  is the rapid acting insulin. 
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6.4. Model Analysis 
The system is non-dimensionalized, as in section 5.3.1, however the variable for plasma 
insulin is now rescaled to give a variable with no units as  𝐼 =
𝐼
𝜏
.  Therefore the unitless 
exercise system for a type 1 diabetic patient is now given by: 
𝑑?̃?
𝑑𝑇
= −𝑝1 ∗ 𝜏 ∗ (?̃? − 1) + ?̃? ∗ (?̃? − ?̃? − ?̃?) +
𝑝13 ∗ 𝑝10 ∗ 𝐺𝑙?̃? ∗ 𝑃𝑉𝑂2
𝑚𝑎?̃?
𝐺𝑏 ∗ (
1
2 + 𝐺𝑙?̃?)
,          (6.10) 
𝑑?̃?
𝑑𝑇
=  −𝑝2 ∗ ?̃? ∗ 𝜏 + 𝑝3 ∗ 𝐼𝑏 ∗ 𝜏
2 ∗ 𝐼,                                                                                (6.11) 
𝑑𝐼
𝑑𝑇
=  −𝑝4 ∗ 𝜏 ∗ 𝐼 + 𝑝5 ∗ 𝜏
2 ∗ ( −e
−π∗T∗τ+tdel 
ton + 𝑒
−π∗T∗τ−t𝑑𝑒𝑙
𝑡𝑑𝑒𝑔 ) − ?̃? ∗ 𝐼,                  (6.12) 
𝑑?̃?
𝑑𝑇
=  −𝑝𝑏 ∗ ?̃? ∗ 𝜏 + 𝑝7 ∗ 𝐸𝑏 ∗ 𝜏
2 ∗ ?̃?,                                                                               (6.13) 
𝑑?̃? 
𝑑𝑇
= −𝑝8 ∗ 𝜏 ∗ (?̃? − 1) +
𝑝9 ∗ 𝐺𝑏 ∗ 𝜏
𝐸𝑏
∗ (1 − ?̃?) + ?̃? ∗ ?̃?,                                          (6.14) 
𝑑𝐺𝑙?̃?
𝑑𝑇
=  −
𝑝10 ∗ 𝐺𝑙?̃? ∗ 𝑃𝑉𝑂2
𝑚𝑎?̃?
𝐺𝑙𝑦𝑏 ∗ (
1
2
+ 𝐺𝑙?̃?)
− 𝑝14 ∗ 𝜏 ∗ (𝐺𝑙?̃? − 1),                                                 (6.15) 
𝑑𝑃𝑉𝑂2
𝑚𝑎?̃?
𝑑𝑇
= −0.8 ∗ 𝑃𝑉𝑂2
𝑚𝑎?̃? ∗ 𝜏 + 0.8 ∗ 𝜏2 ∗ 𝑢3,                                                          (6.16) 
𝑑?̃?
𝑑𝑇
= −𝑝11 ∗ ?̃? ∗ 𝜏 + 𝑝12 ∗ 𝜏 ∗ 𝑃𝑉𝑂2
𝑚𝑎?̃?,                                                                          (6.17) 
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By setting 𝜏 =
1
𝑝4
 the system is rescaled for insulin disappearance and is rewritten as:  
𝑑?̃?
𝑑𝑇
= −𝑝1̃ ∗ (?̃? − 1) + ?̃? ∗ (?̃? − ?̃? − ?̃?) +
𝑝13̃ ∗ 𝐺𝑙?̃? ∗ 𝑃𝑉𝑂2
𝑚𝑎?̃?
(
1
2 + 𝐺𝑙?̃?)
,               (6.18) 
      
𝑑?̃?
𝑑𝑇
=  −𝑝2̃ ∗ ?̃? + 𝑝3 ∗ 𝐼𝑏 ∗ 𝜏
2 ∗ 𝐼,                                                                          (6.19) 
𝑑𝐼
𝑑𝑇
=  −(𝐼 − 1) + 𝑝5̃ ∗ ( −e
−π∗T∗τ+tdel 
ton + 𝑒
−π∗T∗τ−t𝑑𝑒𝑙
𝑡𝑑𝑒𝑔 ) − 𝐼 ∗ ?̃?,                 (6.20) 
𝑑?̃?
𝑑𝑇
=  −𝑝6̃ ∗ ?̃? + 𝑝7̃ ∗ ?̃?,                                                                                           (6.21) 
𝑑?̃? 
𝑑𝑇
= −𝑝8̃ ∗ (?̃? − 1) + 𝑝9̃ ∗ (1 − ?̃?) + ?̃? ∗ ?̃?,                                                    (6.22) 
𝑑𝐺𝑙?̃?
𝑑𝑇
=  −
𝑝10̃ ∗ 𝐺𝑙?̃? ∗ 𝑃𝑉𝑂2
𝑚𝑎?̃?
(
1
2 + 𝐺𝑙?̃?)
− 𝑝14̃ ∗ (𝐺𝑙?̃? − 1),                                              (6.23) 
𝑑𝑃𝑉𝑂2
𝑚𝑎?̃?
𝑑𝑇
=  −0.8 ∗
𝑃𝑉𝑂2
𝑚𝑎?̃?
𝑝4
+
0.8 ∗ 𝑢3
𝑝4
2 ,                                                                        (6.24) 
𝑑?̃?
𝑑𝑇
= −𝑝11̃ ∗ ?̃? + 𝑝12̃ ∗ 𝑃𝑉𝑂2
𝑚𝑎?̃? ,                                                                           (6.25) 
 
where the unitless parameters are defined as: 
𝑝1̃ =
𝑝1
𝑝4
, 𝑝2̃ =
𝑝2
𝑝4
, 𝑝3̃ =
𝑝3 ∗ 𝐼𝑏
𝑝4
2 , 𝑝5̃ =
𝑝5
𝑝4
2 , 𝑝6̃ =
𝑝6
𝑝4
, 𝑝7̃ =
𝑝7∗𝐸𝑏
𝑝4
2  
, 𝑝8̃ =
𝑝2
𝑝4
, 
𝑝9̃ =
𝑝9 ∗ 𝐺𝑏
𝑝4 ∗ 𝐸𝑏
 , 𝑝10̃ =
𝑝10
𝐺𝑙𝑦𝑏
, 𝑝11̃ =
𝑝11
𝑝4
, 𝑝12̃ =
𝑝12
𝑝4
, 𝑝13̃ = 𝑝13 ∗
𝑝10
𝐺𝑏
 and 𝑝14̃ =
𝑝14
𝑝4
.   
The initial conditions then become 
?̃?(0) =
𝐺𝑏
𝐺𝑏
= 1, ?̃?(0) = 0, 𝐼(0) =
𝐼0
𝑝4
, ?̃?(0) = 0, ?̃?(0) =
𝐸𝑏
𝐸𝑏
= 1, 
𝐺𝑙?̃?(0) =
𝐺𝑙𝑦𝑏
𝐺𝑙𝑦𝑏
= 1, 𝑃𝑉𝑂2
𝑚𝑎𝑥̃ (0) = 0 and ?̃?(0) = 0. 
Examining the long term behaviour of the system it becomes clear that the new 
stationary point for the dimensional exercise model becomes 
lim 𝑡 →  ∞𝑓(𝐺(𝑡), 𝑋(𝑡), 𝐼(𝑡), 𝑌(𝑡), 𝐸(𝑡), 𝐺𝑙𝑦(𝑡), 𝑃𝑉𝑂2
𝑚𝑎𝑥(𝑡), 𝐴(𝑡) 
= (𝐺𝑏 , 0,0,
𝑝7
𝑝6
𝐸𝑏 , 𝐸𝑏 , 𝐺𝑙𝑦𝑏 , 0,0) 
therefore in non-dimensional terms this becomes (1,0,0, 
𝑝8  , 1,1,0,0). 
𝑝6 
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The Jacobian matrix evaluated at the critical point is given as: 
 
 
 
𝐽3 = 
[
 
 
 
 
 
 
 
 
 −𝑝1 ̃ −
𝑝2̃
𝑝2̃
+
𝑝7̃
𝑝6̃
−1 0 1 0 0 2 ∗
𝑝13̃
3
−1
0 −𝑝2̃ 𝑝3̃ 0 0 0 0 0
0 0 −1 0 0 0 0 −1
0 0 0 −𝑝6̃ 𝑝7̃ 0 0 0
−𝑝9̃ 0 0 0 −𝑝8̃ 0 0 1
0 0 0 0 0 −𝑝14̃ −2 ∗
𝑝10̃
3
0
0 0 0 0 0 0 −
0.8
𝑝1
0
0 0 0 0 0 0 𝑝12̃ −𝑝11̃]
 
 
 
 
 
 
 
 
 
                                  (6.18)                 
 
The characteristic polynomial was determined in Mathematica (See appendix) as: 
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6.4. Model Simulations 
 
This section will simulate the effects of the proposed term for insulin infusion on the 
minimal model as introduced in chapter 2 and the Glucagon Exercise Minimal Model 
proposed in chapter 5. The models are simulated in MATLAB, solved by ODE45 and 
the parameters are determined by LSQNONLIN. 
6.4.1. Minimal Model and Insulin Infusion 
 
By setting 𝑡𝑜𝑛 = 480 (mins) and 𝑡𝑑𝑒𝑔= 1200 (mins), a long acting insulin treatment is 
simulated, lasting for 24 hours. 
The minimal model was simulated, using the parameter values for the first four 
parameters as obtained by the glucagon minimal model, equations (3.4)-(3.7) in 
section 3.5.2, in figure 6.3, where α=10  and 𝑡𝑑𝑒𝑙  = 0. 
(a) (b) 
 
Figure 6.3: I(t) for 180 minutes following a long acting insulin treatment (a) and I(t) for 24 
hours following a long acting insulin treatment (b). 
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This can be adapted to simulated rapid acting insulin by changing the parameter 
values to give 𝑡𝑜𝑛 = 60(mins) and 𝑡𝑑𝑒𝑔= 300 (mins), e.g. Lispro or Aspart. Including 
this term into the minimal model gives the following responses from insulin in figure 
6.4: 
 
 
 
 
 
 
 
 
 
Figure 6.4: I(t) for 180 minutes following a rapid acting insulin treatment (a) and I(t) for 24 
hours following a long acting insulin treatment (b). 
 
Note that the amount of units the simulated treatment increases the plasma insulin by 
is dependent on both the parameters 𝛼, in equation (6.5), and 𝑝4, in equation (6.6). In 
physiological terms these will represent the strength of the insulin injection and the 
diffusion conditions in the subcutaneous tissue, discussed in section 6.1. 
(a) (b) 
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6.4.2. Exercise Glucagon Minimal Model and Insulin 
Infusion 
As in chapter 5, the parameters 𝑢3 and 𝑇𝑑𝑢𝑟 are fixed to adjust the model for various 
exercise intensities and durations respectively, replicating the protocols to the data 
obtained from various studies used to validate the models. 
The datasets used to validate the models are obtained from Ahlborg et al. (1974), 
Wolfe et al. (1984), Ahlborg and Felig (1982) and Campbell et al. (2014). Despite 
three of the datasets having been obtained by healthy individuals, they will still be 
used to validate the model as insulin production from the beta cells will be replaced 
by exogenous insulin. 
The parameter values will be presented at the end of this chapter in section 6.6 and 
can be found in appendix B. 
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6.5.2.1. Exercise at 30% of 𝐕𝐎𝐦𝐚𝐱 
 
The first simulation will be fitted to the dataset obtained by Ahlborg et al. (1974), 
whose method involved individuals exercising at 30% of their for 4 hours after a 12- 
14 hour fast. To represent individuals taking their basal insulin treatments before 
they went to bed the parameter controlling the time the treatment was taken will be 
set to  tdel=780 minutes (13 hours). The results are shown in figures 6.4 and 6.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5: Exercise at 30% of 𝑉𝑂2
𝑚𝑎𝑥: G(t) against plasma glucose measurements, (a), Gly(t), 
(b), 𝑃𝑉𝑂2
𝑚𝑎𝑥  (t), (c) and A(t) (d). 
(a) (b) 
(d) (c) 
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The model equation for plasma glucose (a) provides an exact fit to the data set, 
predicting a slightly lower amount of muscle glycogen to be broken down than for the 
healthy patients, in addition to a slightly smaller amount of exercise activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6: Exercise at 30% of 𝑉𝑂2
𝑚𝑎𝑥: I(t) against plasma insulin measurements, (a), X(t),  
(b), E(t) against plasma glucagon measurements,(c) and Y(t) (d). 
 
The equation for plasma insulin (a) provides a very close fit, which visually appears to 
have a better accuracy than for the healthy individual (figure 5.4.a). The model shows 
an excellent fit for plasma glucagon (c) to the data set, increasing fourfold accordingly. 
Both glucagon and interstitial insulin activity are of a lower magnitude than the 
simulation for healthy individuals as shown in figures 5.4.b and 5.4.d. 
(a) (b) 
(c) (d) 
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6.5.2.2. Exercise at 40% of 𝐕𝐎𝐦𝐚𝐱 
 
For the second simulation the model will be fitted to the dataset obtained by Wolfe et 
al. (1982), whose method involved individuals exercising at 40% of their 𝑉𝑂𝑚𝑎𝑥 for 1 
hour following an overnight fast. To represent individuals taking their basal insulin 
treatments before they went to bed the parameter controlling the time the treatment 
was taken will be set to  tdel=780 minutes (13 hours). The results are shown in 
figures 6.6 and 6.7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) (b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(c) (d) 
Figure 6.7: Exercise at 40% of 𝑉𝑂2
𝑚𝑎𝑥: G(t) against plasma glucose measurements, (a), Gly(t), 
(b), P𝑉𝑂2
𝑚𝑎𝑥 (t), (c) and A(t), (d). 
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Figure 6.7.a shows a good fit to the measurements for plasma glucose, however the 
fall predicted by G(t) appears exaggerated, as it is unlikely that such a dramatic fall in 
glucose levels would occur over such a short time period, especially given that the 
individuals is exercising at a fairly low intensity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8: Exercise at 40% of 𝑉𝑂2
𝑚𝑎𝑥: I(t) against plasma insulin measurements, (a), 
X(t), (b), E(t) against plasma glucagon measurements, (c) and Y(t), (d). 
Figure 6.8 shows the capability of the model to accurately fit the data measurements 
for plasma glucagon; however it does a poor job at fitting the plasma insulin 
measurements. All simulations for this exercise protocol are almost identical as seen 
in figures 5.5 and 5.6 for the healthy individual, which validates the ability of the term 
for the exogenous insulin. 
(c) (d) 
(a) (b) 
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6.5.2.3. Exercise at 58% of 𝑽𝑶𝒎𝒂𝒙 
 
This simulation sets 𝑢3 = 58 and 𝑇𝑑𝑢𝑟 = 210 to simulate the exercise protocol carried 
out in the studies by Ahlborg and Felig (1984). The participants began exercise 
following an overnight fast, therefore the initial measurements will be assumed to be 
the basal levels. It will also be assumed that individuals did not administer any rapid 
acting insulin, but did take their long acting insulin before they went to bed the 
previous evening. To represent individuals taking their basal insulin treatments 
before they went to bed the parameter controlling the time the treatment was taken 
will be set to tdel=780 minutes (13 hours). The results are shown in figures 6.6 and 
6.7. 
145  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.9: Exercise at 58% of 𝑉𝑂2
𝑚𝑎𝑥: G(t) against plasma glucose measurements, 
(a), Gly(t), (b), 𝑃𝑉𝑂2
𝑚𝑎𝑥 (t), (c) and A(t), (d). 
The model provides an exact fit to the dataset for glucose (a) and shows complete 
depletion of glycogen levels. The model shows less exercise activity than in the 
previous simulation where 𝑃𝑉𝑂2
𝑚𝑎𝑥 = 40, which is highly unlikely to be the case 
given that this protocol is at a higher exercise intensity and for a longer duration, i.e. 
the energy expenditure is significantly greater. 
(b) 
(d) 
(a) 
(c) 
146  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10: Exercise at 58% of 𝑉𝑂2
𝑚𝑎𝑥: I(t) against plasma insulin measurements, 
(a), X(t), (b), E(t) against plasma glucagon measurements, (c) and Y(t), (d). 
The model provides a fairly good fit to both plasma insulin (a) and plasma glucagon 
(c) measurements. The simulation for a type 1 diabetic patient predicts higher levels 
of glucagon activity and lower levels of interstitial insulin activity than is predicted 
for a healthy individual (figure 5.8). 
(b) (a) 
(c) (d) 
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6.5.2.4. Exercise at 70% of 𝑽𝑶𝒎𝒂𝒙 
 
The last simulation is fitted to a dataset obtained by Campbell et al. (2014) which 
consisted of type 1 diabetic individuals taking part in exercise at 70% of their 𝑉𝑂𝑚𝑎𝑥 
for 45 minutes. Unlike the previous studies, these participants did not exercise 
following an overnight fast. Therefore this simulation will require both a long and 
rapid acting insulin treatment in order to accurately emulate the study carried out by 
Campbell and colleagues, as participants consumed a meal 1 hour beforehand. The 
long acting insulin was simulated by setting the parameters as tdel1=780 (mins) to 
represent the insulin administration taken 13 hours before starting exercise, the 
duration set to 𝑡𝑑𝑒𝑔1 = 1200 (mins) and the onset of the treatment as 𝑡𝑜𝑛1 = 480 
(mins). The rapid acting insulin was simulated by setting the time before the 
treatment was taken as tdel2=60 (mins), the duration of the treatment to be set as 
𝑡𝑑𝑒𝑔2  = 300 (mins) and the onset as 𝑡𝑜𝑛1  = 60 (mins). The parameters controlling the 
onset and clearance of the insulins are based on the characteristics as seen in table 
6.1. 
148  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.11: Exercise at 70% of 𝑉𝑂2
𝑚𝑎𝑥: G(t) against plasma glucose measurements, 
(a), Gly(t), (b), 𝑃𝑉𝑂2
𝑚𝑎𝑥 (t), (c) and A(t), (d). 
Figure 6.11.a shows an exact fit to the plasma glucose measurements by G(t), show an 
initial drop in levels followed by a rapid rise as the concentration of the counter- 
regulatory hormones in the plasma are increased in response to the increased 
utilisation of glucose. Figure 6.11.b show glycogen levels close to becoming entirely 
utilised towards the end of the exercise duration. 
(a) (b) 
(c) (d) 
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Figure 6.12: Exercise at 70% of 𝑉𝑂2
𝑚𝑎𝑥: I(t) against plasma insulin measurements, 
(a), X(t), (b), E(t) against plasma glucagon measurements, (c) and Y(t), (d). 
The fit of the model to the plasma insulin measurements (6.12.a) is still not ideal, 
however it is a much closer fit than the Glucagon Exercise Minimal Model was capable 
for a healthy patient as seen in figure 5.10.a. 
Figure 6.12.d shows a fairly good fit for E(t) to the glucagon data, however the rapid 
increase in glucagon concentrations in the initial 5 minutes of exercise is rather 
excessive and, although it is quite likely that glucagon levels may overshoot the 
required level before smoothing out, the extent in which this model predicts is 
considered as unrealistic, although it is impossible to determine with sufficient data. 
(a) (b) 
(c) (d) 
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6.6. Discussion 
 
The Glucagon Exercise Minimal Model adapted for a type 1 diabetic individual has 
been successfully fitted to all four data sets, with the simulations principally 
providing better fits to the datasets than the model for healthy individuals as 
implemented in chapter 5. 
Table 6.3 is given below and shows the parameter values obtained by LSQNONLIN 
from the four simulations. 
Table 6.3: Parameter values from the Glucagon Exercise Minimal Model adapted for 
type 1 diabetes. 
 
 
Parameter 
𝐏𝐕𝐎𝐦𝐚𝐱 𝟐 
30% 40% 58% 70% 
𝑆𝐺   = 𝑝1 0.01027182 5.016009 ∗ 10−7 0.018207975 0.13696906 
𝑝2 4.78573664 2.175737907 4.84584071 4.31249661 
𝑝3 0.00346643 0.029688922 0.01947456 0.05050953 
𝑝4 0.06522939 0.424544428 0.00736092 2.78760207 
𝑝5 6.73082717 4.549747∗ 10−9 1.331945 ∗ 10−12 82.16969825 
𝑝6 0.10781389 0.349566126 0.04045856 0.08585775 
𝑝7 2.320701 ∗ 10−6 5.43164∗ 10−4 2.550857 ∗ 10−6 0.00002443 
𝑝8 0.00351130 0.710479808 0.00785531 0.13772318 
𝑝9 2.175208 ∗ 10−9 1.38473137 4.840995 ∗ 10−8 9.13487573 
𝑝10 0.10927957 0.05874696 0.12256887 0.39720033 
𝑝11 0.00104748 0.18290123 0.01581215 3.340849 ∗ 10−14 
𝑝12 2.551955∗ 10−6 8.73518∗ 10−4 3.773498 ∗ 10−6 9.456928 ∗ 10−6 
𝑝13 0.39720317 0.3254266 0.93952685 1.01646595 
𝑆𝐼 =
𝑝3
𝑝2
 7.243263 ∗ 10−4 0.01364545 0.00401882 106.53106953 
𝑆𝐸 =
𝑝7
𝑝6
 2.152606 ∗ 10−5 0.001553823 6.304863 ∗ 10−5 0.01171236 
𝑆𝐴 =
𝑝12
𝑝2
 0.00243627 0.0047759 2.386455 ∗ 10−4 2.83069598 
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There has been no difference noted between type 1 diabetic and healthy individuals 
in their abilities to respond to insulin, such that values for glucose effectiveness and 
insulin sensitivity are not expected to differ (Greenbaum et al., 2002). This conjecture 
is confirmed by the values for glucose effectiveness for all simulations in table 6.3 
which are all within a close vicinity to the values returned by the model for healthy 
individuals (table 5.12). 
The results for both insulin and glucagon sensitivity are surprising, in the sense that 
they are expected to increase with increasing energy expenditure and with the 
greatest amount of glycogen depletion (Colberg, 2008), (Kang et al. 1996). This would 
suggest that the simulations for 𝑃𝑉𝑂𝑚  = 58 and 𝑃𝑉𝑂𝑚𝑎𝑥  = 70 ought to return   the 2 2 
highest values for the parameters, which is true for the case where 𝑃𝑉𝑂𝑚𝑎𝑥 = 70 but 
not for where 𝑃𝑉𝑂𝑚𝑎𝑥 = 58, which returns significantly lower values than the 
simulation where 𝑃𝑉𝑂𝑚𝑎𝑥 = 40. This may be due to varying individual factors, as it is 
known that insulin sensitivity is likely to be increased in both trained and younger 
individuals than for those who are sedentary and middle-aged or older (Henriksson, 
1995). 
Exercise sensitivity is also expected to increase with increased energy expenditure. 
For this to be the case, it would be anticipated that the simulation where 𝑃𝑉𝑂𝑚  = 58 
would return the highest value and where 𝑃𝑉𝑂𝑚𝑎𝑥 = 40 to return the lowest. The 
results are slightly different from what was expected, however are still within the 
same magnitude of the foreseen results, suggesting the likelihood that this result was 
down to individual variability. This reinforces the need for an additional study 
consisting of the same individuals carrying out exercise at different intensities. 
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6.7. Summary 
 
In this chapter the Glucagon Exercise Minimal Model was adapted to consider an 
individual with T1DM administering exogenous insulin. 
The model provides an excellent fit to the plasma measurements obtained by Ahlborg 
et al. (1974) where 𝑃𝑉𝑂𝑚ax  = 30 and shows reasonable levels of insulin and 
glucagon activity in comparison to the IVGTT model. Exercise activity increases 
linearly with exercise intensity as a function of time, which is expected during low 
intensity exercise. 
The fit against the data from Wolfe et al. (1984), where 𝑃𝑉𝑂𝑚𝑎𝑥 = 40, is reasonable 
with the exception of plasma insulin. This is also the case for the model in chapter 5, 
where no diabetes was assumed; likely to be the result of insufficient data for the 
model to capture insulin dynamics. 
This is also the case for the model in chapter 5 where no diabetes was assumed, 
therefore is likely to be caused by insufficient data for the model to capture insulin 
dynamics. 
The simulations, where  𝑃𝑉𝑂2
𝑚𝑎𝑥 = 58 𝑎𝑛𝑑 𝑃𝑉𝑂2
𝑚𝑎𝑥   = 70, although slightly under   or 
overestimating the concentration of the hormones at certain points, overall provided 
better fits than the Glucagon Exercise Minimal Model for healthy individuals. 
The majority of the key parameters are within reasonable magnitude of the 
acceptable ranges specified within the literature, with any marked differences likely 
to be the result of changes induced by physiological exercise. 
As for the models in chapter 5, typically the ability of the model to fit the data 
improves as exercise intensity decreases, suggesting that either a bi-hormonal model 
is not sufficiently representative of higher intensity exercise or that there are still 
some mechanisms of glucose-insulin-glucagon dynamics that are not fully understood. 
Overall, the term proposed for insulin administration has performed well in replacing 
β-cell secretion, and can be adapted accordingly to mimic the characteristics of 
various insulin treatments. 
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Chapter 7 Conclusions and Future Work 
 
Incorporating regular exercise into the daily lives of individuals has been proven to 
have numerous health benefits, such as decreasing blood pressure, reducing the risk 
of heart disease as well as preventing obesity and the onset of many other health 
conditions. Whilst this is true for patients with diabetes; there is however, an 
additional factor to be considered when controlling glucose levels based on the 
evidence on the wide range of health benefits from regular exercise is growing for 
both type 1 (T1DM) and type 2 diabetics (T2DM). These include an increase in insulin 
sensitivity and glucose uptake; thus resulting in a decreased dependency on insulin 
treatments for patients with T1DM or severe T2DM, and the potential to reverse the 
onset of T2DM. The implications of these effects will not only lead to a reduction of 
the strain on health services but will allow for diabetic patients to have more freedom 
in leading a healthy and normal lifestyle. 
Mathematical models for blood glucose regulation are considered as beneficial tools 
due to their ability to aid our understanding of system behaviours (Lakshmi Kiran et 
al., 2010), contribute towards the progression of artificial pancreas development 
(Herrero et al., 2013), have applications for automated insulin dosage adjustments 
(Lehnmann and Deutsch, 1992) and allow for the assessment of insulin sensitivity, 
glucose effectiveness (Vicini et al., 1997) and now glucagon sensitivity. 
The primary goal of this thesis has been to develop a mathematical model showing 
the effects of exercise on blood glucose and its regulatory hormones. At present the 
majority of mathematical models for the glucose regulatory system consider glucose- 
insulin dynamics, in order to determine whether an individual has or is at risk of 
diabetes by measuring their ability to respond to or produce insulin. However, the 
counter-regulatory hormones become increasingly important during periods of low 
blood glucose, for example during prolonged physical activity. 
The importance of glucagon in particular is increasingly becoming recognised. 
Understanding the contribution of glucagon to hepatic hyperglycaemia can help 
clinicians to identify the presence of diabetes, and which can then be treated by 
manipulating glucagon levels which has been proven to be beneficial to the diabetic 
state (Edgerton and Cherrington, 2011), (Siafarikas et al., 2012). 
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In chapter 3, three mathematical models were presented, each demonstrating 
glucose-insulin-glucagon dynamics during an Intravenous Glucose Tolerance Test 
(IVGTT). An IVGTT was chosen as the first scenario to model the effects of glucagon as 
there are many existing models that the model can be validated against and for the 
key parameter values such as insulin sensitivity, 𝑆𝐼, and glucose effectiveness, 𝑆𝐺, to 
be compared to. Despite glucagon’s minor role, the models highlighted the 
importance of the action of glucagon to stimulate hepatic glucose production in order 
to counter the fall of glucose concentrations below the basal level, as often occurs as a 
result of the hypersecretion of insulin in response to an IVGTT. The results obtained 
from the three glucagon IVGTT models were compared and it was found that the 
linear model was by far inferior to the other two models. This result indicated that a 
model assuming a linear relationship between plasma glucose and insulin was 
insufficient during large fluctuations of the hormone, however there was not a 
significant difference between a nonlinear or a linear relationship between plasma 
glucose and glucagon, which is hypothesized to be due to the minimal role of glucagon 
during an IVGTT. Therefore, it is expected that the Linear Glucagon Minimal Model 
will to be inferior when modelling scenarios faced with low blood glucose, e.g. during 
exercise. 
In chapter 5, the two models identified to be superior in chapter 3 were adapted to 
consider the physiologically mechanisms within the system that regulate glucose 
levels during exercise for a nondiabetic, healthy individual. Both models supported 
the hypothesis that glucose levels decline as glycogen stores are depleted and 
highlight the importance of the increase in the secretion of glucagon in order to 
prevent hypoglycaemia. The Glucagon Exercise Minimal Model was chosen as the 
optimal model for simulating the glucose regulatory system during exercise; it is 
capable of fitting physiological datasets, the performance of the simulations are in 
accordance with behaviour anticipated from literature and the physical implications 
of the key parameters are consistent. In addition, the parameters typically increased 
with increased energy expenditure, whereas the parameters of the Simplified 
Glucagon Exercise Minimal Model did not show any relationship between their values 
and exercise, and were often unreasonably high. Despite its drawbacks, the Simplified 
Glucagon Exercise Minimal Model did provide the better fit to the data for a number 
of simulations, as well as being advantageous in that it consisted of two quantities 
less than the Glucagon Exercise Minimal Model. This result suggests that linear 
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dynamics for glucagon are only suitable when glucagon activity is minimal. In 
addition, the Glucagon Exercise Minimal Model was able to return a parameter value 
for glucagon sensitivity. It is important to determine whether or not an individual, 
particularly a diabetic individual, has poor glucagon sensitivity as they will face an 
increased risk of hypoglycaemia, which, if left untreated, can result in severe health 
problems. 
Chapter 6 adapted the equation for plasma insulin in the Glucagon Exercise Minimal 
Model to be representative of an individual with type 1 diabetes, i.e. the pancreas is 
incapable of producing insulin. From comparing the results of the two models (figures 
5.4.a, 5.6.a, 5.8.a and 5.10.a to 6.6.a, 6.8.a, 6.10.a and 6.12.a) it was concluded that the 
model achieves a much better fit to the dataset for plasma insulin concentrations 
when it is simulated for a type 1 diabetic individual than when it is simulated for a 
nondiabetic, healthy individual. This result suggests that the terms proposed for 
insulin production are too simple for modelling the 𝛽-cell response to exercise. 
From the observations within literature it was expected that insulin sensitivity would 
increase simultaneously with the amount of glycogen utilised for fuel during the 
activity (Colberg, 2008). Results from chapter 5 do not agree with this expectation, 
rather suggesting that insulin sensitivity increases with the rate of glycogen 
degradation, 𝑝10  (see tables 5.7-5.11); however without actual muscle glycogen data 
it is difficult to validate this conclusion. 
The results of chapter 5 show that insulin sensitivity, glycogen mobilisation and 
glucose effectiveness increase with exercise intensity, which are all in agreement with 
the findings of Robergs et al. (1985), Adams (2013) and Hayashi et al. (2005). In 
comparison both glucagon and exercise sensitivity were at their highest when energy 
expenditure was at its greatest. This is to be expected for glucagon, given that the liver 
becomes more sensitised to the activity of glucagon with endurance exercise (Lavoie, 
2005) and studies show that the glucagon response is typically greater the longer the 
exercise duration (Garrett and Kirkendall, 1999). 
In chapter 6, the results for a type 1 diabetic individual slightly deviated from those 
for the healthy person in chapter 5. The model in chapter 6 showed the parameters 
for insulin sensitivity, glycogen mobilisation, glucose effectiveness, glucagon 
sensitivity and exercise sensitivity to all to be the highest the greatest exercise 
intensity. The parameter results in this chapter do not appear to show any particular 
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correlation between their values and exercise intensity or energy expenditure, 
however this is likely to be due to individual variations in fitness levels and diabetic 
states, again a consequence of insufficient data availability. 
From the work of this thesis it can be determined that a combination of both 
endurance and high intensity exercise are beneficial for glucoregulatory health, 
whereas the results suggest that higher intensity exercise appears to be more 
beneficial for individuals with T1DM. This information is obtained from the results 
of the key parameters which offer an insight into glucoregulation, insulin sensitivity 
and glucose effectiveness. Before exercise recommendations can be adjusted these 
models require further validation to ensure the safety of participants and to gain a 
further insight into the duration and intensity of exercise most beneficial for 
improving the diabetic state. 
In order to thoroughly validate the model, more data points are required. Validating a 
model with real life data is essential, as if it provides a bad fit it is unlikely that the 
model can provide good answers to the underlying questions under investigation 
(Guthrie et al., 2002). Due to the timescale and limitations of funding within this 
project, collecting data samples was not possible. It is strongly recommended that for 
a future project on this topic data ought to be obtained. Further, it is recommended 
that a study involving a number of participants with varying bodyweights and fitness 
levels who are required to take part in a number of exercise protocols of varying 
levels of intensity and durations is undertaken. It is suggested that a greater number 
of blood samples are taken than in the datasets presently available in order to 
improve the confidence intervals for the parameter fits. 
The focus of this model is on exercise, therefore, since it is known that during exercise 
catecholamines are the main hormones whose concentrations markedly increase 
(Zouhal et al., 2008), future work ought to introduce the effects of these hormones on 
the glucose regulation system. Catecholamines are potent inhibitors of insulin release 
(Wilcox, 2005) therefore it is anticipated that introducing new variables to model the 
effects of the hormones may improve the accuracy of the model to capture the decline 
in plasma insulin. 
An additional variable worth consideration would be the role of cortisol, which 
becomes particularly amplified in moderate-high intensity exercise (Hill et al., 2008). 
It is notable that the model typically provides better fits to the data from the lower 
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intensity exercise and therefore it may be that for higher intensities a bi-hormonal 
regulation model of glucose is insufficient and needs to take into account the effect of 
other counter-regulatory hormones. 
The variable used to quantify exercise intensity in the models in this thesis was the 
percentage of  𝑉𝑂2
𝑚𝑎𝑥  taken from Roy and Parker (2007) (see chapter 5).   
Using the percentage of 𝑉𝑂2
𝑚𝑎𝑥  to quantify exercise intensity assumes that oxygen 
consumption is linearly proportional to energy expenditure, which may not be true 
for all exercise, as was the case for the studies by Barstow and Mole (1991). It was 
hypothesised from these results that it would be possible that using 𝑃𝑉𝑂2
𝑚𝑎𝑥 may not 
be a suitable for quantifying exercise intensity for individuals exercising at higher 
working rates. In the simulations from both chapters 5 and 6 the models provide 
much better fits to the datasets for the lower intensities. Therefore it is advised that 
further research on the relationship between energy expenditure and oxygen 
consumption should be completed in order to develop a more accurate equation. 
Physiological concepts have been synthesised and implemented within a 
mathematical model that is capable of predicting blood glucose using a bi-hormonal 
approach during exercise, for both healthy and diabetic individuals. The results show 
that high intensity exercise is ideal for improving insulin sensitivity and glucose 
effectiveness, whereas exercise duration is the principal factor for improving the 
liver’s sensitivity to glucagon. Evidence indicates that over a few years, following the 
diagnosis of type 1 diabetes the liver typically becomes desensitised to the action of 
glucagon, whereas type 2 diabetes is typically associated with poor insulin sensitivity. 
Therefore this project and studies of a similar nature could lead to new 
recommendations for managing both T1DM and T2DM. 
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Appendix A 
 
Datasets 
 
Blood measurents from Pacini and Bergman (1984) from a healthy, non-diabetic 
individual during and IVGTT. 
 
Time Glucose (mg/dl) Insulin (µU/ml) 
0 92 11 
2 350 26 
4 287 130 
6 251 85 
8 240 51 
10 216 49 
12 211 45 
14 205 41 
16 196 35 
19 192 30 
22 172 30 
27 163 27 
32 142 30 
42 124 22 
52 105 15 
62 92 15 
72 84 11 
82 77 10 
92 82 8 
102 81 11 
122 82 7 
142 82 8 
162 85 8 
182 90 7 
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Blood measurements taken by Ahlborg et al. ( 1974) from healthy, non-diabetic 
individuals exercising at 30% of their   in the post-absorptive state for 240 minutes. 
 
Time Glucose (mg/dl) Insulin (µU/ml) Glucagon (pg/ml) 
0 81.2 13.9 75 
40 84.6 12.3 76 
90 77.4 10 99 
180 63 7.2 201 
240 56.2 6.2 408 
 
 
Blood measurements taken by Wolfe et al. (1984) from healthy, non-diabetic 
individuals exercising at 40% of their in the post-absorptive state for 60 minutes 
 
Time Glucose (mg/dl) Insulin (µU/ml) Glucagon (pg/ml) 
0 88 13.2 142 
15 86 10.3 207 
30 88 9.4 194 
45 87 8.6 201 
52 86 8.7 194 
60 84 8.4 199 
 
 
Blood measurements taken by Ahlborg and Felig (1982) from healthy, non-diabetic 
individuals exercising at 58% of their in the post-absorptive state for 210 minutes 
 
Time Glucose (mg/dl) Insulin (µU/ml) Glucagon (pg/ml) 
0 4.39 14.5 77 
40 4.09 11.8 66 
90 3.86 9.2 111 
120 3.55 8 158 
180 2.78 6 257 
210 2.56  
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Appendix B Parameter Values 
 
B.1. Linear Glucagon Model 
 
 
Parameter Value Unit 
𝑆𝐺   = 𝑝1 0.02717445 𝑚𝑖𝑛
−1 
𝑝2 0.11739499 𝑚𝑖𝑛
−1(𝑚𝑔/𝑑𝑙) 
𝑝3 0.02085256 𝑚𝑖𝑛
−1(𝑚𝑔/𝑑𝑙) 
𝑝4 0.07243666 𝑚𝑖𝑛
−1 
𝑝5 0.37843489 𝑚𝑖𝑛
−2 (µ𝑈/𝑚𝑙) 
𝑝6 0.00237924 𝑚𝑖𝑛
−1 
𝑝7 0.00800919 𝑚𝑖𝑛
−2 (𝑝𝑔/𝑚𝑙) 
𝐺0 289.00705341 𝑚𝑔/𝑑𝑙 
𝐼0 393.16692531 µ𝑈/𝑚𝑙 
 
B.2. Glucagon Minimal Model 
 
B.2.1. Dimensional Model 
 
 
Parameter Value Unit 
𝑆𝐺   = 𝑝1 0.02059000 𝑚𝑖𝑛
−1 
𝑝2 0.02219000 𝑚𝑖𝑛
−1 
𝑝3 1.37999 ∗ 10−5 𝑚𝑖𝑛
−2 (µ𝑈/𝑚𝑙)−1 
𝑝4 0.32000001 𝑚𝑖𝑛
−1 
𝑝5 0.00367636 𝑚𝑖𝑛
−2 (µ𝑈/𝑚𝐿) 
𝑝6 0.14200001 𝑚𝑖𝑛
−1 
𝑝7 2.17999 ∗ 10−4 𝑚𝑖𝑛
−2 (𝑝𝑔/𝑚𝑙)−1 
𝑝8 0.04940002 𝑚𝑖𝑛
−1 
𝑝9 1.78999 ∗ 10−5 𝑚𝑖𝑛
−2 (𝑝𝑔/𝑚𝑙) 
𝑆𝐼 6.21902 ∗ 10−4 𝑚𝑖𝑛−1(µ𝑈/𝑚𝑙)−1 
𝑆𝐸 0.00153521 𝑚𝑖𝑛−1(𝑝𝑔/𝑚𝑙)−1 
𝐺0 293 𝑚𝑔/𝑑𝑙 
𝐼0 360 µ𝑈/𝑚𝑙 
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B.2.2. Dimensionless Model 
 
 
 
 
Parameter 
 
Dimensional 
Value 
Non- 
Dimensional 
value rescaled 
by 𝝉 =
𝟏
𝒑𝟏
 
 
Non- 
Dimensional 
value rescaled 
by 𝝉 =
𝟏
𝒑𝟒
 
 
 
Non-
Dimensional 
value rescaled 
by 𝝉 =
𝟏
𝒑𝟖
 
 
 
 
𝑆𝐺   = 𝑝1 0.02058 0.01756659 0.00941376 0.00941386 
𝑝2 0.02218 0.11408124 0.03733535 0.037336576 
𝑝3 0.0000137 0.0000360401 0.0000201577 0.0000201556 
𝑝4 0.32 0.03563689 0.2783405 0.278343671 
𝑝5 0.0032 0.00630156 0.00334216 0.003342215 
𝑝6 0.142 1.1440989 0.7025258 0.702525919 
𝑝7 0.000217 0.06857451 0.00796508 0.007964075 
𝑝8 0.0494 0.04687327 0.499999 0.5 
𝑝9 0.0000178 0.001533393 0.000024545 0.00001 
𝑆𝐼 0.000617 0.000315916 0.000539908 0.00053928 
𝑆𝐸 0.001528 0.0599379 0.01539908 0.0113 
𝐺0 293 292 279 279 
𝐼0 360 366 360 360 
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B.3. Linear Glucagon Minimal Model 
 
B.3.1. Dimensional Model 
 
 
Parameter Value Unit 
𝑆𝐺   = 𝑝1 0.02808122 𝑚𝑖𝑛
−1 
𝑝2 0.00996122 𝑚𝑖𝑛
−1 
𝑝3 7.31888 ∗ 10−6 𝑚𝑖𝑛
−2 (µ𝑈/𝑚𝑙)−1 
𝑝4 0.27943170 𝑚𝑖𝑛
−1 
𝑝5 0.00290469 𝑚𝑖𝑛
−2 (µ𝑈/𝑚𝐿) 
𝑝6 0.19225742 𝑚𝑖𝑛
−1 
𝑝7 0.00364470 𝑚𝑖𝑛
−2 (𝑝𝑔/𝑚𝑙) 
𝑝8 0.01530144 (𝑚𝑔/𝑑𝑙)𝑚𝑖𝑛
−1 
𝑆𝐼 7.34737 ∗ 10−4 𝑚𝑖𝑛
−1(µ𝑈/𝑚𝑙)−1 
𝐺0 293 𝑚𝑔/𝑑𝑙 
𝐼0 360 µ𝑈/𝑚𝑙 
B.3.2. Dimensionless Model 
 
 
Parameter Dimensional 
Value 
Non- 
Dimensional 
value rescaled 
by 𝝉 =  
𝟏 
𝒑𝟏 
Non- 
Dimensional 
value rescaled 
by 𝝉 =  
𝟏 
𝒑𝟒 
Non- 
Dimensional 
value rescaled 
by 𝝉 =  
𝟏 
𝒑𝟔 
𝑆𝐺   = 𝑝1 0.010682729 0.01997831 0.0153103 0.0150861 
𝑝2 0.039225779 0.0144932 0.0231139 0.02259839 
𝑝3 0.000020016 0.0000108854 0.00001459 0.000014613 
𝑝4 0.296424834 0.20202604 0.22646731 0.212060508 
𝑝5 0.003663205 0.00197596 0.0023889 0.002129929 
𝑝6 0.097285237 0.485124233 0.1222461 0.221008791 
𝑝7 0.000724184 0.002605806 0.00124715 0.00152487 
𝑝8 0.000724178 0.037376378 0.0116759 0.01809859 
𝑆𝐼 0.000510277 0.000751068 0.00063153 0.000646669 
𝐺0 293 282 279 282 
𝐼0 360 411 406 410 
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B.4. Glucagon Exercise Minimal Model and Simplified 
Glucagon Exercise Minimal Model 
B.4.1. 30% of 𝑽𝑶𝒎𝒂𝒙 
 
 
Parameter GEMM GEMM Parameter SGEMM 
𝑆𝐺   = 𝑝1 0.017553609 𝑝1 0.00150000 
𝑝2 2.239076769 𝑝2 0.30089987 
𝑝3 0.003716462 𝑝3 0.00142961 
𝑝4 0.018928669 𝑝4 0.03692484 
𝑝5 7.17288309 ∗ 10
−5 𝑝5 4.1464406 ∗ 10
−4 
𝑝6 0.98138568 - - 
𝑝7 3.31033229 ∗ 10−5 - - 
𝑝8 0.01758642 𝑝6 0.04036082 
𝑝9 2.56707631 ∗ 10
−6 𝑝7 2.8118593 ∗ 10
−12 
- - 𝑃8 0.10928015 
𝑝10 0.10927865 𝑝9 4.3601980 ∗ 10
−14 
𝑝11 6.66091373 ∗ 10−4 𝑝10 6.42580655 ∗ 10−6 
𝑝12 4.13286068 ∗ 10−6 𝑝11 2.65330416 
𝑝13 0.93794325 𝑝12 0.00503468 
𝑆𝐼 =
𝑝3
𝑝2
 0.00165982 𝑆𝐼 =
𝑝3
𝑝2
 0.00475113 
𝑆𝐸 =
𝑝7
𝑝6
 3.37312064 ∗ 10
−5 
- - 
𝑆𝐴 =
𝑝12
𝑝11
 
 
0.006204645 𝑆𝐴 =
𝑝10
𝑝9
 
 
1.49667911∗ 108 
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B.4.2. 40% of 𝑽𝑶𝒎𝒂𝒙 
 
 
Parameter GEMM Value 
Parameter 
SGEMM 
Value 
𝑝1 9.82210456 ∗ 10−7 𝑝1 
1.294901545 
∗ 10−4 
𝑝2 2.174472150 𝑝2 3.046685906 
𝑝3 0.030060071 𝑝3 0.026127559 
𝑝4 0.427363226 𝑝4 0.155124835 
𝑝5 3.10209295 ∗ 10
−7 𝑝5 2.03958405 ∗ 10
−7 
𝑝6 0.351946257 - - 
𝑝7 5.50234639 ∗ 10−4 - - 
𝑝8 0.710810527 𝑝6 0.238400979 
𝑝9 1.374827718 𝑝7 1.374827718 
- - 𝑃8 0.223552393 
𝑝10 0.061870951 𝑝9 0.061870951 
𝑝11 0.183857888 𝑝10 0.814572420 
𝑝12 8.78558488 ∗ 10−4 𝑝11 0.001336112 
𝑝13 0.314711184 𝑝12 0.362639165 
𝑆𝐼 =
𝑝3
𝑝2
 0.013824077 𝑆𝐼 =
𝑝3
𝑝2
 0.008575731 
𝑆𝐸 =
𝑝7
𝑝6
 0.001563405 - - 
𝑆𝐴 =
𝑝12
𝑝11
 
 
0.004778465 𝑆𝐴 =
𝑝10
𝑝9
 
 
13.16566828 
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B.4.3. 58% of 𝑽𝑶𝒎𝒂𝒙 
 
 
Parameter GEMM Value 
Parameter 
SGEMM 
Value 
𝑆𝐺   = 𝑝1 0.20550317 𝑝1 0.016411558 
𝑝2 1.13046419 𝑝2 0.963873328 
𝑝3 0.02299561 𝑝3 0.000679837 
𝑝4 0.09800001 𝑝4 0.010277818 
𝑝5 0.05600000 𝑝5 7.87208 ∗ 10−14 
𝑝6 5.37961561 - - 
𝑝7 0.00015838 - - 
𝑝8 1.59847556 𝑝6 0.161251435 
𝑝9 9.20837923 𝑝7 0.016193108 
𝑝10 0.09947311 𝑝8 0.001037968 
𝑝11 0.00000188 𝑝9 0.099488025 
𝑝12 0.00001003 𝑝10 0.010979608 
𝑝13 6.40031140 𝑝11 0.000003678 
- 
 
 
0.02034174 𝑝12 
 
 
2.681901231 
𝑆𝐼 =
𝑝3
𝑝2
 0.00002944 𝑆𝐼 =
𝑝3
𝑝2
 0.000705317 
𝑆𝐸 =
𝑝7
𝑝6
 5.32583804 - - 
𝑆𝐴 =
𝑝12
𝑝11
 
 
0.20550317 𝑆𝐴 =
𝑝10
𝑝9
 
 
0.110361102 
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B.4.4. 70% of 𝑽𝑶𝒎𝒂𝒙 
 
 
Parameter GEMM Value 
Parameter 
SGEMM 
Value 
𝑆𝐺   = 𝑝1 0.21299553 𝑝1 0.346341523 
𝑝2 1.29778516 𝑝2 9.633789789 
𝑝3 0.03443631 𝑝3 1.173031 ∗ 10−4 
𝑝4 0.24788057 𝑝4 14.231816526 
𝑝5 0.01799555 𝑝5 8.603068353 
𝑝6 0.09630926 - - 
𝑝7 0.00004806 - - 
𝑝8 1.43637670 𝑝6 0.001000000 
𝑝9 0.22328702 𝑝7 23.707465199 
- - 𝑃8 3.124506262 
𝑝10 0.30186851 𝑝9 0.953347919 
𝑝11 0.07182015 𝑝10 4.189026 ∗ 10−6 
𝑝12 0.00009171 𝑝11 8.169374 ∗ 10−4 
𝑝13 1.73064711 𝑝12 4.454932251 
𝑆𝐼 =
𝑝3
𝑝2
 0.02653468 𝑆𝐼 =
𝑝3
𝑝2
 1.217621 ∗ 10−5 
𝑆𝐸 =
𝑝7
𝑝6
 4.989975 ∗ 10−4 - - 
𝑆𝐴 =
𝑝12
𝑝11
 
 
0.00127690 𝑆𝐴 =
𝑝10
𝑝9
 
 
4.394016 ∗ 10−6 
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B.6. T1DM Glucagon Exercise Minimal Model 
 
 
Parameter 
𝐏𝐕𝐎𝐦𝐚𝐱 𝟐 
30% 40% 58% 70% 
𝑆𝐺   = 𝑝1 0.01027182 5.016009 ∗ 10−7 0.018207975 0.13696906 
𝑝2 4.78573664 2.175737907 4.84584071 4.31249661 
𝑝3 0.00346643 0.029688922 0.01947456 0.05050953 
𝑝4 0.06522939 0.424544428 0.00736092 2.78760207 
𝑝5 6.73082717 4.549747∗ 10−9 1.33194 ∗ 10−12 82.16969825 
𝑝6 0.10781389 0.349566126 0.04045856 0.08585775 
𝑝7 2.32071 ∗ 10−6 5.43164∗ 10−4 2.550857 ∗ 10−6 0.00002443 
𝑝8 0.00351130 0.710479808 0.00785531 0.13772318 
𝑝9 2.17520 ∗ 10
−9 1.38473137 4.840995 ∗ 10−8 9.13487573 
𝑝10 0.10927957 0.05874696 0.12256887 0.39720033 
𝑝11 0.00104748 0.18290123 0.01581215 3.340849 ∗ 10−14 
𝑝12 2.55196∗ 10−6 8.73518∗ 10−4 3.773498 ∗ 10−6 9.456928 ∗ 10−6 
𝑝13 0.39720317 0.3254266 0.93952685 1.01646595 
𝑆𝐼 =
𝑝3
𝑝2
 7.24326 ∗ 10−4 0.01364545 0.00401882 106.53106953 
𝑆𝐸 =
𝑝7
𝑝6
 2.15261 ∗ 10−5 0.001553823 6.304863 ∗ 10−5 0.01171236 
𝑆𝐴 =
𝑝12
𝑝11
 
 
0.00243627 0.0047759 2.386455 ∗ 10−4 2.83069598 
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Appendix C Code Examples 
 
C.1. MATLAB 
 
C.1.1. IVGTT Linear Glucagon Minimal Model 
 
Main 
function [] = Molly_Glucagon_Model 
format compact 
format long 
 
data = [0 92 11 
  2 350 26 
  4 287 130 
  6 251 85 
  8 240 51 
  10 216 49 
  12 211 45 
  14 205 41 
  16 196 35 
  19 192 30 
  22 172 30 
  27 163 27 
  32 142 30 
  42 124 22 
  52 105 15 
  62 92 15 
  72 84 11 
  82 77 10 
  92 82 8 
  102 81 11 
  122 82 7 
  142 82 8 
  162 85 8 
  182 90 7]; 
 
t_data = data(2:length(data),1); 
glucose_data = data(2:length(data),2); 
insulin_data = data(2:length(data),3); 
 
G_b = 92.5; 
I_b = 13.2; 
E_b = 142; 
 
options = optimset('MaxFunEvals',10000,'MaxIter',5000,'TolX',1e- 
4000,'TolFun',1e-4000); 
guess = [ 0.02 
0.05 
1.28e-005 
0.142 
0.002 
0.05 
2.9e-005 
0.02 
293 
3.6e+002]; 
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lb = [0.008 0.05 0.000001 0.05 0.0005 0.01 0.000001 0.00001 279 360]; 
ub = [0.03 0.5 0.0001 0.5 0.05 0.0495 0.2 0.5 293 403]; 
 
model_param = 
lsqnonlin(@Glucagon_Error_Func,guess,lb,ub,options,t_data,glucose_data,in 
sulin_data,G_b,I_b,E_b); 
 
 
tspan = 0:.5:max(t_data); 
 
IC = [model_param(9),0,model_param(10),E_b]; 
 
sol = ode45(@Glucagon_system,tspan,IC,[],model_param,G_b,I_b,E_b); 
disp('parameter values') 
for i = 1:10 
disp(model_param(i)) 
end 
disp('S_I'),disp(model_param(3)/model_param(2)) 
 
final_soln = deval(sol,tspan); 
G = final_soln(1,:); 
X = final_soln(2,:); 
I = final_soln(3,:); 
E = final_soln(4,:); 
 
disp('Do you wish to view G, X, I or E') 
disp('1=Blood Glucose Level') 
disp('2=Interstitial Insulin Level') 
disp('3=Plasma Insulin Level') 
disp('4=Plasma Glucagon Level') 
plot_choice = input(''); 
 
if plot_choice == 1 
plot(t_data,glucose_data,'o') 
hold on 
plot(tspan,G,'g') 
ylabel('Plasma Glucose (mg/dL)') 
xlabel('Time (mins)') 
legend('Plasma Glucose Data IVGTT','Model for Plasma Glucose 
Concentration IVGTT') 
elseif plot_choice == 2 
plot(tspan,X,'--g') 
ylabel('Interstitial Insulin (1/min)') 
xlabel('Time (mins)') 
legend('Interstitial Insulin Activity IVGTT') 
elseif plot_choice == 3 
plot(t_data,insulin_data,'o') 
hold on 
plot(tspan,I,'g') 
ylabel('Plasma Insulin (uU/mL)') 
xlabel('Time (mins)') 
legend('Plasma Insulin Data IVGTT','Model for Plasma Insulin 
Concentration IVGTT') 
elseif plot_choice == 4 
plot(tspan,E,'g') 
ylabel('Plasma Glucagon (pg/mL)') 
xlabel('Time (mins)') 
legend('Model for Plasma Glucagon Concentration IVGTT') 
end 
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System of ODEs 
function dydt = Glucagon_system(t,y,param,G_b,I_b,E_b) 
if y(1)-G_b<=0 
F1 = 0; 
F2 = G_b-y(1); 
else 
F1 = y(1)-G_b; 
F2 = 0; 
end 
 
if y(3)-I_b<0 
F3=0; 
else 
F3=y(3)-I_b; 
end 
dydt = [-param(1)*(y(1)-G_b)-y(2)*y(1)+param(8)*(y(4)-E_b) 
-param(2)*y(2)+param(3)*F3 
-param(4)*(y(3)-I_b)+param(5)*F1*t 
-param(6)*(y(4)-E_b)+param(7)*F2*t]; 
 
Error Function 
 
function error = 
Glucagon_Error_Func(guess,t_data,glucose_data,insulin_data,glucagon_data, 
G_b,I_b,E_b) 
 
IC = [guess(9),0,guess(10),E_b]; 
tspan = 0:0.01:max(t_data); 
 
sol = ode45(@Glucagon_system,tspan,IC,[],guess,G_b,I_b,E_b); 
approx_soln = deval(sol,t_data); 
glucose_approx = approx_soln(1,:); 
insulin_approx = approx_soln(3,:); 
 
N = length(glucose_data); 
error = [glucose_data(3:N).'-glucose_approx(3:N) insulin_data(3:N).'- 
insulin_approx(3:N)]; 
 
C.1.2. Glucagon Exercise Minimal Model for T1DM at 30% of 
𝐕𝐎𝐦𝐚𝐱 
 
Main 
function [] = Molly_Glucagon_Model 
format compact 
format long 
data = [0 4.51*18 13.9 75 
40 4.57*18 12.3 76 
90 4.3*18 10 99 
180 3.5*18 7.2 201 
240 3.12*18 6.2 408]; 
 
t_data = data(1:length(data),1); 
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glucose_data = data(1:length(data),2); 
insulin_data = data(1:length(data),3); 
glucagon_data = data(1:length(data),4); 
 
options = optimset('MaxFunEvals',1000,'MaxIter',5000,'TolX',1e- 
400,'TolFun',1e-400); 
 
guess = [ 0.01 
4.79 
0.0035 
0.065 
6.7 
0.11 
2.32e-006 
0.0035 
2.175e-009 
0.11 
0.00105 
2.55e-006 
0.397 
]; 
 
lb 
0]; 
= [0.008 0.5 0.00001 0.008 0 0.0002 0 0.00028 0 0.05 0 0 
ub = [1 5 1 0.5 100 3 0.00008 0.4 1 1 1 1 3]; 
 
G_b = 81.2; 
I_b = 13.9; 
E_b = 75; 
 
model_param = 
lsqnonlin(@Glucagon_Error_Func,guess,lb,ub,options,t_data,glucose_data,in 
sulin_data,glucagon_data,G_b,I_b,E_b); 
 
% CONFIDENCE INTERVAL OF PARAM FITTING 
[x,resnorm,residual,exitflag,output,lambda,jacobian] = 
lsqnonlin(@Glucagon_Error_Func,guess,lb,ub,options,t_data,glucose_data,in 
sulin_data,glucagon_data,G_b,I_b,E_b); 
ci = nlparci(x,residual,jacobian,0.05); 
disp('Parameter confidence intervals') 
disp(ci) 
t = tinv(0.95/2,length(data)-length(x)); 
se = (ci(:,2)-ci(:,1)) ./ (2*t); 
disp('standard error'),disp(se) 
 
 
tspan = 0:0.01:max(t_data); 
IC = [G_b,0,I_b,0,E_b,500,0,0]; 
sol = ode45(@Glucagon_system,tspan,IC,[],model_param,G_b,I_b,E_b); 
disp('parameter values') 
for i=1:13 
disp(model_param(i)); 
end 
disp('Insulin Sensitivity'),disp(model_param(3)/model_param(2)) 
disp('Glucagon Sensitivity'),disp(model_param(7)/model_param(6)) 
disp('Exercise Sensitivity'),disp(model_param(12)/model_param(11)) 
 
final_soln = deval(sol,tspan); 
G = final_soln(1,:); 
X = final_soln(2,:); 
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I = final_soln(3,:); 
Y = final_soln(4,:); 
E = final_soln(5,:); 
gly = final_soln(6,:); 
pvo2max = final_soln(7,:); 
exac = final_soln(8,:); 
 
disp('Do you wish to view G, X, I, Y or E') 
disp('1=Blood Glucose Level') 
disp('2=Interstitial Insulin Level') 
disp('3=Plasma Insulin Level') 
disp('4=Glucagon Activity') 
disp('5=Plasma Glucagon Level') 
disp('6=Glycogen') 
disp('7=pvo2max') 
disp('8=Exercise Activity') 
plot_choice = input(''); 
if plot_choice == 1 
plot(t_data,glucose_data,'o') 
hold on 
plot(tspan,G,'b') 
ylabel('Plasma Glucose (mg/dl)') 
xlabel('Time (minutes)') 
legend('Plasma Glucose Samples','Plasma Glucose Concentration') 
elseif plot_choice == 2 
plot(tspan,X,'--b') 
xlabel('Time (minutes)') 
ylabel('Interstitial Insulin 1/min') 
elseif plot_choice == 3 
plot(t_data,insulin_data,'o') 
hold on 
plot(tspan,I,'b') 
xlabel('Time (minutes)') 
ylabel('Plasma Insulin (uU/ml)') 
legend('Plasma Inslulin Samples','Plasma Insulin Concentration') 
elseif plot_choice == 4 
plot(tspan,Y,'--b') 
ylabel('Glucagon Action 1/min') 
xlabel('Time (minutes)') 
elseif plot_choice == 5 
plot(tspan,E,'b') 
hold on 
plot(t_data,glucagon_data,'o') 
ylabel('Glucagon (pg/ml)') 
xlabel('Time (minutes)') 
legend('Plasma Glucagon Samples','Plasma Glucagon Concentrations') 
elseif plot_choice == 6 
plot(tspan,gly,'b') 
ylabel('Muscle Glycogen (g)') 
xlabel('Time (minutes)') 
legend('Amount of Glycogen Available in Skeletal Muscle (g)') 
elseif plot_choice == 7 
plot(tspan,pvo2max,'b') 
ylabel('PVO2max (%)') 
xlabel('Time (minutes)') 
legend('Percentage of VO2max') 
elseif plot_choice == 8 
plot(tspan,exac,'--b') 
ylabel('Exercise Action 1/min') 
xlabel('Time (minutes)') 
end 
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System of ODEs 
 
unction dydt = 
Glucagon_system(t,y,param,G_b,I_b,E_b) Exdur = 240; 
if t > 0 && t < 
Exdur u3 = 30; 
else 
u3 = 0; 
end 
 
if y(1)>=G_b  
F1 = y(1)-G_b; 
else 
F1 = 0; 
end 
 
if y(1)<=G_b 
F2 = G_b-y(1); 
else 
F2 = 0; 
end 
ton = 240; 
tdeg = 1200; 
IexgL = param(5)*(-exp(-pi*(t+780)/ton)+exp(-pi*(t+780)/tdeg)); 
 
 
dydt = [-param(1)*(y(1)-G_b)-y(1)*(y(2)- 
y(4)+y(8))+param(13)*(y(7)*y(6)*param(10))/(250+y(6)) 
-param(2)*y(2)+param(3)*y(3) 
-param(4)*(y(3))-(y(8)*y(3))+IexgL 
-param(6)*y(4)+param(7)*y(5) 
-param(8)*(y(5)-E_b)+param(9)*F2+y(5)*y(8) 
-(y(7)*y(6)*param(10))/(250+y(6)) 
-0.8*y(7)+0.8*u3 
-param(11)*y(8)+param(12)*y(7)]; 
 
Error Function 
 
function error = 
Glucagon_Error_Func(guess,t_data,glucose_data,insulin_data,glucagon_data, 
G_b,I_b,E_b) 
 
IC = [G_b,0,I_b,0,E_b,500,0,0]; 
tspan = 0:0.01:max(t_data); 
 
sol = 
ode45(@Glucagon_system,tspan,IC,[],guess,G_b,I_b,E_b); 
approx_soln = deval(sol,t_data); 
glucose_approx = approx_soln(1,:); 
insulin_approx = approx_soln(3,:); 
glucagon_approx = 
approx_soln(5,:); 
 
N = length(glucose_data); 
error = [glucose_data(1:N).'-glucose_approx(1:N) 
insulin_data(1:N).'- insulin_approx(1:N) glucagon_data(1:N).'-
glucagon_approx(1:N)]; 
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C.2. Mathematica Characteristic Equations and Eigen 
Values 
C.2.1. Linear Glucagon Exercise Minimal Model 
 
